The role of constrictor prostanoids in the development of aortic  coarctation-induced hypertension in male and female rats by Baltzer, Wendy Irene
THE ROLE OF CONSTRICTOR PROSTANOIDS IN THE DEVELOPMENT OF 
AORTIC COARCTATION-INDUCED HYPERTENSION IN MALE AND 
FEMALE RATS 
 
 
 
 
 
A Dissertation  
 
by 
 
WENDY IRENE BALTZER 
 
 
 
 
Submitted to the Office of Graduate Studies of  
Texas A&M University 
in partial fulfillment of the requirements for the degree of  
 
DOCTOR OF PHILOSOPHY 
 
 
 
 
 
 
December 2003 
 
 
 
 
 
 
Major Subject: Veterinary Physiology
THE ROLE OF CONSTRICTOR PROSTANOIDS IN THE DEVELOPMENT 
OF AORTIC COARCTATION-INDUCED HYPERTENSION IN MALE AND 
FEMALE RATS 
 
A Dissertation  
 
by 
 
WENDY IRENE BALTZER 
 
 
Submitted to Texas A&M University  
in partial fulfillment of the requirements for the degree of  
 
DOCTOR OF PHILOSOPHY 
 
 
Approved as to style and content by: 
 
 
 
_________________________________  _____________________________ 
John N. Stallone     Theresa W. Fossum 
        (Co-Chair of Committee)            (Co-Chair of Committee) 
 
 
_______________________________  ___________________________ 
Jay D. Humphrey     David M. Hood 
     (Member)           (Member) 
 
 
_______________________________ 
             Glen Laine 
         (Head of Department) 
 
 
December 2003 
 
Major Subject: Veterinary Physiology 
 iii
ABSTRACT 
 
 
The Role of Constrictor Prostanoids in the Development of Aortic Coarctation-Induced 
Hypertension in Male and Female Rats. (December 2003) 
Wendy Irene Baltzer, B. S., University of California Davis; D.V.M., University of 
California Davis 
Co-Chairs of Advisory Committee: Dr. John N. Stallone 
       Dr. Theresa W. Fossum 
 
 
Vascular reactivity to vasopressin and phenylephrine is potentiated by constrictor 
prostanoids (CP) in normotensive female (F) but not male (M) rat aorta and CP function 
is estrogen-dependent. This study investigated the effects of estrogen on CP function and 
arterial blood pressure (MAP) during development of aortic coarctation-induced 
hypertension (HT). M and F rats, (15-18 wks.) in four groups: normotensive (NT), 
hypertensive (HT), ovariectomized (OVX), and OVX estrogen-replaced (OE), 
underwent abdominal aortic coarctation or sham surgery (NT). At 14 days, SQ 29,548 
(SQ, Thromboxane A2 (TXA2) receptor antagonist) was given i.v. to the groups. In 
another experiment, rats received Ridogrel (TXA2 receptor antagonist+TXA2 synthase 
(TXS) inhibitor) or vehicle (methyl cellulose) daily, for 14 days. Thoracic aortae were 
analyzed for morphology, incubated in Kreb’s Henseleit Buffer (KHB) ± angiotensin II 
(ANG II), or underwent continuous pulsatile flow and pressure experiments (PFP) with 
KHB ± ANG II. Perfusate was analyzed for thromboxane B2 (TXB2) and prostaglandin 
F1α (PGF1α). RT-PCR and immunohistochemistry were performed for TXS. MAP was 
higher in F-HT than in M-HT after 14 days. SQ infusion reduced MAP substantially 
 iv
more in F-HT and OE-HT than in others. Ridogrel prevented increases in MAP in F/OE-
HT rats, but not M/OVX-HT. Basal release of TXB2 and PGF1α increased to a greater 
extent in F-HT than in M-HT relative to their controls. ANG II-stimulated TXB2 and 
PGF1α release increased to a greater extent in F-HT than in M-HT. With or without 
ANG II, TXB2 production in HT during PFP increased with estrogen. PGF1α increased 
during PFP with estrogen, however not with ANG II. Pressurization resulted in less 
diameter change in F and OE-HT than in OVX-HT. Elastin increased with HT (inhibited 
by Ridogrel) in all but M. Collagen increased in HT with estrogen (inhibited by 
Ridogrel). Neither OVX-HT nor Ridogrel had any effect on morphology. Estrogen 
increased TXS with HT. Estrogen enhanced vascular CP and MAP in F-HT by increased 
expression of TXS and collagen density in the vasculature indicating that in aortic 
coarctation-induced HT, CP are upregulated by estrogen. Specific forms of HT in human 
beings may involve estrogen-induced vascular CP upregulation. 
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CHAPTER I 
 
 
INTRODUCTION 
 
 
1.1 Hypertension and Vascular Disease Incidence in Women 
Coronary artery disease and hypertension are more common in men than in 
premenopausal women; however, after menopause, the incidence of these diseases in 
women increases to a level similar to that of men (4; 108; 249). These findings suggest 
that estrogen exerts a beneficial (protective) effect on cardiovascular health in 
premenopausal women. In contrast, more recent epidemiological studies have shown 
that ovarian steroid hormone replacement therapy, particularly with estrogen, does not 
reduce the incidence of cardiovascular or cerebrovascular disease, and actually increases 
the risk of myocardial infarction and venous thromboembolic disease in postmenopausal 
women (108; 176; 233). Despite previous epidemiological data that suggest the 
protective effects of ovarian steroid hormones on the cardiovascular system, recent 
findings do not show any significant protection against cardiovascular disease.  
For example, recent clinical trials including the Heart and Estrogen/Progestin 
Replacement Study (HERS) and others, indicate that neither estrogen alone nor estrogen 
plus medroxyprogesterone acetate affect the risk for cardiovascular events or peripheral 
arterial events; furthermore, they do not affect the progression of coronary 
atherosclerosis in women (75; 98; 102).  
____________________ 
This dissertation follows the style and format of the American Journal of Physiology. 
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Increased systolic blood pressure and pulse pressure in women aged 45 to 64 
years increases the risk of coronary heart disease, stroke, other cardiovascular diseases 
and all-cause mortality, but in men of the same age, increased systolic pressure increases 
only the risk of coronary heart disease and not other causes of mortality (6; 214). Most 
importantly, the incidences of specific vascular diseases such as primary pulmonary 
hypertension (129; 272), Raynaud’s Disease (22; 193; 271), oral contraceptive-induced 
hypertension and pulmonary hypertension (89; 129) are substantially higher in women 
than men. Indeed, the incidence of primary pulmonary hypertension is four-fold higher 
in women than in men (272), and Raynaud’s Disease is up to seven-fold higher in 
women than in men (271). Clearly, the effects of estrogen on the vascular system are not 
well understood and are more complex than originally thought.  
Women with essential hypertension that do not have a nocturnal fall in blood 
pressure (so called “nondippers”) have a significantly higher risk for a future 
cardiovascular event compared to male nondippers (264; 267). In addition, female 
nondippers have a significantly larger left ventricular mass than female dippers; but 
there is no difference in left ventricular mass between male dippers and nondippers (265; 
266; 268). Antiestrogens such as tamoxifen appear to protect against the risk of 
cardiovascular disorders (160). In a clinical trial of tamoxifen use for breast cancer, 
administration of the drug tended to decrease urinary thromboxane B2 excretion in 
hypertensive patients, but not significantly. This was most likely due to a small sample 
size (n=7) and the fact that the patients were concurrently being treated with 
antihypertensive drugs such as angiotensin converting enzyme inhibitors (157). 
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Antihypertensive therapy has proven less successful in women than in men at reducing 
and controlling elevations in blood pressure (214; 281), but the reasons for these 
differences are unknown. One explanation for the increase in left ventricular mass in 
nondipper women may be due to a response to pressure overload by the heart, indicating 
the presence of a higher systemic pressure in the women. Taken together, these findings 
suggest the ovarian steroid hormones may exacerbate some cardiovascular diseases in 
women, particularly those of vascular origin.  
 Atherosclerosis is characterized by the development of plaques in the walls of 
arteries. The incidence of atherosclerosis in premenopausal women is lower than in men 
and is reduced in postmenopausal women by hormone replacement therapy (162). This 
is in part due to the ability of estrogen to decrease circulating low-density lipoprotein 
cholesterol levels and increase high density lipoprotein cholesterol (98; 162; 182). The 
effects of estrogen can be rapid nongenomic in action or genomic (stimulation or 
inhibition of gene expression). Estrogen rapidly stimulates the release of nitric oxide 
from endothelial cells by binding to a receptor in the caveolae that then activates the 
endothelial nitric oxide synthase enzyme. Estrogen can also increase gene expression of 
prostacyclin synthase and endothelial nitric oxide synthase (93; 162) (21; 125; 166; 217) 
by acting on the nuclear DNA of endothelial cells. In addition, estrogen acutely 
modulates vascular smooth muscle tone by opening calcium-activated potassium 
channels through a nitric oxide-cGMP pathway and by inhibiting migration and 
proliferation of the cells (21; 125; 162; 166; 182; 280; 283). Estrogen also decreases 
insulin resistance, serum fibrinogen, clotting factor VII and plasminogen activator 
  
4
inhibitor-1 (166; 176; 177; 182; 291). These actions combine to reduce systemic blood 
pressure, prevent plaque deposition in arteries, decrease circulation cholesterol, and 
increase high-density lipoproteins.  
Paradoxically, estrogen only induces small reductions in blood pressure at low 
doses and causes increases in blood pressure with doses of 1.25 mg or higher in 
postmenopausal women with hypertension (91). This may be due, at least in part, to the 
effect of estrogen to elevate gene expression and blood levels of angiotensinogen (92; 
214). These previous findings reveal that the actions of estrogen are diverse and 
multiform and not fully understood in vascular disease.   
Several clinical studies support the idea that ovarian steroid hormones play an 
important role in vascular diseases in women. For example, estradiol levels are higher in 
both men and women with essential hypertension than in normotensive controls (107) 
and hypertensive men with increased estradiol levels have a high renin profile and a 
trend toward an increased risk of myocardial infarction (198). In postmenopausal 
hypertensive women, hormone replacement therapy increases plasma levels of 
angiotensin I, angiotensin II, bradykinin and plasma renin activity (258). In the 30 to 50 
year old age group with renovascular hypertension, fibromuscular hyperplasia or 
primary aldosteronism are most often the underlying cause in women, whereas in men 
the hypertension is commonly due to atherosclerotic stenosis of their proximal renal 
arteries (154; 207; 300). This would suggest that estrogen protects against 
atherosclerosis but not other vascular alterations that result in elevated vascular tone and 
hypertension. Small elevations in plasma angiotensin II (that may not be detected 
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clinically) may induce significant increases in mean arterial pressure and induce 
hypertension (212). When postmenopausal women with risk factors for vascular 
dysfunction (hypertension, hypercholesterolemia, diabetes or coronary artery disease) 
were infused with 17β-estradiol, their vasodilator responses to acetylcholine and sodium 
nitroprusside were significantly reduced compared to healthy postmenopausal women 
(76). Again, these data suggest that the ovarian steroid hormones may exert deleterious 
effects on the vasculature and underlie male-female differences in vascular disease.  
Estrogens and constrictor prostanoids (CP) have been implicated in primary 
pulmonary and essential systemic hypertension, and have been shown to increase 
pulmonary vascular tone in normotension and/or pulmonary hypertension (30; 38; 48; 
107; 197; 272).  Further, in pulmonary hypertension, arachidonic acid induces the 
release of thromboxane A2 (TXA2), a potent vasoconstrictor, which is considered to be 
an important mediator of this disease (12; 38; 210). In contrast to the pulmonary 
vasculature, little is known about the role of CP in the systemic vasculature. Although 
CP production by the systemic vasculature is elevated in some forms of experimental 
hypertension, little is known about the importance of these substances in the regulation 
of systemic vascular tone in normotension or during the development of hypertension. In 
women with gynecologic cancer, production of prostaglandins shifts from the 
vasodilator prostacyclin (prostaglandin I2, PGI2) to the vasoconstrictor TXA2. In 
preeclampsia and other chronic placental insufficiency syndromes, there is a deficiency 
in production of prostacyclin and an overproduction of TXA2, resulting in the increased 
vasoconstriction that occurs in hypertensive pregnancies (295). In hypertensive women 
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with breast cancer, administration of tamoxifen, an antiestrogen, induced a slight 
decrease in urinary thromboxane B2 excretion (the stable metabolite of TXA2, TXB2). 
Although this decrease was not significant, the patients were concurrently treated with 
antihypertensive drugs and no control groups were included (157). Regardless of the 
shortcomings in these studies, they suggest that in vascular diseases, estrogen may 
contribute to enhanced CP production.  
In addition to their acute effects to potentiate vascular tone, CP also function as 
mitogens to stimulate vascular smooth muscle cell proliferation (192; 222). This would 
suggest that the increase in TXA2 release during the development of hypertension, could 
be responsible, at least in part, for the vascular remodeling that occurs with 
hypertension. It would follow that such remodeling may be enhanced in females 
compared to males if the release of vascular TXA2 is greater in females, but this has not 
been investigated. After acute internal vascular injury, estradiol administration reduces 
arterial wall thickening and neointimal formation, while increasing re-endothelialization 
of arteries in a dose dependent manner (35; 134; 190; 223). This suggests that estrogen 
inhibits vascular smooth muscle proliferation, but this is following acute endothelial 
barotrauma and not induction of hypertension, two very dissimilar disturbances in 
vascular function. Thus, ovarian steroid hormones may play a very different role in 
regulation of vascular remodeling in endogenous vascular diseases, compared to acute 
exogenous, vascular barotrauma; and this remodeling response may occur through a 
mechanism involving the mitogenic action of CP. Estrogen may affect vascular 
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remodeling either through direct actions on the endothelium, and/or vascular smooth 
muscle, or through stimulation of CP production.  
 
1.2 The Effects of Estrogen on the Vascular Wall 
The estrogens are a family of steroid hormones in the female, synthesized from 
the universal steroid precursor molecule, cholesterol. The androgens, the family of 
testicular steroid hormones in the male, are obligate precursors of estrogen, see Figure 1 
for the synthesis of estrogen (17; 17). The key step in all steroid hormone biosynthesis is 
aromatization of the cholesterol A ring by a cytochrome P-450 enzyme located in the 
endoplasmic reticulum in the ovary and placenta (where most estrogen synthesis occurs) 
as well as the adrenal gland and testes. The starting point for the specific synthesis of 
estrogen is the 17-hydroxylated derivative of ∆5- pregnenolone and progesterone, which 
yield the androgens, the immediate precursors to estrogens. The second rate-limiting step 
in estrogen biosynthesis is the conversion of androgens to estrogens via the enzyme 
aromatase. Once in the circulation, most estrogen is loosely bound to sex-steroid binding 
globulin albumin but it can also circulate bound to albumin. A small amount of estrogen 
is also synthesized from testosterone by adipose tissue and the liver (17), which contain 
variable amounts of aromatase. The aromatase enzyme is also present in the vasculature 
and can synthesize estrogen locally to have paracrine/autocrine effects on the vasculature 
without increasing systemic levels of estrogen (234). Human endothelial cells do not 
contain aromatase, however, vascular smooth muscle cells of the aorta and pulmonary 
artery do (90).  
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Cholesterol 
(rate-limiting step) 
Pregnenolone     Progesterone 
        CH3             CH3   
        C = O             C = O 
            
 
OH      O   
17-OH-pregnenolone   17-OH-progesterone 
              
     O              O        O
                
 
 
OH    O       HO 
Dehydroepiandrosterone Androstenedione   Estrone 
             
  OH    OH        OH 
       Rate limiting step 
       Aromatase 
 
OH           O         HO 
Androstenediol  Testosterone    Estradiol 
Figure 1: Synthesis of estrogen from cholesterol (adapted from Berne and Levy, eds. 
Physiology, 4thedition)(17). 
 
OH OH 
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  Estrogen is metabolized to sulfated and glucuronidated derivatives in the liver 
and excreted in the urine or undergoes 2-hydroxylation to catechol estrogen. 
Interestingly, catechol estrogens can bind to estrogen receptors but do not activate the 
receptor and may increase gonadotropin releasing hormone secretion. Further, catechol 
estrogens bind neoplastic mammary cells and induce proliferation of these cells (225). 
Catechol estrogens also antagonize uterine artery calcium channels in the pig uterus to 
decrease arterial tone during pregnancy (66). The metabolites of estrogen may therefore 
have vascular effects systemically that have yet to be characterized. Table 1 shows the 
plasma concentration, production and clearance rate of the estrogens (17). 
 
Table 1: Estrogen and progesterone turnover in adult women (adapted from Berne and Levy, 
eds. Physiology, 4th edition)(17). 
Steroid 
Plasma 
Concentration
(ng/dl) 
Production 
Rate 
(µg/day) 
Metabolic 
Clearance 
Rate (L/day)
Estradiol 6-50 80-700 1400 
Estrone 5-20 100-500 2200 
17-hydroxyprogesterone 30-200 600-4000 2000 
Progesterone 100-1000 2000-25000 2200 
 
 
The actions of estrogen include development of female sex organs and female 
secondary sex characteristics, stimulation of ovulation, inhibition of bone resorption, 
reabsorption of sodium by the renal tubules and stimulation of hepatic synthesis of 
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proteins. Some of the proteins stimulated by estrogen include thryroxine binding 
globulin, cortisol-binding globulin, sex steroid-binding globulin, angiotensinogen, and 
lipoproteins (very low density and high density) (17).  
Estrogen decreases low-density lipoprotein and lipoprotein (a) levels in the blood 
(17). It also increases high-density lipoprotein-cholesterol (98; 163; 182). The effect is 
believed to help protect women against the development of atherosclerosis. In addition, 
estrogen also has other “protective” effects, including decreasing insulin resistance, 
decreasing serum fibrinogen, clotting factor VII and plasminogen activator inhibitor-1 
(163; 182). Estrogen also possesses antioxidant and calcium antagonist activities (163; 
182). Monocyte and platelet adhesion to the vascular wall and platelet aggregation are 
inhibited by estrogen as well (163; 203-205). Therefore, it is not surprising that elevated 
serum levels of estrogen result in increased fibrinolytic activity and a reduced incidence 
of atherosclerosis in premenopausal women than in men (163; 289). 
 
1.2.1 The Protective Effects of Estrogen on the Vasculature 
Estrogen also exerts direct effects on the vasculature through both genomic and 
nongenomic mechanisms of action. Via rapid, nongenomic pathways, estrogen can 
induce vasodilation by acting on the endothelium in two ways. The first involves the 
release of nitric oxide, a potent vasodilator (202; 288). Estrogen can bind to the estrogen 
receptor α located in the endothelial cell membrane caveolae (162), which activates the 
endothelial nitric oxide synthase enzyme (93; 163). These findings were confirmed in a 
clinical study in which, after ovariectomy, endothelial responses to acetylcholine-
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induced vasodilation were impaired, but returned after estrogen replacement therapy 
(270). In addition, female spontaneously hypertensive rats have a more pronounced 
vasodilation to acetylcholine than male spontaneously hypertensive rats (116). These 
two examples could be genomic or nongenomic however, estrogen binds to the cell and 
activates nitric oxide synthase via a receptor mediated nongenomic system (36; 93).    
The second, rapid non-genomic mechanism of vasodilation involves stimulation 
of calcium-activated potassium channels in vascular smooth muscle cells. Estrogen 
stimulates cGMP-mediated phosphorylation of calcium-activated potassium ion channels 
in the cell membrane thus stimulating efflux of potassium from the cell. The efflux of 
potassium results in relaxation of the cell (162; 283). Supraphysiologic concentrations of 
estrogen will also acutely inhibit L-type calcium channels (voltage-gated), preventing 
calcium influx and therefore decreasing vascular smooth muscle cell contraction (162; 
163; 227).  Whether these effects are clinically relevant is unknown.  
Binding of estrogen to DNA can also affect cell function in a genomic manner. 
Estrogen can affect the vasculature by increasing the expression of genes for 
prostacyclin synthase and nitric oxide synthase in endothelial cells (63; 163; 288). 
Estrogen binds to estrogen receptors in the cytosol of the cell and the resulting complex 
transforms into a dimer, which then moves into the nucleus and binds to DNA at specific 
promotor sites to increase gene expression (178).   
Other effects of estrogen on the production of prostaglandins in the vasculature 
remain unclear. In addition to the increased expression of genes for prostacyclin 
synthase, workers have found evidence that estrogen enhances vasodilation induced by 
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methacholine in rats and cultured bovine coronary endothelial cells; a nitric oxide-
dependent mechanism of vasodilation (50; 250). If PGH2 synthesis or the TXA2/PGH2 
receptor was blocked in ovariectomized rats, then the vasodilator response to 
methacholine matched that of intact female rats. However, estradiol in these studies 
reduced 6-keto-PGF1α and TXB2 production and did not alter the expression of PGH2 
synthase (50; 250). Therefore in normotension, estrogen may act to enhance vasodilation 
through nitric oxide synthesis, but potentially through inhibition of vasoconstrictor 
prostanoids as well. This possibility was also investigated in canine coronary arteries, 
where estrogen decreased the maximal response to the TXA2/PGH2 receptor agonist U-
46619 (119). In early, partial aortic coarctation-induced hypertension (up to 10 days 
post-coarctation), virgin and early-stage pregnant (14-15 days) female rats did not 
develop an increase in systemic blood pressure (96; 219). There are no published data 
for blood pressure in chronically aortic coarcted female rats. Nonetheless, many previous 
studies of the vascular effects of estrogen have indicated that it protects against 
cardiovascular disease and hypertension; however, there is also evidence that estrogen 
exerts deleterious effects on the vasculature.  
 
1.2.2 The Detrimental Effects of Estrogen on the Vasculature 
Several studies have revealed the potentially deleterious effects of estrogen on 
the vasculature. The effects of estrogen are no longer believed to influence the 
progression of coronary atherosclerosis (98).  In fact recent evidence suggests that 
estrogen has the ability to stimulate platelet aggregation and to destabilized 
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atherosclerotic plaques (94; 108; 187) which may result in potentially life-threatening 
thromboembolism. Women with thrombosis gene polymorphisms, including Factor V 
Leiden, prothrombin 20210A, and fibrinogen (-455G/A) variants, receiving estrogen or 
with elevated serum estrogen levels, have a significantly increased risk of venous 
thrombosis and myocardial infarction (97).  The only independent predictor of reduced 
primary venous graft patency in women post-surgery is hormone replacement therapy 
(254). Therefore, one of the major detrimental effects of estrogen on the vasculature is 
though its promotion of thrombosis.  
 
Table 2: Contracting and relaxing factors derived from the endothelium (Adapted from White et 
al. 1995)(285). 
Vasoconstrictors Vasodilators 
Angiotensin II Endothelium Derived Hyperpolarizing Factor 
Arachidonic Acid Histamine 
Endothelin I Leukotrienes 
Endothelium Derived Contracting 
Factor Nitric Oxide 
Histamine Prostaglandin E2 
Leukotrienes Prostaglandin I2 
Prostaglandin H2 Shear Stress 
Stretch Superoxide Anion 
Superoxide Anion  
Thromboxane A2  
 
 
Another mechanism by which estrogen may adversely affect the vasculature is 
through its influence on vascular tone. Vascular tone is maintained through a balance of 
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vasoconstrictor and vasodilator mechanisms (Table 2). Most investigators report that 
estrogen stimulates the nitric oxide pathway and that nitric oxide synthesis is one of the 
major mechanisms by which estrogen exerts protective effects on the vasculature (228) 
by decreasing vascular tone, yet others report that estrogen inhibits nitric oxide synthase 
(298). Estrogen decreases inducible nitric oxide synthase expression and its activity in 
vascular smooth muscle cells via estrogen receptor α (which is likely the same receptor 
that stimulates nitric oxide synthase in endothelial cells (298)). Therefore, depending on 
which nitric oxide synthase enzyme is stimulated or inhibited, and its location will 
determine if an increase or decrease in vascular tone will result.  
Estrogen may act indirectly through other factors. One of these is the renin 
angiotensin system. In this system, angiotensin II (ANG II) and aldosterone are 
produced which induce vasoconstriction (ANG II) and sodium retention (Aldosterone 
and ANG II), resulting in increased systemic blood pressure (17). Hypertensive women 
receiving estrogen replacement therapy develop elevated plasma renin activity, and 
plasma angiotensin I and ANG II levels (258). At the molecular level, estrogens may 
stimulate angiotensinogen synthesis 2-fold (34; 136) over that in males. Estrogen 
responsive elements (DNA sequences that bind the estrogen-estrogen receptor dimer) 
have been identified in the 5’ flanking region of the rat angiotensinogen gene (7). 
Functionally, when estradiol is administered to ovariectomized rats, there is a significant 
increase in the pressor response to angiotensin II (over ovariectomized controls) (219). 
The actions of estrogen are thus important in the aortic coarctation model of 
hypertension where the renin-angiotensin system is stimulated. ANG II stimulation in 
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the presence of estrogen may result in increased blood pressure via a combination of 
genetic and functional actions.   
Another detrimental effect of estrogen is through its action on catecholamines 
and adrenergic agonists. Male and female rat arteries do not respond similarly to 
stimulation of contraction by norepinephrine and the α-adrenergic agonist phenylephrine 
(3; 41; 244; 247; 299).  The maximum contractile response to phenylephrine in some 
studies was 40% greater in males than in females, and this difference was attenuated in 
the female by administration of a nitric oxide synthase inhibitor NG-monomethyl-L-
arginine (L-NMMA) (244; 299). This difference in male and female vasoconstriction in 
response to phenylephrine was abolished by ovariectomy in the female (245). This again 
links estrogen to the vasodilator nitric oxide and it also links estrogen to adrenergic 
influence on vascular tone. In contrast to the Zhang et al investigations where estrogen is 
thought to suppress the expression of α1-adrenergic receptors in mesenteric arteries 
(299), studies conducted by Altura (3) and Colucci et al. (41) reported increased 
vasoconstrictor response to catecholamines and phenylephrine in female rats and male 
rats treated with estrogen compared to males. Other investigators have found similar 
results indicating increased vasoconstriction in response to phenylephrine and 
vasopressin in female rat aortae (68; 244; 245; 247). Mesenteric arteries were used in 
other experiments and concurred with the studies in rat aortae (3; 243; 246). Given the 
conflicting results other, as yet unknown, factors may be involved in the vascular 
response to phenylephrine in the female rat.  
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As stated above, arginine vasopressin (AVP) has been found to stimulate larger 
contractions in females than males (68; 244; 245). AVP is released from the posterior 
pituitary in response to extracellular fluid hyperosmolality and/or hypovolemia. AVP is 
the primary regulator of renal water excretion and is also a potent systemic 
vasoconstrictor. The renal and vascular actions of AVP are important in the maintenance 
of arterial blood pressure in altered states such as dehydration and hemorrhage (17). The 
maximal contractile response to AVP is substantially higher in the female rat aorta at 
any stage of the estrus cycle than in the male (3; 244; 247). The increased response of 
the female rat aorta to AVP is believed to be due to, at least in part, to CP, since 
inhibition of cyclooxygenase attenuates vasoconstrictor responses pf the female aorta by 
25 to 30% (244). There may be elevated CP synthesis in response to phenylephrine in 
females where increased vasoconstriction over male aortae occurs as well (68). In 
chronic deoxycorticosterone acetate (DOCA)-salt induced hypertension, vascular 
reactivity to AVP was elevated in females compared to males (246). In the acute stage, 
the female rats had an elevated 6-keto-PGF1α (stable metabolite of PGI2) output and not 
until the chronic stage did the output increase in males which may account for the 
differences seen in vascular reactivity to AVP in this particular model of hypertension.  
Thus, differences in the production of vasodilators (PGI2, nitric oxide) and 
vasoconstrictors (constrictor prostanoids) may be the defining element to whether 
increased constriction occurs in the female.  
The effects of estrogen on vascular prostaglandin synthesis is not fully 
understood. Administration of estrogen reduces production of prostacyclin in the uterus 
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of rats (77) and in the vasculature of rabbits (61). In the rabbit aorta, estrogen enhances 
endothelium-dependent contractions to arachidonic acid, the precursor to prostaglandins 
and vasoconstriction to norepinephrine was inhibited by the cyclooxygenase inhibitor 
indomethacin (168). Similarly, indomethacin also attenuates vasoconstrictor responses to 
AVP and PE in female but not male rat aortae (68). Ovariectomy abolishes the 
attenuating effect of indomethacin and SQ 29,548 (thromboxane/endoperoxide receptor 
antagonist) to the vasoconstrictor response of the female aorta to AVP and PE (67; 67; 
68). The vasoconstriction induced by CP does not appear to be mediated by calcium 
channels in female pulmonary arteries since contraction stimulated by U-46619 (a 
TXA2/PGH2 receptor agonist) was not attenuated by verapamil, a calcium channel 
blocker. Male rat pulmonary arteries, on the other hand, exhibited attenuated contraction 
to U-46619 when exposed to verapamil (48). Estrogen stimulates the production of 
constrictor prostanoids and dilator prostanoids but the balance of these in vascular 
disease, especially in association with renin-angiotensin system upregulation, may be 
skewed toward CP production.  
In addition, most of estrogen’s actions on the vasculature are likely mediated by 
the endothelium since many vasodilators and vasoconstrictors are derived from 
endothelial cells(68; 285). The possibility exists that endothelial dysfunction must occur 
in some vascular diseases to induce alterations in the balance of vasodilator and 
vasoconstrictor production.   
In the spontaneously hypertensive rat, both male and female rats respond 
similarly to TXA2/PGH2 receptor stimulation with U 46619; the vasoconstriction 
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produced in each sex was not significantly different (123). However, in this model of 
hypertension, nitric oxide appears to play a larger role in the females. Female aortae 
have a greater relaxation response to acetylcholine and do not respond to elevated 
acetylcholine concentrations with contraction as male rats do unless nitric oxide 
synthesis has first been inhibited by NG-nitro-L-arginine (123). Therefore, the possibility 
exists that upregulation of the renin-angiotensin system must occur in conjunction with 
increased CP production to induce elevated vascular contractility in certain cases in 
female rats. This would help to explain the conflicting results of previous studies. 
Regardless, it appears that estrogen has the ability to affect vascular tone negatively by 
inducing hypertension through imbalances in vasodilators and vasoconstrictors in the 
female. Since many mediators are likely involved (CP, PGI2, nitric oxide, ANG II, etc) 
different models and vascular states may result in many seemingly conflicting results.   
Estrogen may exert adverse effects on the vasculature depending on the estrogen 
receptor (ER) it binds to. The endothelium (40)  and vascular smooth muscle cells both 
contain estrogen receptors (101; 120). There are two classical types of estrogen 
receptors: α and β (115; 178) and both have been identified in vascular endothelium and 
vascular smooth muscle cells (5). These receptors have been identified in both human 
and animal vessels with estrogen receptor β predominantly expressed in the vascular 
smooth muscle (100; 251). Cytosolic estrogen receptors bind to estrogen to form a 
receptor-dimer complex, move to the nucleus, and act as transcription factors at specific 
sites on the DNA, called estrogen responsive elements (178). In this way, estrogen can 
modulate protein synthesis by its target cells. Estrogen receptor α (ERα) and estrogen 
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receptor β (ERβ) can bind together to act synergistically or act separately so that they 
may give rise to opposing regulatory signals (178). Endothelial cells also express 
estrogen receptors located on the cell membrane (in addition to the cytosol and nucleus) 
that may stimulate mitogen-activated protein kinase and are similar in structure to ERα 
(216). ERβ has been identified at the plasma membrane as well. Finally, there are 
estrogen receptors in the cytosol that act solely in the cytosol and do not translocate to 
the nucleus (178). Estrogen, bound to either ERα or ERβ can activate the 
Src/Ras/extracellular signal-regulated kinase (MAPK) pathways in the cytosol which 
then stimulate cellular proliferation (178). The various ways and types of receptors that 
estrogen may bind to can result in many combinations to have varying effects on a single 
cell type or organ such as the vasculature. This again not only demonstrates the 
complexity of estrogen’s potential actions but also the variety of results a single model 
of vascular disease may demonstrate.  
There may even be more than just the two classical estrogen receptors α and β. 
These new receptors appear to be located in the membrane of cells and one receptor has 
the pharmacologic profile of γ-adrenergic receptors (178; 179). Given that these 
receptors have not been characterized, their relationship and functions in the vascular 
wall remain yet to be identified and may help to explain many of the complex actions of 
estrogen.  
The epidemiological and experimental evidence discussed here identify estrogen 
as a complex hormone with many actions on the vasculature that are not fully 
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understood, however, estrogen clearly can act on vasodilators and vasoconstrictors to 
alter vascular tone.  
 
 
 
1.2.3 Estrogen as a Mitogen 
Estrogen has been said to have atheroprotective effects in that it prevents or 
slows the progression of atherosclerosis (289). One of the mechanisms for protection is 
through modulation of vascular endothelial and smooth muscle cell growth and response 
to injury. Estrogen inhibits smooth muscle cell proliferation (35; 63; 190) and migration 
(133; 162). In culture, 17β-estradiol inhibits smooth muscle cell proliferation, DNA 
synthesis, collagen synthesis, platelet-derived growth factor-induced cell migration, and 
mitogen-activated protein kinase activity (59). Estrogen prevents neointima formation 
and thickening after vascular injury (35; 63). The inhibition of proliferation may be due 
to the increased nitric oxide released by estrogen stimulation of nitric oxide synthase, 
since nitric oxide can directly inhibit vascular smooth muscle cell proliferation (43). 
On the other hand, after injury, estrogen enhances re-endothelialization (134). 
Estrogen induces basic fibroblast growth factor and vascular endothelial growth factor 
production, and this may be the mechanism by which estrogen stimulates endothelial cell 
growth and proliferation (176; 223). It also accelerates functional endothelial recovery 
after injury (134; 284). This is due, at least in part, to increased local expression of 
vascular endothelial growth factor and the ability of estrogen to inhibit apoptosis in 
endothelial cells (42; 241; 242). By inhibiting smooth muscle growth and at the same 
time stimulating endothelial cell proliferation, recovery after injury is enhanced in 
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females. The effect of estrogen in hypertension on vascular remodeling is unknown. 
Fischer et al. found in 1985 (65) that inhibition of estrogen receptors with the estrogen 
antagonist Tamoxifen reduced collagen production after injury, but that progesterone 
had a more profound stimulatory effect on collagen synthesis than estrogen. Recently 
however, investigators have found that estrogen and not progesterone increases aortic 
stiffness, induces left ventricular hypertrophy, increases thoracic aorta pulse pressure, 
and decreases medial thickness, internal diameter and luminal cross-sectional area in 
normotensive rats (252). Estrogen has also been found to potentiate endothelial vascular 
function in the hindquarters but not the carotid vascular bed (252). The changes that 
occur in hypertension versus injury may result in very different responses of the vessel 
wall under the influence of estrogen, but regardless, given our current understanding of 
the mitogenic effects of estrogen, it is likely that the hormone plays a significant role in 
the response of the vasculature to hypertension. The roles that estrogen may play in 
vascular responses may vary with the location of the vascular bed.  
 
1.3 Prostaglandins and Their Receptors in the Vascular Wall 
Prostaglandins were first identified by von Euler in 1934 and later determined to 
be acidic lipids responsible for smooth muscle relaxation (224). They were called 
prostaglandins because they were first isolated from seminal fluid and believed to be 
released by the prostate. Much later, many different prostanoids were identified and their 
formation from the “arachidonic acid cascade” was characterized. Prostaglandins, 
together with leukotrienes and other hydroperoxy and hydroxy fatty acids, are termed the 
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eicosanoids (224). Eicosanoids function in inter- and intracellular signaling virtually 
throughout the body, including the cardiovascular system. Their synthesis is regulated by 
the availability of arachidonic acid, which is formed from polyunsaturated fatty acids by 
acylhydrolases in the cell membrane (138; 156). The enzyme responsible for prostanoid 
formation in the cardiovascular system is phospholipase A2 which forms arachidonic 
acid. Phospholipase A2 is present in endothelial cells, smooth muscle cells, 
macrophages, platelets, neutrophils, eosinophils, alveolar epithelial cells, renal 
mesangial cells, keratinocytes, fibroblasts, and osteoblasts (138; 156). Regulation of free 
arachidonic acid levels in the cell is thought to be controlled mainly by the enzymes 
responsible for incorporation of arachidonic acid into phospholipids in the cell 
membrane. These enzymes are arachidonyl coenzyme A synthetase and lysophosphatide 
acyltransferase and their activity is controlled by protein kinase C (156). As the activity 
of these enzymes that form phospholipids from arachidonic acid increases, less 
arachidonic acid will be available for prostanoid synthesis.  
Many stimuli activate phospholipase A2 resulting in the formation and release of 
arachidonic acid. These include ATP, cytokines, growth factors, hormones, interferons, 
mitogens, monocyte chemotactic protein, neurotransmitters, and vasoactive peptides. 
Oxygen stress, hyperglycemia, UV light, and shear stress also activate phospholipase A2 
resulting in subsequent increase in free arachidonic acid. These many stimuli increase 
cytosolic calcium in their target cells, which then causes phospholipase A2 to move from 
the cytosol to the endoplasmic reticular and nuclear membranes, from which it can 
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generate arachidonic acid (138; 156). Arachidonic acid may also be generated from 
diacylglyerol (DAG) by DAG lipase. 
 
 
Prostaglandin H Synthase (cyclooxygenase function) 
Arachidonic acid  Cyclic Endoperoxides (Prostaglandin G2) leukotrienes 
 
     Prostaglandin H Synthase(Hydroperoxidase function) 
     
Prostaglandin H2 
Prostacyclin Synthase      Thromboxane Synthase 
   PGFα  
   Synthase 
Prostaglandin I2       Thromboxane A2 
(Prostacyclin)  
 Non-enzymatic   PGE Synthase      Non-enzymatic 
 Hydrolysis  PGD          Hydrolysis 
Prostaglandin F1α  Synthase    Thromboxane B2 
      Thromboxane Synthase 
Prostaglandin F2α  Prostaglandin E2  
Prostaglandin D2 C17 Hydroxyacid-HHT-Malondialdehyde 
 
 
Figure 2: Metabolism of arachidonic acid (adapted from Moncada and Higgs, 1986; and Marks 
and Furstenberger, eds. 1999)(156; 175).  
 
 
 
Thus, changes in arachidonic acid production in the cell, which is the rate-
limiting step in eicosanoid synthesis, are mediated in 3 ways: 1) generation by 
phospholipase A2, 2) rate of removal by incorporation into phospholipids by arachidonyl 
coenzyme A synthetase and lysophosphatide acyltransferase, and 3) generation via the 
DAG pathway (156).  
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Once arachidonic acid is free in the cytosol, it can be processed by prostaglandin 
endoperoxide synthase-cyclooxygenase into prostaglandin G2 endoperoxide (See Figure 
2), located in the endoplasmic reticulum and nuclear membranes (183). Cyclooxygenase 
or COX is a membrane-bound protein that has two isoforms: constitutive COX-1 and 
inducible COX-2. COX-2 is produced after cell stimulation by inflammatory cytokines, 
growth factors, and bacterial endotoxin (156; 183). It is interesting to note that some of 
the same stimuli that increase free arachidonic acid also stimulate the COX-2, enzyme 
most likely to quickly increase prostaglandin production. COX-2 then forms 
prostaglandin H2 from G2. As shown in Figure 2, PGH2 is processed into many different 
prostaglandins including prostacyclin (prostaglandin I2 or PGI2) and thromboxane A2 
(TXA2).  
 
1.3.1 Prostaglandin I2 or Prostacyclin 
Prostacyclin is produced in most endothelial cells and in all vascular and 
nonvascular smooth muscle cells. The PGI2 synthase enzyme is located in the plasma 
and nuclear membranes of smooth muscle cells (183). Thromboxane A2 and PGH2 
analogues as well as thrombin, histamine, bradykinin, shear stress, trypsin, platelet 
derived growth factor, epidermal derived growth factor, choline esters, interleukin-1 and 
adenosine nucleotides all stimulate PGI2 synthesis in endothelial cells (19; 183). 
Inhibitors of PGI2 synthesis include glucocorticosteroids, lipocortin, low density 
lipoproteins loaded with lipid hydroperoxides and vitamin K1(19). PGI2 has a half-life of 
only 2-3 minutes because it spontaneously hydrolyzes to 6-keto-prostaglandin F1α 
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(PGF1α) which is then excreted in the urine (175). PGI2 may stimulate proliferation and 
differentiation of some cells such as preadipocytes (112; 183). PGI2 mainly functions as 
a vasodilator produced by the endothelium, and has an antiaggretory influence on 
platelets, as well as causing disaggregation of platelets in vitro (81; 183; 224). The 
antiaggretory effect on platelets is mediated by increasing cAMP levels within the cell or 
platelet, and this is accomplished within a very short half-life of the prostaglandin (2-3 
minutes) (224; 229). PGI2 also acts on platelets to prevent their aggregation by inhibiting 
platelet phospholipase and cyclooxygenase (224). Endothelial cells can make PGI2 from 
endoperoxides released by platelets as well as from endoperoxides generated by the 
endothelial cells themselves (224). PGI2 synthesis decreases from the endothelium 
outward toward the vessel wall adventitia, and the reason for this has been hypothesized 
to be that PGI2 protects the vasculature from platelet adhesion and aggregation (174; 
183; 224). Obviously, if a blood vessel was damaged or torn out to the adventitia 
contraction rather than dilation would serve to decrease bleeding and help to form a clot. 
Therefore, it makes sense that little or no PGI2 is produced in the outer layers of the 
vessel wall. As mentioned above, PGI2 inhibits platelet aggregation by increasing cAMP 
levels (by stimulating the adenyl cyclase enzyme) thereby, increasing sequestration of 
calcium (the opposite of TXA2 which increases cytosolic calcium) (183; 224). This is 
likely to decrease calcium-calmodulin complexes that are capable of binding to myosin 
kinase, and then phosphorylating myosin, resulting in cross bridge formation with actin 
and smooth muscle contraction (17). PGI2 also inhibits smooth muscle cell proliferation, 
extracellular matrix production and growth factor release by increasing intracellular 
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cAMP (156). PGI2 has a local negative feedback system that prevents further production 
of itself by inhibition of cyclooxygenase (24; 126; 183). PGI2 production is further 
antagonized by oxygen free radicals, which may be important in reperfusion injury (156) 
and in vascular diseases where angiotensin II is increased (angiotensin II increases 
oxygen free radical release (79; 206)). Schror, Vane, and others have hypothesized that 
PGI2 and TXA2 work together to maintain a homeostatic balance in platelet aggregation 
and vessel tone because they have nearly opposite effects on platelets and vascular 
smooth muscle (156; 173; 183; 224). Furthermore, the distribution of PGI2 synthase and 
TXA2 synthase in the layers of the vascular wall is nearly opposite from endothelium to 
adventitia with PGI2 synthase having its highest concentration in the endothelium (174; 
183; 224). If in disease the balance of PGI2 and TXA2 production were upset, then 
excessive vasodilation/constriction or platelet aggregation/bleeding disorders could 
develop. Indeed, this is the case in some diseases where there is a tendency for 
thrombosis to develop and increased TXA2 is present and/or decreased PGI2 are present. 
The opposite occurs for diseases in which an increased bleeding tendency is present 
(224). Because PGI2 works together with TXA2 to maintain homeostasis and 
prostaglandins have been implicated in renin angiotensin system-dependent hypertension 
(113), its functions and actions are central to this investigation of vascular diseases in 
women. It follows that if estrogen increases production of TXA2 in the presence of 
angiotensin II, then postmenopausal women with hypertension who are receiving 
hormone replacement therapy may have an increased tendency toward thrombosis (108; 
176; 233) because they have an imbalance in PGI2/TXA2 production in their vasculature. 
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Most likely there is an overproduction of TXA2 resulting in increased platelet 
aggregation on the vascular endothelium. In women with gynecologic cancer, production 
of prostaglandins shifts from PGI2 to TXA2. In preeclampsia and other chronic placental 
insufficiency syndromes, there is a deficiency in production of prostacyclin and an 
overproduction of TXA2, resulting in the increased vasoconstriction that occurs in 
hypertensive pregnancies (295). In addition, oxygen free radicals (produced by 
angiotensin II) inhibit the synthesis of two very important vasodilators, PGI2 and nitric 
oxide. Thus, the homeostasis between vasoconstrictors and vasodilators may be out of 
balance.  The increased incidence of vascular diseases in premenopausal women 
(primary pulmonary hypertension, Raynaud’s disease, oral contraceptive-induced 
hypertension) may be explained by such an imbalance in constrictors and dilators in the 
vasculature.  
 
1.3.2 Prostaglandin D2 
Prostaglandin D2 (PGD2) is generated from prostaglandin H2 endoperoxide (Fig. 
2) by prostaglandin D synthase and albumin (175; 259). This prostanoid is synthesized 
predominately by the spleen, macrophages, dendritic cells, and mast cells (37; 183). 
Platelets also produce a small amount of PGD2, but this amount increases if 
thromboxane synthase and therefore, TXA2 production, is inhibited (175). PGD2 induces 
sleep, regulates nociception, inhibits platelet aggregation and mediates allergic reactions 
(259). When PGD2 is infused intravenously, it acts as a peripheral renal vasodilator, 
opposing the actions of noradrenaline, angiotensin II and antidiuretic hormone (156; 
  
28
183). Intravenous PGD2 also induces pulmonary vasoconstriction and is a potent 
bronchoconstrictor (183).  In primary pulmonary hypertension, there is a two-fold 
increase in urinary excretion of the PGD2 metabolite, PGD-M (37). Inhibition of 
thromboxane A2 synthase can result in an accumulation of prostaglandin endoperoxide 
PGH2, and as such increase PGD2 synthesis by platelets and albumin. PGD2 could then 
induce vasodilation and inhibit platelet aggregation, unrelated to a decrease in TXA2 
(156; 175; 224), resulting in conflicting data. Therefore, studies involving inhibition of 
thromboxane synthase may result in ambiguous results, and inhibition of the 
thromboxane A2/prostaglandin H2 endoperoxide receptor may be a more appropriate 
means of investigating the effects of TXA2 on the vasculature.  
 
1.3.3 Prostaglandin E2 
PGE2 synthase is stimulated by glutathione and PGE2 is the major arachidonic 
acid metabolite produced by the kidney (183). PGE2 is present in high concentrations at 
sites of inflammation and has a central role in fever generation. This prostaglandin can 
also induce thermal hyperalgesia in rats (181). In reproduction, PGE2 stimulates 
luteinizing hormone-releasing hormone secretion from the hypothalamus and may be 
involved in embryo implantation (181). PGE2 has many effects on kidney function, 
including antagonism of antidiuretic hormone-induced water resorption and modulation 
of renin release (183); therefore, it may play a significant role in vascular diseases where 
renin release is stimulated. PGE2 also regulates ion transport and glomerular filtration in 
the kidney. As with PGD2, PGE2 is a renal vasodilator and inhibits norepinephrine and 
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angiotensin II-induced vasoconstriction in the kidney (156).  In addition, PGE2 can 
induce platelet aggregation (175) and can either stimulate smooth muscle constriction or 
vasodilation in the systemic vasculature, depending on the receptor subtype stimulated. 
Prostaglandin E2  (PGE2) has 4 different receptor subtypes: EP1-4 that have different 
distributions throughout the body (181). For example, the EP2 receptor induces 
vasodilation and hypotension when stimulated, whereas stimulation of the EP1 or EP3 
receptor induces vasoconstriction. Knockout mice deficient in the EP2 receptor fed a 
high-salt diet develop severe hypertension (181). PGE2 may have an important role in 
some vascular diseases but further study is needed.  
 
1.3.4 Prostaglandin F2α 
Prostaglandin F2α (PGF2α) is expressed in the kidney, heart, lung, stomach and 
corpus luteum. The main function of PGF2α and the main expression of its receptor is in 
the corpus luteum. This prostanoid induces luteolysis and it is also important in 
parturition, as mice deficient in the FP receptor do not undergo parturition even with 
oxytocin administration (181). Like PGE2, PGF2α is involved in the induction of fever, 
but likely plays a lesser role than does PGE2 (181). Finally, in fibroblast cells PGF2α can 
act as a mitogen (181) to stimulate their replication.  
 
1.4 Thromboxane A2 in Normotension and Hypertension 
Thromboxane A2 (Figure 3), a potent vasoconstrictor and platelet aggregator, is 
elevated in humans with a genetic propensity for coronary heart disease and is elevated 
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significantly more in these affected females than in males (2). In general, hypertension 
and increased platelet aggregability are associated with increased TXA2 levels in humans 
and experimental animal models of hypertension (175; 213). Elevated plasma TXA2 
levels have been documented in patients with Prinzmetal’s and vasotonic angina and 
cerebral ischemic syndromes and implicated in preeclampsia, pregnancy-induced 
hypertension and pulmonary hypertension (156; 195; 224; 282). Further, TXA2 also has 
been associated with asthma, acute respiratory distress syndrome, and endotoxin-induced 
pulmonary ventilation-perfusion mismatch (62). 
 
   COOH             COOH 
     
    HO         
                  
       OH          OH 
 
 
 
Figure 3: Thromboxane A2 and thromboxane B2 (Adapted from Moncada, S and Higgs 
EA)(175). 
 
 
TXA2, like PGI2, is produced from the PGH2 endoperoxide precursor (Figure 2) 
and has a short half-life of 30 seconds due to its spontaneous hydrolysis to the stable 
metabolite thromboxane B2 (TXB2) (183), Figure 3. Thromboxane synthase (the enzyme 
that catalyzes TXA2 formation) acts on PGH2 to synthesize TXA2 and 12-hydroxy-
heptadeca-trienoic acid and is located near dense tubular membranes within the cell 
(such as the endoplasmic reticulum) (183). TXB2 is excreted in the urine (183) and has 
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no vascular activity. TXA2 not only stimulates platelet aggregation and vascular smooth 
muscle contraction, but it also causes the release of platelet constituents, 
bronchoconstriction and seritonin release via the TXA2/PGH2 receptor (62; 175; 183). 
TXA2 is synthesized in many vascular tissues including arterial and venous endothelium 
and smooth muscle, blood cells (platelets, neutrophils, macrophages) and cardiac 
myocytes (including the endocardium) (156; 175; 183). TXA2 is the most potent platelet 
aggregator of the prostaglandins, but when synthesis is inhibited, PGH2 and PGG2 may 
induce aggregation in its place by binding to the TXA2/PGH2 endoperoxide receptor 
(175).  TXA2 synthesis and release is activated by a number of humoral and physical 
factors including cholesterol, acetycholine, histamine, angiotensin I and II, ADP, ATP, 
arachidonic acid, superoxide anion (O2-), 5-hydroxytryptamine, substance P, A23187 
(calcium ionophore) and stretch (122; 175). In both humans and Wistar-Kyoto rats, 
TXA2 production increases with age, which may contribute to increased vascular disease 
in older people (122; 175). It is unknown whether activity of TXA2 synthase increases 
with age, but there is a decrease in prostacyclin synthase and subsequent PGI2 formation, 
while the level of COX enzyme does not change (175). This may result in increased 
shunting of COX products toward the TXA2 synthase pathway, resulting in an increase 
in TXA2 synthesis.  
TXA2 acts by binding to the TXA2/PGH2 endoperoxide receptor to activate 
phospholipase C and increase intracellular Ca2+ and protein kinase C (through formation 
of inositol-1,4,5-trisphosphate (IP3) and diacyl glycerol). TXA2 also inhibits cAMP 
formation in the cytosol, resulting in activation and aggregation of platelets and 
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contraction of vascular smooth muscle (85; 156). Through these actions, TXA2 promotes 
rupture of plaques and occlusion of vessels in atherosclerosis (156) (page 278). TXA2 
also stimulates mesangial cell contraction in the kidney, which can a decrease 
glomerular filtration rate (156).  
TXA2 is thought to be an important mediator of sepsis and endotoxic shock 
(156). Inhibition of TXA2 synthase by dazoxiben in animals given endotoxin prevents 
the increase in pulmonary artery and pulmonary wedge pressures as well as the decrease 
in cardiac output that occur with endotoxic shock (290), therefore TXA2 is thought to 
play an important role in the pathogenesis of sepsis.  
With regard to the renin-angiotensin-aldosterone system, there appears to be a 
negative feedback mechanism between renin and TXA2. When TXA2 receptor 
antagonists or TXA2 synthase inhibitors are given to anesthetized rats, plasma renin 
activity increases. In contrast, when a TXA2 mimetic is administered, plasma renin 
activity declines (201; 279). In addition, angiotensin II stimulates vascular TXA2 and 
PGI2 release (148; 156; 287); therefore, it is logical that TXA2 would decrease renin and 
subsequent angiotensin II formation in the plasma. In this way, during both 
normotension and hypertension the vasculature may regulate the renin-angiotensin 
system to stabilize systemic blood pressure. This system is likely overridden by the 
macula densa cells and vascular baroreceptors to control systemic blood pressure, but 
with prostaglandins and the renin-angiotensin-aldosterone system working in concert, a 
balance may be achieved. Inhibition of the TXA2/PGH2 receptor in male rats subjected to 
renovascular hypertension (two kidney-one clip Goldblatt hypertension) both arterial 
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blood pressure and mortality (286). However in one study, this occurred only in the male 
rats that developed malignant hypertension, and TXA2/PGH2 receptor 
antagonism/blockade had no effect on 40% of the renovascular-hypertensive rats (20).  
 
 
    
         O2-   Transforming Growth Factor β 
ATP/ADP     5-hydroxytryptamine Arginine Vasopressin 
   Arachidonic Acid    Stretch  Thrombin 
 Angiotensin I Angiotensin I,II     Substance P  Angiotensin II 
 Hypoxia  
 
  Angiotensin I 
Endothelium  Angiotensin Cyclooxygenase  Proendothelin↑  P02 ↓ 
   Converting 
   Enzyme 
  Angiotensin II 
 
 
 
 
  Angiotensin II  Prostaglandin H2  Endothelin EDCF1 
     Thromboxane A2 
 
 
   
 
 
 
 
 
 
 Smooth Muscle Cell 
 
 
Figure 4: Endothelium-derived contracting factors produced by the vascular wall (Adapted from 
Katusic and Shepherd, 1991)(122). A = angiotensin II receptor, ET = endothelin receptor, 
TXA2/PGH2 = thromboxane/endoperoxide receptor, ? = unidentified receptor (122).   
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The TXA2-angiotensin II feedback system may play a more important role in 
females than in males, since stimulation of females with vasoconstrictors such as 
vasopressin results in greater TXB2 production and vasoconstriction than in males (67; 
67; 244; 247). In males, other endothelium-derived contracting factors may contribute 
more to the development and maintenance of hypertension than the PGH2/TXA2 
pathway (Figure 4). 
Sexual dimorphism with respect to TXA2 has been identified in normotensive 
rats (68). Maximum contractile responses to vasopressin and phenylephrine are higher in 
female rat aortae than in males (68). The endothelium of the female rat, at least in the 
pulmonary vasculature and aorta, potentiates the contractile response to U 46619 but it 
does not in the male (48; 68). Further, normotensive female rats have an increased 
vasoconstrictor response to angiotensin II and arachidonic acid compared to males (3; 
197; 247).  Approximately 30 % of vascular responsiveness in the female rat has been 
attributed to TXA2/PGH2 (68; 145; 168; 248). Therefore, it would appear that the female 
vasculature has increased CP release in response to vasopressors such as angiotensin II 
and arginine vasopressin over the male vasculature. If this is the case, then vascular 
diseases involving the renin-angiotensin system and/or arginine vasopressin would result 
in elevated TXA2 production, at least while the above hormones were elevated in the 
plasma.  
The response of male and female normotensive and spontaneously hypertensive 
rats (SHR) to the TXA2 mimetic U 46619 differs significantly. Normotensive rats have 
an increase in mean arterial blood pressure when administered U 46619, however, the 
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endothelium potentiates contraction to U 46619 only in the normotensive female (48; 
68).  Both male and female SHR have a similar increase in pressure (253) in response to 
U 46619. Giving the COX inhibitor acetylsalicylic acid to male SHR abolishes any U 
46619-induced increase in blood pressure (253) thus indicating activation of the CP 
pathway (PGH2) in the male. Female SHR, on the other hand, did not exhibit any change 
in MAP with the administration of acetylsalicylic acid (253). Further, administration of 
U 46619 increases plasma TXB2 concentrations in male SHR but it decreases TXB2 in 
the plasma of female SHR (221). These results suggest that the vasoconstrictor responses 
in SHR to u 46619 are different in SHR males and females. The response is unlikely due 
to PGI2 formation in the female since no change in 6-keto-PGF1α plasma levels occurred 
with U 46619 administration (221). If stimulation of the TXA2/PGH2 endoperoxide 
receptor in males resulted in increased blood pressure and plasma levels of TXB2, then 
displacement of TXB2 from the receptor and activation of the receptor likely occurred in 
male SHR. The lack of response in the female (no change in BP or plasma levels of 
TXB2) to U 46619 may therefore be due to a difference in the receptor in the female and 
does not necessarily indicate that the CP pathway is not involved in females.   
There are conflicting reports in male SHR concerning the involvement of CP (74; 
122; 263; 293).  In male rats upregulation of the CP system has been implicated as the 
mediator of hypertension in SHR (74; 263). Other reports have found no evidence of 
involvement of TXA2 in male SHR (293) In male SHR, the immediate precursor to 
TXA2, PGH2, may be actively taking the place of TXA2. If the TXA2/PGH2 
endoperoxide receptors are different in male versus female SHR, then there may be 
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increased affinity in the male receptor for PGH2 compared to the female receptor, 
explaining, at least in part, the differing responses of the two sexes to U 46619.  
The aortic coarctation model was used here since in the acute phase in male rats 
the model is renin-angiotensin system-dependent and a CP-mediated mechanism of 
vasoconstriction is responsible, at least in part, for the elevation in blood pressure and 
vascular tone (56; 148). An investigation of the effects of estrogen 45 minutes after 
partial acute aortic coarctation in female rats showed that estrogen increased the 
sensitivity of ovariectomized rat arteries to angiotensin II stimulation (219). Henzel and 
Alsip (96) investigated the effects of partial aortic coarctation in pregnant and virgin 
female rats for 10 to 11 days. No elevation in mean arterial blood pressure was identified 
in the virgin females by 10-11 days after partial coarctation. This investigation did not 
follow these rats chronically (14 days or more) and did not investigate complete aortic 
ligation, which has the effect of maximally stimulating the renin-angiotensin-aldosterone 
system. It is important to remember that in the aortic coarctation model, the hypertension 
is renin-angiotensin system-dependent in the acute phase (148). Chronically, the 
vasculature has remodeled and the baroreceptors have reset so that the peripheral 
vascular resistance and systemic blood pressure remain elevated without the 
involvement of the renin angiotensin system. 
 TXA2 is a potent mitogen and stimulates vascular smooth muscle cell 
proliferation and vascular remodeling (130; 156). If the acute phase of aortic coarctation-
induced hypertension is CP-dependent to a much greater extent in females than in males, 
then the remodeling that occurs in the vascular wall may be different between sexes due 
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to the influence of TXA2 and estrogen (which also regulates cellular proliferation). 
TXA2 directly stimulates extracellular matrix protein production independent of its 
mitogenic effect or its ability to increase cellular protein. TXA2 increases the steady state 
levels of mRNA for the proteins fibronectin, laminin, and type IV collagen (26; 165). It 
also decreases the level of mRNA for heparin sulfate proteoglycan (27). TXA2 also 
stimulates angiogenesis and endothelial cell migration induced by basic fibroblast 
growth factor or vascular endothelial growth factor (185). If TXA2 is elevated to a 
greater extent in females, then the vascular remodeling seen may display a more 
pronounced increase in extracellular matrix protein. Estrogen inhibits vascular smooth 
muscle cell proliferation (59; 60; 297) by increasing intracellular cAMP and adenosine 
(59). The presence of estrogen may inhibit vascular smooth muscle proliferation and 
some protein synthesis in early aortic coarctation while elevated TXA2 levels may 
stimulate increases in collagen and other extracellular matrix proteins that results in a 
very specific remodeling unlike that seen in males.  
 
1.5 Thromboxane A2 Synthase Enzyme and the Thromboxane/Endoperoxide 
Receptor in the Aorta 
Thromboxane Synthase is an enzyme that catalyzes conversion of PGH2 to TXA2 
(62; 135). Table 3 summarizes some of the properties of the enzyme. Thromboxane 
synthase was originally isolated from platelets, but has since been found in neutrophils, 
macrophages, monocytes, endothelium and in the tissues of the colon, kidney, liver, lung 
and utero-placental unit (62; 282). In approximately 80% of neoplastic cells investigated, 
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mRNA for TXA2 synthase was present (156). This enzyme has been seen as a possible 
target for pharmacological regulation of tumor growth, but the ability of PGH2 to also 
stimulate the TXA2/endoperoxide receptor negated this possibility (156). In the lung, the 
distribution of TXA2 synthase closely follows that of the COX-1 and COX-2 (62).  
 
Table 3: Properties of Thromboxane A2 Synthase (Adapted from Marks F, et al., 1999)(156). 
Molecular Mass (Da)  60,487 (cDNA sequence) 
Optical Absorption Spectrum 
              Oxidized Protein                 418,537 and 5+0 
               Reduced plus CO 424,450 and 545 
EPR Spectra  Heme-thiolate (ferric state) 
Isoelectric point 4.8 
Molecular Activity 27s-1 (TXA2 + HHT) 
 
 
 
The enzyme has similarities to the cytochrome p450-type hemoproteins and may 
be related to them (257) (36% homology (156) (page 91); and also forms 12-hydroxy-
heptadeca-trienoic acid along with TXA2 as a byproduct. It is located near dense tubular 
membranes within the cell (183). Surprisingly, TXA2 synthase shares only 16% 
homology with the prostacyclin synthase enzyme, which catalyzes conversion of PGH2 
to PGI2 (156). Although the mRNA and protein levels of the enzyme do not increase in 
hypertensive diseases such as preeclampsia or endotoxin induced pulmonary 
hypertension, post-transcriptional mechanisms for enzyme regulation may account for 
the possible role of TXA2 in these diseases (62; 282). Alternate splicing of the mRNA 
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for TXA2 synthase can result in either an active or inactive (lacks the Fe3+ binding site) 
enzyme (274). The enzyme is also a “suicide” enzyme in that it is inactivated by 
catalysis of PGH2 to TXA2 (114). In addition, TXA2 synthase antagonists can protect the 
enzyme from inactivation and thereby induce increased TXA2 production following 
reduction or removal of the TXA2 antagonist (114). Further control of TXA2 function 
also could be conferred by regulation of the COX enzymes and redirection TXA2 of 
precursors to other prostanoid or leukotriene pathways, see Figure 2.  
TXA2 synthase inhibitors include imidazole, dazoxiben, and pyridine derivatives 
(OKY 046, OKY 1555, OKY 1581), (135; 183). These inhibitors have been shown to 
inhibit the production of TXA2 but not it’s actions which led to the discovery that 
endoperoxides such as PGH2 and PGG2 can bind to the TXA2/PGH2 endoperoxide 
receptor to induce platelet aggregation, vasoconstriction, etc (175; 183; 224). Increases 
in PGI2 and prostaglandin E2 have been documented in rats after oral ingestion of the 
thromboxane A2 synthase antagonist CGS 13080, at a dose that suppressed elevations of 
TXA2 in response to calcium ionophores (135).  
Only inhibitors of the TXA2/PGH2 receptor are able to prevent any actions 
induced by TXA2 or its endoperoxide precursors (175; 201; 213). Thromboxane receptor 
antagonists include BM 13.177, BP 13.505, SQ 29,548, GR 32,191, ifetroban and S 
18,886 (32; 213; 235). Combination TXA2/PGH2 receptor antagonists and TXA2 
synthetase inhibitors have been synthesized as well and include Ridogrel and azo 
analogue I (52-54; 175; 201). These compounds have the potential to not only prevent 
TXA2 actions, but also those of its endoperoxide precursors, which may prove useful 
  
40
clinically(175). On the other hand, competitive receptor antagonists that do not affect the 
formation of other prostanoids or eicosanoids would have the benefit of not shunting 
synthesis from one prostanoid to another the way that synthase inhibitors can. Therefore, 
the use of receptor antagonists to study the effects of TXA2/PGH2 receptor binding may 
provide more conclusive results in the research of CP actions.  
The TXA2/PGH2 receptor is a glycoprotein and has been identified in platelets, 
vascular smooth muscle, vascular endothelium, kidney, brain and immature and mature 
thymocytes (72; 84-86; 88; 181; 278). In thymocytes, it has been suggested that the 
receptor may play a role in antigen-mediated immunomodulation and T-cell maturation 
and development, for if a receptor agonist is administered to immature thymocytes, 
apoptotic cell death is induced (181). Receptor binding is reduced in the presence of 
basic fibroblast growth factor and phosphorylation enzymes such as protein kinase A 
and C (128). 
Two subtypes of the TXA2/PGH2 receptor have been suggested- a platelet 
subtype named α, and a vascular receptor named τ (85). Studies of atherogenesis in apo 
E-deficient mice support the concept of TXA2/PGH2 receptor subtypes. Inhibition of the 
receptor with S 18886 inhibited atherosclerosis by a mechanism independent of platelet-
derived TXA2 synthesis; and inhibition of the cyclooxygenase enzyme with aspirin 
prevented platelet-derived TXA2 synthesis but did not prevent atherosclerosis (32). If the 
receptor subtypes respond differently to antagonism, the effects of receptor blockade on 
endothelium versus smooth muscle and male versus female tissues may differ 
significantly. In male rats, no difference in receptor type were found between aortic 
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smooth muscle cells and platelets (87), and  the receptor has the same affinity for SQ 
29,548 in both cell types(87). With respect to sex differences in receptor function, male 
vascular smooth muscle cells express increased numbers of TXA2/PGH2 receptors 
compared to females. Testosterone and not 17β-estradiol induces increased receptor 
density in rat aortic smooth muscle cells of normotensive rats (99; 158) and in human 
platelets (1). RT-PCR in our lab has identified increased receptor density in the 
normotensive female rat aorta. It is unknown whether the density of receptors changes in 
males and females in vascular disease or to what extent with induction of hypertension. 
Since angiotensin II stimulates TXA2 release, one may speculate that it also increases 
receptors but this is unknown.  
The receptor, once bound, is coupled to second messenger systems through a 
guanine nucleotide regulatory protein and increases intracellular free Ca2+. Through 
second messenger systems, platelet aggregation and activation as well as smooth muscle 
contraction occur (84; 85). TXA2/PGH2 receptor antagonists such as SQ 29,548 and BM 
13.505 are reported to decrease myocardial ischemia-reperfusion injury , endotoxin-
induced thrombocytopenia and pulmonary hypertension (235-237). In hypertension, the 
receptor has been correlated with salt intake. Salt loading increases receptor expression 
in the kidney and brain (neurons) of rats; and rats fed a high salt diet exhibit increases in 
systemic blood pressure when given the TXA2 mimetic U-46619 either intravenously or 
intracerebroventricularly (72; 278). This may indicate upregulation of the CP receptor in 
hypertensive states. In spontaneously hypertensive rats, administration of the 
TXA2/PGH2 receptor antagonist ifetroban restores normal endothelial cell function. 
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However, in these rats, mean arterial blood pressure remained elevated (213). In aortic 
coarctation-induced hypertensive male rats, vascular tone was reduced by up to 75% by 
ifetroban (213), indicating not only the upregulation of the CP system with aortic 
coarctation, but also that differences exist in the various models used to study 
hypertension. Blockade of the TXA2/PGH2 receptor in a clipped kidney in the Goldblatt 
model of hypertension in rats diminishes the pressor response to nitric oxide synthesis 
inhibition (232), indicating again a very important role for TXA2 in hypertension, 
especially renin angiotensin system-dependent hypertension. Both losartan (an 
angiotensin I receptor antagonist) and ifetroban significantly reduce blood pressure to 
the same degree in early, intermediate, and late phases of Goldblatt hypertension (286). 
Therefore, TXA2 and its receptor have been implicated in vascular disease, but very little 
information is known about its presence and/or action in vascular diseases in the 
presence of estrogen.   
 
1.6 Mechanobiology of the Aorta 
Mechanics involves the study of how matter responds to applied loads (109). This is 
of interest in the physiology of the aorta because the aorta is constantly exposed to 
applied loads and therefore its behavior is relevant under these conditions. To understand 
the behavior of the aorta in the intact animal will allow for understanding and insight 
into its behavior under pathological conditions such as hypertension. There is much 
evidence that arteries are affected by the loads applied to them, including pressure and 
shear stress (131; 132). Acute shear stress elicits acute nitric oxide and prostacyclin 
  
43
release, and transcriptional activation of many genes (endothelial nitric oxide synthase, 
cyclooxygenase II, intracellular adhesion molecule-1, MCP-1, tissue factor, platelet-
derived growth factor-B, transforming growth factor-β1) as well as transcription factors 
(nuclear factor kappa B, c-fos, c-jun, specific protein-1) (9; 103; 103; 150; 155; 172; 
180; 189; 209; 231; 255; 292).  
 
 
 
 
 
 
 
 
 
 
Figure 5. Wall shear stress. Wall shear stress as defined by the Hagan-Poiseuille Law assuming 
fully developed laminar flow. Adapted from (155).   
 
 
First, let us define the forces applied to the aorta.  Strain is a measure of the change 
in length or angle that occurs within a material when placed under a load. Stress is a 
measure of a force applied to an area, such as an area of aorta wall, which is the pressure 
placed on that area. (109). Stiffness is the change in stress that occurs when there is a 
change in strain (109) such as the change in pressure that occurs with a change in the 
diameter of a vessel that results. The two most important hemodynamic forces on the 
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aorta wall are tensile stress and wall shear stress (71). Tensile stress on the wall has both 
circumferential and longitudinal components as blood pressure is exerted on the vessel. 
Wall shear stress is the frictional force per unit area of vessel wall and is the tractive 
force of the blood acting on the wall parallel to the long axis of the wall.  
In the artery, shear stress is determined by blood flow and viscosity as well as the 
geometry of the vessel (71), Figure 5. The equation for the shear rate is 
    γ = (m + 2)f/ (πr3); 
and the wall shear stress is 
τ = ηγ; 
where m=2 if there is laminar flow. The internal radius is r and the total blood flow is f, 
while the blood viscosity is η (117; 155). Therefore, if we assume fully developed 
laminar flow, the wall shear stress is defined by the Hagen-Poiseuille Law: 
   wall shear stress = τ = 4ηf/πr3. 
Vessels have been tested in the past in uniaxial strips (170; 294) and flat sheets 
(171) . Cylindrical specimens are preferred in biomechanical research (44; 46; 261; 269) 
however, because they preserve the vessel ultrastructure and therefore can better mimic 
in vivo loading conditions (46; 110). In cell culture, endothelial cells respond to a steady 
state flow by elongating and orienting their long axis in the direction of the flow as well 
as by increasing their stiffness by orienting their actin fibers parallel to the direction of 
flow (184). In vivo experiments have shown that increases in wall shear rate result in an 
increase in the diameter of the artery lumen whereas with decreases in shear stress, the 
intima thickens and the lumen diameter decreases (51; 117; 139; 140). Increased wall 
  
45
shear stress likely induces a flow dependent vasodilation and remodeling (16) through 
induction of membrane phospholipid metabolism that then results in alterations in 
intracellular cell signals (18). Shear stress has been found to induce expression of 
endothelial enzymes such as prostacyclin synthase and endothelin converting enzyme 
(39) and nitric oxide production increases as flow increases (9; 26; 111; 132; 137)). 
Increased blood flow and resulting shear stress elicits a long-term structural expansion 
so that the internal radius of the artery increases to the point that shear stress returns to 
it’s previous value of approximately 15 dyn/cm2  (117). 
Vessels respond to tensile stress in addition to shear stress. When blood flow is 
reduced in the carotid artery at the same time that hypertension is induced vessel wall 
hypertrophy due to smooth muscle cell proliferation results (256). Therefore, although 
there was no increase in wall shear stress (i.e. r remains the same), the smooth muscle 
cells still responded to an elevation in tensile stress (hypertension). Smooth muscle cell 
hypertrophy and fibrosis has been documented to result from increased wall tensile 
stress (elevation in blood pressure) (16).  
Unlike smooth muscle cells, the endothelium responds to hypertension in the 
face of normal blood flow by increasing apoptosis as well as proliferation (i.e. increased 
cell turn over) (256). This response may be due to nitric oxide production in the 
endothelium. Nitric oxide production is enhanced by increased shear stress (which 
stimulates increased endothelial nitric oxide synthase expression (9; 208)) and nitric 
oxide then inhibits smooth muscle cell proliferation (226) . Therefore, it follows that if 
there is no change in shear stress but an increase in blood pressure as with hypertension, 
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nitric oxide production will not increase and there will be no inhibition of smooth 
muscle cell proliferation. 
A key question, however, is: does prostaglandin production change with 
endothelial cell biomechanical responses? As stated previously, expression of 
prostacyclin synthase in endothelial cells is augmented in a shear stress intensity-
dependent manner (9; 39; 132).  An acute effect of shear stress is release of prostacyclin 
(9; 28; 29; 132). An initial burst of prostacyclin is produced by arteries followed by a 
steady state release over a 3 hour period in arterial perfusion studies (29). The increased 
prostacyclin would likely enhance vasodilation of the artery and along with nitric oxide 
promote a return of shear stress to it’s previous level of approximately 15 dyn/cm2.  
With regard to CP, production is also stimulated by changes in wall shear stress. 
Thromboxane A2 production is increased in the initial period of perfusion and then 
reaches a steady state release over the next 3 hours (28; 29). The reason for release of CP 
is not known, but it may act to balance the release of the potent vasodilators nitric oxide 
and prostacyclin. CP release is higher during perfusion at physiologic pressure and 
pulsatile flow (100 mm Hg, 90 ml/min, respectively) than in static incubation (28). In 
addition, prostanoid release has been found to have no consistent correlation when 
measured by static incubation versus perfusion of the vessel lumen (28; 161). This 
indicates a need to measure prostanoid release during perfusion as well as static 
incubation. Indeed, in hypertension, increased shear stress increases the release of CP 
such as prostaglandin H2 and thromboxane A2 (105), which may mean that these 
prostanoids are important mediators in hypertension that require further study. In the 
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model of hypertension used in this investigation, namely renovascular hypertension, 
thromboxane A2/prostaglandin H2 play major roles in the maintenance of the elevated 
blood pressure (286). In hypertension, at least, CP may do more than just balance the 
actions of shear stress-induced vasodilators.  
Investigators have studied enhanced release of CP in male rats but estrogen may 
influence the regulation of shear stress-induced prostaglandin release as well. Estrogen 
has been found to enhance nitric oxide release stimulated by increased shear stress in 
female rats (104) and in hypertension as well (106). Estrogen inhibits cultured vascular 
smooth muscle cell mitogenesis produced by cyclic mechanical strain (151).  If nitric 
oxide synthesis is chronically inhibited, then estrogen continues to enhance shear stress 
induced dilation but through endothelium-derived hyperpolarizing factor and not via 
prostacyclin (106). The mechanism behind estrogen’s ability to inhibit smooth muscle 
cell hypertrophy is likely mediated through its ability to stimulate endothelial nitric 
oxide synthase. Interestingly, the effect of estrogen on CP production with changes in 
shear stress has not been investigated. It is likely, however, that estrogen, along with 
changes in shear stress and tensile stress, contributes to the vascular remodeling that 
occurs in hypertension, perhaps through activation of CP. Both male and female human 
aortae decrease distensibility with increasing age but these changes (i.e. an increase in 
stiffness) occur much earlier in men than in women (240). The subjects in this study 
were healthy and not hypertensive and may not reflect what occurs in forms of 
hypertension where ANG II is involved.  
 
  
48
1.7 Aortic Coarctation-Induced Hypertension Model in the Rat 
The aortic coarctation model of hypertension was used in the rat in this 
investigation. First developed by Rojo-Ortega and Genest (211) and characterized by 
Fernandes, et al. (64), this model involves complete ligation of the abdominal aorta 
between the right and left renal arteries, cranial to the superior mesenteric artery.   
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Thus, the left renal artery becomes ischemic, which in turn stimulates renin 
release from the juxtaglomerular renin-secreting granular cells of that kidney (64) (277). 
Renin in turn stimulates conversion of angiotensinogen to angiotensin I, which is 
converted to angiotensin II in the lungs (17). Through angiotensin II (ANG II), 
aldosterone and antidiuretic hormone (Figure 6), acute hypertension is induced in the rat 
in the upper half of the body, cranial to the aortic ligature (64) (220). See Figures 7 and 
8. There is a peak in renin and mean arterial pressure at approximately 5 days post-aortic 
coarctation. Therefore, the renin-angiotensin-aldosterone system is responsible for the 
acute phase hypertension that occurs, while a later chronic phase develops through 
vascular remodeling and likely changes in baroreceptor set point. Once the chronic phase 
appears, the hypertension will persist indefinitely. By 30 days post-aortic coarctation, 
renin blood levels have returned to pre-coarctation levels, yet hypertension will persist 
cranial to the aortic ligature and normotension is present caudal to the ligature (64). The 
administration of captopril, an angiotensin I converting enzyme inhibitor, will 
significantly reduce the acute increase in blood pressure that follows after aortic 
coarctation (8; 141).  No change in arterial blood pressure in the cranial half of the rat 
will result and no increase in blood renin levels will occur if total infarction or removal 
of the left kidney is performed (64; 113). This model, then, relies upon the renin 
angiotensin system for the induction of hypertension.  
Evidence for the involvement of not only the renin angiotensin system but also 
the eicosanoids was first reported by EK Jackson et al in 1981 (113). Injections of 
indomethacin, an inhibitor of the cyclooxygenase enzyme and prostaglandin 
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biosynthesis, at six days post-aortic coarctation, decreased both mean arterial blood 
pressure and plasma renin activity in rats (113).  Further, chronically-coarcted rats (4 
weeks after coarctation) also exhibit a persistent vascular response to CP that interact 
with nitric oxide to maintain a homeostatic, although elevated systemic blood pressure. 
When the TXA2/PGH2 receptor is antagonized, there is a decrease in the pressor 
response to nitric oxide synthesis inhibition, indicating that at least part of the elevated 
blood pressure is maintained by CP (232). It is likely there is a change in the balance of 
vasodilators such as prostaglandin I2 and nitric oxide and vasoconstrictors such as 
thromboxane A2 and prostaglandin H2. 
The pathology of essential hypertension has been deemed polygenic and 
endothelial dysfunction has been suggested as a contributing factor (229). If substances 
produced by the vascular wall contribute to resetting of the arterial baroreceptors, then 
hypertension would remain after the renin-angiotensin-aldosterone system is no longer 
involved. Endothelial dysfunction could cause increases in peripheral vascular resistance 
(229) due to relative or absolute increases in vascular contracting factors, resetting of the 
arterial baroreceptors, remodeling of the vascular wall through stimulation by mitogens 
such as thromboxane A2, and/or acute increases in renin release (229). Once vascular 
remodeling has occurred to the point that vascular resistance is increased, then 
hypertension would persist despite the return of renin and ANG II to baseline levels, and 
regardless of whether the arterial baroreceptors have reset or not.  
The form of vascular remodeling that occurs in this model of hypertension has 
been investigated extensively in male rats. Thoracic aortic vascular smooth muscle cells 
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undergo hyperplasia with a 25-fold increase in DNA synthesis and a 25% increase in 
smooth muscle cell number. Inhibition of the ANG II type 1 receptor results in an 
attenuation of arterial medial thickening in coarcted rats and spontaneously hypertensive 
rats (188) (239; 296). The endothelium, on the other hand, has a 23-fold increase in cell 
turnover, but no change in absolute cell number (191). Although the endothelium does 
not undergo hyperplasia, there is a marked increase in cytoplasmic microfilaments seen 
in the endothelial cells that contain actin (69; 70); however, the function of this 
apparatus in the endothelium is unknown.  
The characteristic vascular hypertrophy of the vascular smooth muscle that 
develops with this renin-angiotensin-dependent model is important because it decreases 
arterial compliance and increases impedance, which perpetuates the hypertension and 
eventually leads to heart failure due to pressure-overload left ventricular hypertrophy 
(144). In addition to vascular cell changes the aortic basement membrane loses 
chondroitin sulfate proteoglycans and gains fibronectin and laminin components (83; 
152). These basement membrane changes occur in association with induction of the 
renin-angiotensin-aldosterone system and to a much greater extent than in nonrenin-
angiotensin system-dependent models of hypertension (83). This indicates that the rat 
aortic coarctation model, which depends upon renal ischemia and induction of the renin-
angiotensin system, represents a specific form of hypertension with its own vascular 
responses. Hypertensive male rats exhibit an increased vascular reactivity to ANG II via 
increased thromboxane A2 release during the first two weeks following aortic coarctation 
(148) and an increase in total vascular resistance can be induced in normotensive male 
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rats by infusion of U-46619, a thromboxane/endoperoxide receptor agonist (73). It is 
likely that the renin-angiotensin system induces vascular remodeling directly via the 
actions of ANG II and/or through CP in aortic coarctation, which leads to maintenance 
of the hypertension after the renin and ANG II levels have declined to normal (Figs. 7 
and 8). Although these findings are limited to the specific model of hypertension called 
aortic coarctation, they may be significant in some forms of hypertension where the 
renin-angiotensin system is activated. Elevated ANG II levels have been documented in 
essential hypertension in humans (107; 198; 258). Further, release of vasoconstrictor 
prostanoids, such as thromboxane A2 by the vasculature of humans with essential 
hypertension reduce endothelium-dependent relaxations (230). Therefore, mechanisms 
of vascular remodeling similar to those that occur in aortic coarctation may also occur in 
essential hypertension. Thus, continued investigations using this model are warranted.  
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Figure 7: Plasma renin concentrations of the male rat following aortic coarctation (Adapted 
from Fernandes et al., 1976 (64)). 
 
 
 
 
 
Figure 8: Mean arterial blood pressure of the male rat following aortic coarctation (Adapted 
from Fernandes et al., 1976 (64)). 
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The relationship between the renin-angiotensin system and CP in coarctation-
induced hypertension has been investigated. Coarcted male rats exhibit dose-dependent 
increases in perfusion pressure response to ANG II that are 3-fold greater compared to 
normotensive controls. Moreover, U-46619 (TXA2/endoperoxide receptor agonist) 
increases perfusion pressure to a similar extent in both coarcted-hypertensive and 
normotensive rats (47). Other studies of thromboxane A2 receptor antagonists and 
thromboxane synthase inhibitors have reported decreases in arterial blood pressure in 
renin-angiotensin-dependent models of hypertension in response to these compounds 
(20; 31; 55; 148). Although these experiments have determined that CP such as 
thromboxane A2 and prostaglandin H2 play important roles in the elevation of the arterial 
blood pressure following aortic coarctation, inhibition of CP synthesis or CP receptor 
antagonism decreases but does not return blood pressure to pre-coarctation levels. 
Therefore, a second unknown vasoactive agent has been proposed (31). Boussairi et al. 
documented two responses to TXA2/PGH2 receptor inhibition in male Goldblatt 
hypertensive (two kidney-one clip) rats. In one group of male rats, there was no response 
to receptor blockade and in the other (termed “malignant hypertensive group”) both 
blood pressure and mortality were decreased (20). This may indicate that two different 
responses to renal ischemia exist in these rats that may result in two very different forms 
of hypertension; or it may indicate that the degree of renal ischemia induced alters the 
vascular responses seen. The degree of ischemia induced may vary with the amount of 
ligation of the aorta, and this may explain the apparent discrepancies in blood pressure 
responses observed in coarctation-induced hypertension. 
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Inhibition of the prostanoid biosynthesis pathway enzymes cyclooxygenase or 
thromboxane synthase, and/or inhibition of the thromboxane A2/endoperoxide receptor, 
reduces basal arterial tone by up to 75%, decreases renin production, and decreases mean 
arterial pressure in aortic coarcted rats (56; 124; 149; 273; 286). Various antagonists 
used in these studies included the cyclooxygenase inhibitors indomethacin (56) and SC 
58,236 (273), the thromboxane A2 synthase inhibitors: CGS 13,080 (149) and U63557A 
(124), and the thromboxane A2/endoperoxide receptor antagonists: SQ 29,548 (149) and 
ifetroban (56; 286). Further, urinary excretion of thromboxane B2 (thromboxane A2 
metabolite) is increased in rats with ANG II administration (153), and the rate of 
conversion of prostaglandin endoperoxide H2 to prostaglandin I2 (prostacyclin) in 
hypertensive rats is less than 50% that of normotensive rats (146). In people with 
essential hypertension, urinary 6-keto-prostaglandin F2α (stable metabolite of 
prostaglandin I2) excretion is decreased. Importantly, this excretion is significantly lower 
in normotensive and hypertensive females compared to their male counterparts (80). 
This indicates that in ANG II-dependent forms of hypertension, prostaglandin synthesis 
is shifted away from the vasodilator prostanoids such as prostaglandin I2 and toward the 
CP such as thromboxane A2. This may explain, at least in part, why mean arterial blood 
pressure remains elevated after renin and ANG II levels return to baseline.  
Aortic coarctation in male rats not only induces vascular remodeling and altered 
ANG II sensitivity through enhanced CP synthesis, but also disrupts nitric oxide 
synthesis (14; 82; 95). ANG II stimulates the formation of reactive oxygen species (79; 
206) which in turn inactivates the nitric oxide pathway (14; 82). Although endothelial 
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nitric oxide synthase and neuronal nitric oxide synthase are upregulated in aortic 
coarctation and the pressor response to nitric oxide synthase inhibition with NG-nitro-L-
arginine methyl ester is enhanced in rats after aortic coarctation (13; 14; 200), the 
contribution of nitric oxide to arterial blood pressure  in this model of hypertension is 
significantly decreased (due to ANG II-stimulated reactive oxygen species). The 
impairment of nitric oxide-dependent vasodilation mechanisms is particularly relevant in 
these investigations, because 17β-estradiol induces rapid release of nitric oxide and 
activation of guanyl cyclase in endothelial cells (21; 93; 162; 202; 215; 216). 17β-
estradiol increases endothelial nitric oxide synthase expression as well (125; 162; 216; 
217; 275). If the actions of nitric oxide are impaired by ANG II-stimulated reactive 
oxygen species, then this model may be more appropriate to the study of hypertension in 
females.  
In the aortic coarctation model of hypertension, the CP may also play an 
important role in the regulation of the renin-angiotensin system. This control could then 
influence ANG II-induced production of oxygen free radicals and the ability of nitric 
oxide to inhibit vasoconstriction. The aortic coarctation model is therefore useful in the 
investigation of hypertension at the vascular level in the female (a vascular system with 
enhanced ability to produce nitric oxide) and the role that CP play in the development of 
hypertension in females. Use of a renin-angiotensin system-dependent model of 
hypertension in females is also appropriate because estrogen elevates gene expression 
and blood levels of angiotensinogen (92; 214). 
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Previous use of the aortic coarctation model of hypertension in female rats has 
been quite limited. An investigation of the effects of estrogen 45 minutes after partial 
acute aortic coarctation revealed that estrogen increased the sensitivity of 
ovariectomized rat arteries to ANG II stimulation (220), but the effects of chronic 
coarctation were not determined. Henzel and Alsip investigated the effects of partial 
aortic coarctation in pregnant and virgin female rats for 10 to 11 days. In their study, 
significant increases in mean arterial blood pressure occurred in pregnant rats but not in 
coarcted virgin rats. This discrepancy is likely due to: 1) partial aortic occlusion rather 
than complete ligation; and 2) study of the animals at 10 to 11 days did not allow 
sufficient time for peak arterial blood pressure to develop.   
The aortic coarctation model in exploration of the effects of estrogen on the 
vasculature is appropriate since it is dependent on the renin-angiotensin-aldosterone 
system and estrogen clearly has the ability to regulate ANG II in females. 
 
1.8 Statement of Objectives and Investigation Rationale 
1.8.1 Objectives 
As discussed in Section 1.4, the renin-angiotensin system and CP (PGH2/TXA2) 
have been implicated in aortic coarctation-induced hypertension in the rat and primary 
pulmonary and essential hypertension (8; 38; 107; 113; 141; 147; 230; 286). However, in 
the male rat, there is still debate about the mechanism of induction of hypertension and a 
second unknown vasoactive agent has been proposed (31). In the female rat, little is 
known about the roles of any of the vasoactive agents such as ANG II and TXA2 in 
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hypertension. Given the greater activity of the TXA2 pathway in the normotensive 
female rat (67), it seems likely that vascular reactivity to ANG II in aortic coarctation-
induced hypertension would be potentiated to a much greater extent in the female than 
the male. However, sex differences in the vasculature of this hypertension model have 
not been studies previously. Therefore, the objectives of the proposed project are: 1) to 
determine male and female differences in the role of TXA2/PGH2 in the acute and long-
term regulation of vascular tone during development of aortic coarctation-induced 
hypertension in the rat, and 2) to elucidate the role of ovarian steroid hormones in the 
regulation of TXA2-pathway function during the development of aortic coarctation-
induced hypertension in the female rat. Thus, the central hypothesis to be tested is: 
Ovarian steroid hormones upregulate CP function in the female rat aorta during the 
development of aortic coarctation-induced hypertension, thereby altering the functional 
and structural responses of the aorta to a greater extent in female than in male rats. If so, 
then CP-mediated changes in vascular reactivity, vascular structure, and systemic blood 
pressure during the development of aortic coarctation-induced hypertension would play 
a larger role in female than in male rats. 
 
1.8.2 Rationale 
Studies of the pulmonary vasculature have established that constrictor 
metabolites of arachidonic acid play a greater role in the regulation of pulmonary 
vascular tone in females than in males, and that estrogen is an important regulator of 
this mechanism. Further, disturbances in this mechanism may be responsible for the 
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greater incidence of primary pulmonary hypertension in women than in men (48; 197; 
272; 282).  Recent studies by Stallone et al. suggest that significant male-female 
differences exist in CP-mediated regulation of systemic (peripheral) vascular tone and 
that this mechanism appears to be upregulated by the ovarian steroid hormones (67; 
67); however, little else is known about male-female differences in constrictor 
metabolites of arachidonic acid in the systemic vasculature. Very little is also known 
about the role that these substances play in normal vascular regulation or in peripheral 
vascular diseases such as Raynaud’s disease or hypertension in women. TXA2 is also 
known to be a potent mitogen and in this way may also contribute to vascular wall 
remodeling during the development of HT (159; 192; 196; 222). Thus, the goals of this 
research are to determine male-female differences in the role of CP (TXA2) in the 
regulation of vascular tone and vascular remodeling in a model of hypertension known 
to involve enhanced release and actions of TXA2, aortic coarctation-induced 
hypertension; and to determine the role that ovarian steroid hormones (estrogen) play in 
the regulation of this mechanism in normotension and hypertension.   
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CHAPTER II 
 
 
MATERIALS AND METHODS 
 
 
 
 
2.1 Animal Preparation 
 
Male (M) and female (F) Sprague-Dawley rats were obtained from Harlan, Inc 
(Houston, TX) at 4 weeks of age (females) and 11 weeks of age (males). The rats were 
housed in pairs in standard plastic laboratory rat cages and were segregated by sex at the 
Texas A&M University Laboratory Animal Research and Resources (LARR) facilities. 
Animals were fed a soy- and alfalfa-free diet (Global diet, formulation 2016, Harlan 
Teklan Inc., Houston, TX) and tap water was provided ad libitum. The temperature (21-
26°C) and photoperiod (12 hours dark: 12 hours light) were controlled. At 5 weeks of 
age, one group of F rats were ovariectomized bilaterally (OVX) under general 
anesthesia. General anesthesia consisted of preanesthetic with atropine sulphate (0.05 
mg/kg, subcutaneously) and anesthesia with ketamine HCl (50 mg/kg) and chloral 
hydrate (150 mg/kg) administered intraperitoneally. At 8 to 12 weeks of age, some of the 
OVX rats received two time-release pellets placed subcutaneously over the right 
paralumbar area, each containing 0.05 mg 17β-estradiol or a placebo (Innovative 
Research, Sarasota, FL). Previous trial studies by the manufacturer and our laboratory 
have shown that this dose produces physiological plasma levels of estrogen in the rat 
(57; 58). After 2-4 weeks of estrogen replacement (14-16 weeks of age), estradiol and 
placebo (OVX) rats underwent aortic coarctation surgery.  
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To ensure adequate supplementation of estrogen in the ovariectomized 
estrogen-replaced rats (OE), after euthanasia, plasma from the OE and OVX rats was 
collected and stored at -80°C until analysis of estrogen levels. Estrogen levels were 
determined via a double antibody RIA for 17β-estradiol (Diagnostic Products Corp., 
Los Angeles, CA), which was validated previously on unextracted rat plasma. At the 
time of experimentation, the rats in all experimental groups (M, F, OVX and OE) 
were age matched at 12-16 weeks old. Because the reactivity of the F rat aorta does 
not vary with respect to the phase of estrous cycle when exposed to vasoconstrictors 
such as vasopressin and phenylephrine, intact F rats were studied without regard to 
phase of the estrous cycle (246; 247). All surgical and experimental procedures used 
in these studies were reviewed and approved by the Texas A&M University 
Laboratory Animal Care and Use Committee (ULACC).  
 
2.2 Induction of Aortic Coarctation-Induced Hypertension 
   Experimental groups consisted M, F, ovariectomized female (OVX), and 
ovariectomized female supplemented with estrogen (OE) and each group was divided 
into either aortic coarctation-induced hypertension (HT) or sham-operated 
normotensive-control (NT). Age-matched rats from all experimental groups were 
anesthetized using a preanesthetic of atropine sulfate  (0.05 mg/kg, subcutaneous 
injection) and an anesthetic combination of ketamine hydrochloride (50 mg/kg) and 
chloral hydrate (150 mg/kg), administered by intraperitoneal injection. After stable 
anesthesia was achieved, the abdominal cavity was exposed and a silk ligature (4-0) 
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placed around the aorta between the origins of the left and right renal arteries, caudal to 
the superior mesenteric artery. The aorta was ligated completely to produce coarctation-
induced hypertension. Control rats were sham operated: a ventral midline incision was 
made and the aorta visualized and isolated, but not ligated (64; 148). Following aortic 
coarctation, a chronic arterial catheter (polyrenethane, Braintree Scientific Inc, 
Braintree, MA) was placed in the right carotid artery and tunneled subcutaneously to 
exit at the dorsal neck to monitor arterial blood pressure in some groups of rats. 
Catheters were flushed every other day with heparinized saline and closed with metal 
stylets. After flushing, a heparin lock was placed in the catheter lumen by administering 
0.02-0.03 ml of 50% dextrose with 200 Units per ml Heparin. The heparin lock was 
removed prior to flushing the catheter the next day.  
  For the experiments involving SQ 29,548, a right jugular vein catheter was 
placed at the same time as and in a similar manner to the carotid arterial catheter and 
tunneled subcutaneously to exit at the same location as the carotid artery catheter on the 
dorsal aspect of the rat’s neck. The jugular catheter was flushed and a heparin lock 
placed in the catheter when not in use as described above.   
 
2.3 Monitoring of Arterial Blood Pressure  
  Prior to aortic coarctation, M, F and OVX rats were acclimated for 1-2 weeks to 
gentle restraint in a specially designed plastic cage that allowed the rats to freely move 
forwards and backwards but prevented them from turning around or climbing. The rats 
were acclimated in the room in which blood pressure experiments were to occur for one 
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hour each day. Starting on the second day after aortic coarctation surgery, rats were 
placed in the restraint cage. The heparin lock was removed from the catheter. It was 
flushed with heparinized saline (5 Units heparin sulfate per 1 ml 0.09% normal saline), 
connected to PE-50 tubing (0.58 mm polyethylene tubing, Becton Dickinson and Co., 
Parippany, NJ) that was filled with heparinized saline, and connected to a pressure 
transducer (Model DTX, Becton Dickinson and Co., Parsippany, NJ). The pressure 
transducer readings were recorded to a chart recorder (Gould 2600S) for a continuous 
record of blood pressure. Before recording blood pressure, each rat was allowed to 
acclimate to the restraint cage for a period of 5 to 20 minutes. Arterial blood pressure 
(MAP) and heart rate (HR) were recorded at approximately the same time every other 
day for 14 days. After recording MAP and HR each catheter was flushed with 
heparinized saline and a heparin lock placed in the catheter to maintain patency. The 
pressure transducer and chart recorder were calibrated using a manometer at least twice 
a week.  
 
2.4 Acute Inhibition of Thromboxane/Endoperoxide Receptor in vivo 
Acute inhibition of the TXA2/PGH2 receptor was accomplished by intravenous 
infusion of the receptor inhibitor SQ 28,548 in fully conscious adult rats. HT and NT M, 
F, OVX and OE rats were implanted with carotid artery and jugular vein catheters. At 14 
days post aortic coarctation or sham surgery, the rats were placed in the blood pressure 
monitoring restraint cages and their arterial blood pressures and heart rates recorded 
after an acclimation time in the cage of 10 to 20 minutes. The jugular vein catheter of 
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each rat was attached to PE-50 tubing and a syringe pump. Following arterial blood 
pressure recording the SQ 29,548 vehicle (0.9% saline with 14 mM Na2C03) was infused 
into the jugular vein for 20 minutes at a rate of 1 ml/hour. During infusion of the vehicle 
and subsequent infusion of SQ 29,548, arterial blood pressure and heart rate were 
recorded (Gould 2600S). Following vehicle infusion, each rat was given a bolus of 2 
mg/kg SQ 29,548 IV, followed immediately by a continuous intravenous infusion of SQ 
29,548 at 2 mg/kg/hour.  The arterial catheter was flushed with heparinized saline as 
needed to keep the line patent during the continuous rate infusions. At the end of the SQ 
29,548 bolus and every 10 minutes during the vehicle and SQ 29,548 infusions mean 
arterial blood pressure and heart rate were recorded (5 replicates at each time point). The 
average mean arterial blood pressure and heart rate recorded for each time point.  
 
2.5 Inhibition of Thromboxane Synthase and the Thromboxane/Endoperoxide 
Receptor during the Early Phase of Aortic Coarctation-Induced Hypertension  
  In order to determine the effects of CP on the development of aortic 
coarctation-induced hypertension, rats received the TXA2/PGH2 receptor inhibitor and 
TXA2 synthase antagonist. Four to 5 animals from each treatment group received oral 
Ridogrel (12.5 mg/kg) twice daily for the first 14 days post-aortic coarctation or sham 
surgery. During the initial aortic coarctation or sham surgery, a right carotid artery 
catheter was implanted and tunneled subcutaneously to exit at the dorsal neck of each 
rat. Mean arterial blood pressure and heart rate were recorded every other day from the 
rats as described above. Each rat had been acclimated to the pressure reading cage prior 
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to the study and pressures were recorded until a stable pressure was reached (5 to 20 
minutes). Data over the 14-day period were analyzed and compared to the initial mean 
arterial blood pressures and heart rates obtained from rats that did not receive Ridogrel. 
 
2.6 Release of Prostanoids from Aortic Rings in vitro 
 M-HT, F-HT and M-NT M, F-NT rats were prepared without catheters to 
determine vascular prostanoid release from the thoracic aorta. Fourteen days after 
coarctation or sham surgery, the rats were sacrificed by rapid decapitation and the 
thoracic aortae removed rapidly and placed in chilled (4ºC) Krebs' Henseleit 
bicarbonate (KHB) solution (concentration in mM: 118.0 NaCl, 25.0 NaHCO3, 10.0 
glucose, 4.74 KCl, 2.50 CaCl2, 1.18 MgSO4, and 1.18 KH2PO4, pH = 7.40, osmolality 
= 292 ± 1.0 mosmol/kg H2O), gassed with 95% O2/5% CO2. The aortae were cleaned of 
all adipose and connective tissue, with care being taken to avoid damage to the 
endothelium. The vessels were then cut into 3-mm length rings and placed in chilled, 
gassed KHB for 30 minutes. The rings were then transferred to 12x75 mm plastic 
culture tubes containing 2 ml of fresh KHB, gradually warmed to 37°C, and then 
preincubated for 30 minutes while continually gassed with 95% O2/5% CO2. The KHB 
was aspirated from each tube and 1.0 ml of fresh KHB or KHB with 1 x 10-6 M ANG II 
was added to the tubes and incubated at 37°C for 45 minutes while gassed as above. 
Following incubation, the KHB was removed from the tubes, aliquoted, and frozen at -
80°C until specific radioimmunoassays (RIA) for TXB2, the stable metabolite for 
TXA2, and PGF1α, the stable metabolite of PGI2, were performed, using antisera 
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developed by Leffler and Busija (142) and RIA methods described by Stallone and 
Weis (246; 276). 
 
2.7 Release of Prostanoids from Aortae in vitro under Constant Pulsatile Pressure 
and Flow Conditions with and without Angiotensin II Stimulation 
 Rats from the experimental groups:  F-HT, F-NT, OVX-HT, OVX-NT, OE-HT, 
OE-NT, were decapitated 10-14 days after sham or aortic ligation surgery. The thoracic 
aortae were removed rapidly and placed in chilled Krebs' Henseleit bicarbonate (KHB) 
solution (at 4ºC), gassed with 95% O2/5% CO2. Prior to removal, a 2 to 3 cm segment 
of aorta was measured at the ends where the cuts were to be made, and the in-situ 
length was recorded. The aorta was then excised and cleaned of all adipose and 
connective tissue, with care being taken to avoid damage to the endothelium. The 
vessel segments were also prepared by ligation of the intercostal arteries with 6-0 silk. 
The segments were mounted on glass vessel cannulae, on a custom computer-controlled 
apparatus used to evaluate the aorta biomechanically (Figure 9). The perfusate was 
recirculated through the vessel using a peristaltic pump, with waveforms occurring at 
approximately 250 per second. The flow rate was maintained at approximately 10 
ml/min or the flow rate that yielded a wall shear stress of 15 dyn/cm2. An adjustable 
clamp was placed over the tubing located between the reservoir and the vessel so that 
downstream resistance could be adjusted in order to change the perfusate pressure at the 
vessel.  
 
  
67
 
 Computer with A/D board  Video Recorder 
     
 
 
    Camera     
        Clamp (AdjustsPressure) 
 
    Pump   Reservoir 
 Three Way  
Stopcock 
 
p 
 
Pressure  
Transducer         Three-way                                     
                                                                                                                                 Stopcock 
 
 
 
 
Aorta in KHB Bath X-stage (Adjusts Vessel Length) 
 
    
Direction of Flow        
 
 
    
Figure 9: Schema of the test apparatus. Aortic segments are mounted at the in-situ length, using 
two opposing cannulae, one of which is connected to a platform that rides on an x-stage. The 
specimen is perfused with warmed/oxygenated KHB at a constant rate which yields a mean wall 
shear stress of 15 dyn/cm2 and mean pressure (100 mm Hg or 150 mm Hg), using a digitally 
controlled pump. Axial force f, luminal pressure P, and outer diameter b (via a video data 
acquisition system) are measured on-line using a 12 bit analog digital converter and computer. The 
mean wall shear stress τ = 4µQ/πa3, where µ is the viscosity, Q the volumetric flow rate and a the 
inner diameter. Mean radial, circumferential, and axial stresses are σ = - Pa / (a + b), σθ = Pa / (b – 
a), σz = F / π (b2 – a2). Inner and outer diameter are related by b2 – B2 = π (a2 – A2) / λθo where A 
and B are stress-free values, λ is the in-situ stretch and θo is the opening angle (118). 
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 The connector of one end of the cannulation apparatus was on a movable slide to 
adjust the overall length of the aorta to the in-situ value recorded at the time of removal 
from the rat. The length was adjusted and set to the in situ vessel length. To maintain a 
seal to pressurize the vessel, the ends of the vessel were secured to the cannula by 
ligatures tied over the ends with 6-0 silk suture. The other end connector was attached 
to a 3-way stopcock with one port attached to a pressure transducer to measure the 
perfusion pressure attained as the KHB solution flowed through the aortic segment (set 
to 100 or 150 mm Hg).  
  A video camera mounted on a stage above the cannulated vessel was used to 
record changes in axial and circumferential strains in response to pressurization of the 
aortic segment and agonist challenge (Figure 9). Changes in diameter in response to 
ANG II were recorded. Single frames were captured from the videos using Adobe 
Premiere 5.1 (Adobe Systems Inc, San Jose, CA). For each experiment a micrometer 
was also recorded and later used to calibrate the computer program Scicon Image β 3b 
(Scion Corp., Frederick, MD) to pixels per mm.  
 The approximately 6.8 mls of KHB that continuously recirculated through the 
vessel segment was collected (after 30 minutes per condition) from the reservoir located 
before the pump but after the clamp used to adjust resistance and pressure to flow. 
Basal release of TXA2 and PGI2 were determined by perfusion of the cannulated vessel 
segment at 100 mm Hg. The aortic segment was bathed in a warm KHB solution (37°) 
that was continually gassed with 95% O2 and 5% CO2. The KHB used to perfuse the 
aortic segment was similarly warmed and gassed as well. The aortic segment was 
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allowed to stabilize for 30 minutes at a perfusion pressure of approximately 60 mm Hg. 
During constant flow conditions (approximately 10 ml/min), the aortic segment was 
pressurized at 100 mm Hg and the perfusate recycled through the system for 30 
minutes, while 300 µl of perfusate was collected from the reservoir at 1, 3, 10, and 30 
minutes. The perfusate was placed on ice until storage at    –80 °C. The collected 
solutions were analyzed for prostacyclin (PGI2) and TXA2 by RIA of their stable 
metabolites, 6-keto-prostaglandin F1α (6-keto-PGF1α) and TXB2, respectively. 
Immediately after perfusion at 100 mm Hg, the aorta was perfused with fresh KHB for 
an additional 30 minutes at a pressure of 150-mm Hg and the perfusate collected for 
TXA2/ PGI2 analysis at 1, 3, 10, and 30 minutes. The aortic segment was allowed to 
equilibrate at 100 and 150 mm Hg before the perfusate was collected. PGI2 and TXA2 
release was reported as picograms per mg dry weight of aortic segment. The pressures 
of 100 and 150 mm Hg were chosen to mimic MAP’s found in normotension (100 mm 
Hg) and hypertension (150 mm Hg).   
 After the pressure tests at 100 and 150 mm Hg, the aortae were maintained at 
constant flow (approximately 10 ml/min) and pressure (150 mm Hg) conditions and then 
challenged with a high dose of the α1-adrenergic agonist phenylephrine (PE, 25.0 nmol) 
to stabilize the vasoconstrictor and vasodilator mechanisms. The bolus of PE was 
administered into the 6.8 ml reservoir. A 15-minute recovery period was allowed 
between injections of PE and all subsequent vasoconstrictors, during which the aorta was 
perfused at a pressure of 150 mm Hg. After the first PE challenge, a second dose of PE 
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(25.0 nmol) was administered exactly as the first, followed by another 15-minute 
recovery period.  
 After the perfusate was changed to fresh KHB, the aortic segment was perfused 
with KHB at 150 mm Hg and 3 doses of ANG II (0.005, 0.02 and 0.1 nmol) were 
administered (15 minutes recovery between doses). At the end of each 15 minute time 
period, and before administration of the next dose of ANG II, 0.4 mls of perfusate was 
removed and placed on ice until frozen at -80°C. The perfusate was later analyzed for 
TXB2 and PGF1α content by RIA. Previous studies have demonstrated that prostanoid 
output peaks within 2 minutes after administration of vasoconstrictor agonists, and that 
administration of PE and ANG II vehicles have no effect on perfusion pressure or 
prostanoid output (167; 246). The perfusate samples collected did not change the 
pressure or shear rate present in the aortic segment, since sample collection resulted in a 
decrease in the reservoir volume only. When the calculations were made for TXA2 and 
PGI2 concentrations, the decreases in recirculating volume were taken into account in the 
concentration calculations. Dose-response relationships to determine the change in 
diameter of the vessel with each dose of ANG II was then established from the data.  
 The perfusate was replaced after each 30-minute perfusion period, including the 
stabilization at 60 mm Hg, the 100 mm Hg test, the 150 mm Hg test and after each PE 
challenge, but not between doses of ANG II. The perfusate was changed by filling a 
syringe connected to the perfusion circuit with fresh KHB, clamping first the tubing 
leading to the vessel and detaching the pump, then flushing through the line fresh KHB 
through to the reservoir. Then the tubing towards the reservoir was clamped and the line 
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and vessel flushed with fresh KHB through to the reservoir with care taken to avoid 
exceeding a pressure of 80 mm Hg at the vessel. Changing the perfusate took less than 4 
minutes each time.  
 After the experiment, the aorta was carefully removed from the cannulae, the 
sutures removed, and the vessel placed in a 12x75 mm plastic culture tube. The aorta 
was allowed to dry several days at room temperature, then dried at 85°F for 3 hours. 
After drying, the aorta segments were placed in a room temperature dessicator overnight. 
The following day, the weight of each dried aorta was recorded to the nearest 0.001 mg. 
TXB2 and PGF1α release were calculated as pg/mg aorta dry weight/30 minutes for the 
100 mm Hg and 150 mm Hg pressure tests and as pg/mg aorta dry weight/15 minutes for 
the ANG II challenge tests. 
 
 
2.8 Radioimmunoassay of Perfusate Prostanoids 
The radioimmunoassays for TXB2 and PGF1α used antisera developed by Leffler 
and Busija (142). An equilibrium RIA was performed by incubating prostanoid 
standards (1.95-1,000 pg) or unextracted perfusate samples with [3H] TXB2 or [3H] 6-
keto-PGF1α and with the corresponding antiserum overnight at 4°C. Bound and free 
fractions of [3H] TXB2 or [3H] PGF1α were separated by the charcoal-dextran method. 
Bound radioactivity was determined by liquid scintillation spectroscopy. Cross-
reactivity of the 6-keto-PGF1α is <0.1% with the TXB2 antibody. The limit of detection 
for these RIAs was 1.95 pg/tube and the intra-assay and interassay coefficients of 
variation were 5.0 and 7.6% for TXB2 and PGF1α, respectively (142; 246; 276).  
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2.9 Immunohistochemistry of the Aortic Thromboxane A2 Synthase Enzyme 
 Thoracic aortae from all 8 treatment groups (M-HT, M-NT, F-HT, F-NT, OVX-
HT, OVX-NT, OE-HT, OE-NT) were subjected to immunohistochemical analysis to 
detect changes in vascular wall thromboxane synthase enzyme content among the 
sexes and experimental groups. Four µm thick sections of aorta that had previously 
been embedded in paraffin (see Section 2.7) were rehydrated in ethanol and deionized 
water. The sections were rinsed in PBS buffer (120 mM NaCl, 2.7 mM KCl, 10 mM 
phosphate buffer), PH 7.4 at 25°C. Antigen retrieval was achieved by microwaving the 
tissue for a total of 13 minutes in citrate buffer (5.0 mM, pH 6.0). The sections were 
allowed to cool in the citrate buffer for 20-30 minutes. They were incubated with 
normal equine serum (RTU Vectastain Kit-Universal Elite ABC kit, Vector 
Laboratories, Burlingame, CA). After 30 minutes of equine serum incubation, the 
sections were incubated for 15 minutes each with avidin then biotin (Avidin/Biotin 
Blocking Kit, Vector Laboratories). The primary antibody (monoclonal mouse TXA2 
synthase antibody, diluted 1:500 with common antibody diluent, BioGenex, San 
Ramon, CA) was incubated on the tissues overnight. The secondary antibody 
(universal biotinylated equine anti-rabbit and mouse IgG antibody, Vector 
Laboratories) was incubated on the sections for 30 minutes the next morning. The 
sections were counter stained with hematoxylin (Gill No. 3, Sigma Diagnostics, St. 
Louis, MO). Intensity of antibody staining was determined by a blinded investigator in 
our laboratory. Three sections of aorta per animal were scored on a scale of 0 to 4; 
with sections that had no staining receiving a score of 0 and those with most intense 
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staining receiving a score of 4. Each animal had three consecutive sections analyzed 
and each section was scored independently 3 different times by the blinded 
investigator. The average of the scores was determined for each section, then each 
animal, and finally for each group, to determine intensity of staining. The results were 
reported as the mean score ± standard error.  
 
2.10 RT-PCR of Aortic Thromboxane A2 Synthase Enzyme 
2.10.1 Isolation of Total RNA from Aorta 
Rats from all 8 experimental groups (M-HT, M-NT, F-HT, F-NT, OVX-HT, OVX-
NT, OE-HT, OE-NT) underwent aortic coarctation or sham surgery 14 days prior to 
sacrifice by decapitation. After the thoracic aorta was removed from each animal and 
cleaned of all adipose and connective tissue, the wall was incised longitudinally. The 
endothelium was then removed from the underlying internal elastic lamina and smooth 
muscle with a cotton swab. Endothelial cells were placed in a 1.5 ml RNAse-free 
Eppendorf tube containing 1 ml Trizol (Invitrogen Corp., Carlsbad, CA). The smooth 
muscle was placed in a second tube also containing 1 ml Trizol. Both samples were kept 
on ice until homogenized. After the samples were homogenized (1 minute for 
endothelium, 5 minutes for smooth muscle, Polytron Model MR 2100, Kinematica Ab, 
Switzerland), they were incubated at room temperature for 5 minutes. Two hundred µl 
of chloroform (Fisher Scientific, Fair Lawn NJ) was added to each tube of homogenized 
tissue, shaken vigorously by hand for 15 seconds, and then incubated at room 
temperature for 3 minutes. After the samples were centrifuged at 10,000g for 15 minutes 
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at 4°C, the aqueous RNA-containing top layer was removed (400-500 µl) and 
transferred to a 500 µl Eppendorf tube. Glycogen (5 µl, 25 µg/ml) and sodium acetate 
(50 µl of 5 M) were added to the RNA solution. After vortexing the tube, 400-500 µl of 
isopropyl alcohol was added. These samples were then stored at -20°C overnight.  
The following day, the samples were centrifuged at 10,000g for 15 minutes at 
4°C. The supernatant was removed without disturbing the pellet and 1 ml of 75% 
ethanol was added to the pellet, then vortexed. The samples were centrifuged again at 
8,000g for 10 minutes at 4°C. The supernatant was removed, being careful not to disturb 
the pellet at the bottom of the tube. The tube was allowed to air dry for 1–2 minutes at 
room temperature. DEPC (diethyl pyrocarbonate) water (12-17 µl) was added to the 
pellet and mixed with a pipette tip. The RNA concentration was determined at 260 and 
280 nm with 2 µl of RNA solution diluted with 98 µl of deionized water, using a 
universal microplate spectrophotometer (µQuant model, Bio-Tek Instruments, Inc, 
Winooski, VT). The remainder of the sample was stored at –80 °C until further use.  
 
2.10.2 Reverse Transcriptase Reaction 
 To 1 µl of RNA in a 1.5 ml RNAse-free Eppendorf tube, 9 µl of DEPC water, 
and 1 µl of the 3’oligonucleotide primer for thromboxane synthase were added. The 3’ 
oligonucleotide sequence for thromboxane synthase was: 5’ GAA GCA TCA CAA 
ACA TTT ATTC and for 5’ sequence was 5’-TCC ACA GGT GTT ACT GCT GT. 
Constituitively expressed glyceraldehydes phospho-dehydrogenase (GAPDH) was used 
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as an exogenous control to correct for potential variation in cDNA synthesis, RNA 
loading or amplification reactions (Doroudi 2000). The GAPDH primers (Sigma-
Genosys Inc, The Woodlands, TX) used were 3’: 5’-CAC AGT CTT CTG AGT GGC 
AGT GAT-3’; and 5’: 5’-GTG AAG GTC GTG TCA ACG GAT TT-3’. The samples 
were heated to 75-80°C for 5 minutes.  After cooling, the following reagents were added 
on ice: 4 µl 5x TBE buffer (50% diluted 10x tris boric acid buffer: 27 g 
trishydroxymethylaminomethane base, 13.75 g boric acid, 2.25 g 
ethylenediaminetetraacetic acid dihydrate (EDTA)), 2µl 10 mM dNTP, 1 µl DTT (0.1 
M), 1 µl RNAse Out, 1 µl Thermoscript RT (Invitrogen Corp); then incubated at 60°C 
for 60 minutes. The reverse transcriptase reaction was terminated by heating the sample 
to 85°C for 5 minutes. The RNA was removed with the addition of 1.0 µl RNAse 
(Invitrogen Corp).  
 
2.10.3 Polymerase Chain Reaction 
 The cDNA sample (2 µl) was used for each reaction (thromboxane synthase and 
GAPDH). The following reagents were added: 35 µl water, 5 µl 10x PCR buffer without 
MgCl2, 2 µl of 10 mM dNTP, 3 µl MgCl2, 1 µl Taq (Expand high fidelity system, 
Roche Diagnostics Corp, Indianapolis, IN), 1 µl 5’ oligonucleotide and 1 µl 3’ 
oligonucleotide thromboxane synthase (diluted stock 10x). PCR cycles were performed 
on the above solution with an initial denaturation period of 3-4 minutes at 94°C and a 
final extension of 7 minutes. Each step during the cycles was 30 minutes and the tubes 
were not added to the thermocycler (Thermocycler T3, Biometra, Gottinger, Germany) 
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until the temperature in the cycler had reached 90°C. The housekeeping gene GAPDH 
was cycled at 94, 60, and 72°C for 33 cycles and thromboxane synthase cycled at 94, 54, 
72 °C for 30 cycles. 
  
2.10.4 Gel Electrophoresis 
 The 1.8% agarose gel  was placed in a container and submerged in ethidium 
bromide for staining. One µl of stain was added to 3 µl of each amplified cDNA sample 
and pippetted into each well. The first well on the left was always filled with 3 µl of 
DNA ladder (X174 RF DNA/Hae III hexamer fragments, Invitrogen Inc). An electrical 
gradient across the gel was created at 100 mVolts. The gel was allowed to run for 20 to 
30 minutes, then the gel was removed and scanned. Relative density of staining was 
determined with Quantity One SWPC Imaging Analysis software, Bio Rad Laboratories, 
Hercules, CA.    
 
2.11 Aorta Morphology  
 Thoracic aortae from all 8 treatment groups (M-HT, M-NT, F-HT, F-NT, OVX-
HT, OVX-NT, OE-HT, OE-NT) were analyzed histologically for morphologic 
differences between sexes and changes in the vascular wall with hypertension. Rings 
of aorta (1-2 mm) were obtained from the rats immediately after decapitation and 
placed in chilled (4°C) KHB. The aortae were cleaned of all adipose and connective 
tissue, with care being taken to avoid damage to the endothelium. One end of the 
aortic segment was cannulated with a 23-gauge needle cannula and the end tied to the 
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needle with 4-0 silk. The vessels were perfused with 10% neutral buffered formalin 
using a syringe and silicon tubing. Once the vessel was free of air and contained only 
formalin, the end of the vessel opposite to the cannulated end was ligated with 4-0 silk 
suture. The needle cannula with the aorta segment and attached tubing was placed in a 
beaker of formalin with the vessel completely submerged. The tubing was connected 
to a 60 ml syringe and hung 43 cm above the aorta in the beaker. The aorta was 
immersed in formalin and the syringe was filled with 40 mls of formalin and the 
syringe plunger was removed. The formalin in the syringe was allowed to flow 
through the aorta and its intercostal arteries overnight in order to fix the vessel in an 
expanded position equal to approximately 80 mm Hg pressure. After fixation, the aorta 
was removed from the cannula and placed in 70% ethanol until embedded in paraffin. 
Four-µm thick sections of aorta were placed on glass slides and stained with 
hematoxylin and eosin. The stained sections were photographed and with an image 
analyzer and National Institutes of Health image analysis software the morphology of 
the aorta sections was determined. The area between the internal and external elastic 
laminae was defined as the media. The media cross-sectional area was determined at 
20 X and wall thickness, wall area and wall to lumen ratio were determined as well 
(188) (142; 159). Results were reported as mm/g body weight (wall thickness), mm2/g 
body weight (media area, wall area), and lumen to wall area ratio.  
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2.12 Collagen and Elastin Density 
 An adjacent section of aorta to those obtained for aortic morphology was also 
stained with Movat’s solution to determine collagen and elastin density. Densities 
were measured with a computerized morphometric system, the Optimus at 2.5 x 1.6X 
and the percentage of the total tissue area occupied by collagen or elastin per cross-
section calculated (25). Results were reported as the percentage of elastin or collagen 
per 4 µm thick tissue section and the collagen: elastin ratio was calculated from these 
data.   
 
2.13 Chemicals and Reagents 
Phenylephrine hydrochloride (Sigma Chemical, St. Louis, MO) was prepared fresh 
daily in KHB solution. ANG II (BACHEM-California, Torrence, CA) was prepared 
daily from stock solutions (10-3 M) maintained at -80°C and diluted with KHB solution. 
PE and ANG II solutions were kept on ice during the experiments. Ridogrel was a gift of 
Janssen Research Foundation (Beerse, Belgium). SQ 29,548 was a gift of Bristol Myers 
Squibb Co. (Princeton, NJ) and prepared daily (0.5 mg/ml in 0.9% saline with 14 mM 
Na2C03).  
The immunohistochemistry reagents were purchased from Vector Laboratories, Inc. 
(Burlingame, CA). The TXA2 synthase monoclonal antibody was a gift of Dr. William 
B. Campbell at the University of Wisconsin, Milwaukee, WI.  
The TXA2 synthase primer for the RT-PCR experiment was obtained from Sigma 
Genosys (The Woodlands, TX). Trizol and Thermoscript RT-PCR were obtained from 
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Gibco BRT (Grand Island, NY). The PCR nucleotide mix and Expand High Fidelity 
PCR System were from Roche, Inc (Indianapolis, IN). All other chemical compounds 
were obtained from Sigma Chemical or Fischer Scientific (Fair Lawn, NJ) and were of 
reagent grade quality. 
 
2.14 Data Analysis 
All data were expressed as the mean ± standard error with “n” indicating the number 
of animals studied for each sex and/or experimental treatment group. Prostanoid output 
is expressed as picograms of 6-keto-PGI2 or TXB2 per mg dry weight of aorta. To detect 
significant differences among means of experimental groups, data groups were analyzed 
by sex and experimental treatment. using 2-way analysis of variance. Unpaired t-tests 
were used to determine significant pair-wise differences among the means of the various 
experimental groups. The Bonferroni test was employed to correct for type I error 
associated with multiple comparisons (127); and differences between means were 
accepted as significant if P<0.05. 
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CHAPTER III 
 
RESULTS 
 
 
3.1 Plasma Estrogen Concentrations 
Plasma estrogen levels were significantly higher in F and OE rats than in OVX rats (one-
way ANOVA; P<0.001). There were no differences in plasma estrogen between F and 
OE rats (P>0.2). See Table 4.   
 
 
 
Table 4: Plasma estrogen concentrations. 
 
Treatment Group 
Plasma 17-β-estradiol 
(pg/ml)  
F-NT 8.4 ± 3.4a 
F-HT 6.3 ± 1.6a 
OVX-NT 0.6 ± 0.5b 
OVX-HT 0.8 ± 0.3b 
OE-HT 10.5 ± 1.8a 
OE-NT 15.6 ± 3.9a 
Concentration was determined in each F, OVX, and OE rat. Upon sacrifice, trunk blood was 
collected and the resulting plasma was stored at –80°C until radioimmunoassay for 17-β-
estradiol. Data are reported as the means ± SE of plasma estrogen levels in pg/ml. F-NT (female 
normotensive-control), OVX-NT (ovariectomized female normotensive-control), OE-NT 
(ovariectomized estrogen-replaced female normotensive-control), F-HT (female hypertensive), 
OVX-HT (ovariectomized female hypertensive), OE-HT (ovariectomized estrogen-replaced 
hypertensive). 
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3.2 Effects of Aortic Coarctation on Arterial Blood Pressure and Heart Rate   
The heart rate and MAP were recorded every other day for 14 days following 
aortic coarctation. See Table 5 for heart rates. A two-way ANOVA over time and 
between groups was significant (P<0.05).  
Very few differences in heart rate were present over time within a treatment 
group. All NT groups had similar heart rates throughout the study period (P>0.05). All 
HT groups had slower heart rates on day 2 than later in the study period (P<0.05). F-NT 
had a faster heart rate on day 4 than on days 10 through 14. OVX-HT had a slower heart 
rate on day 6 than on days 10 and 12.  
 
 
Table 5. Heart rate (beats per minute) following aortic coarctation or sham surgery.  
Heart Rate (beats per minute) 
Group F-HT M-HT OVX-HT F-NT M-NT OVX-NT 
Day 2 408 ± 36 383 ± 23 371  ± 28 488  ± 10 435  ± 44 430  ± 13 
Day 4 435  ± 21 446  ± 7 459  ± 42 515  ± 11 428  ± 31 495  ± 23 
Day 6 459  ± 20 473  ± 23 443  ± 13 475  ± 20 450  ± 17 495  ± 9 
Day 8 476  ± 12 458  ± 10 476  ± 13 480  ± 25 430  ± 5 510 * 
Day 10 470  ± 14 446  ± 22 500  ± 10 460  ± 20 480 * 480 * 
Day 12 478  ± 15 446  ± 15 491  ± 9 430  ± 17 428  ± 53 470  ± 57 
Day 14 468  ± 14 437  ± 15 460  ± 18 461  ± 17 428  ± 8 450  ± 15 
Results are reported as means ± SE. * n=1, all others n=3-7, n= no. of animals per group.  
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There were some minor differences in heart rates among the groups on a given 
day. On day 2, M-HT and OVX-HT had slower heart rates than F-NT, while on day 4 F-
HT and M-HT had slower heart rates than F-NT (P<0.05). No differences in HR were 
seen on days 12 and 14 between any of the groups (one-way ANOVA, P>0.05). The data 
suggest that sex influenced the heart rate responses to aortic coarctation during the first 4 
days following surgery, but not later when MAP was significantly different among the 
treatment groups (see below).  
Following aortic coarctation, all animals exhibited significant increases in MAP 
compared to sham-operated normotensive-controls (P<0.01, Fig. 10). In contrast, there 
were no changes in MAP in any of the normotensive-control groups over the 14 day 
period following sham surgery (P>0.05).  
Only F-HT exhibited a continuous increase in MAP over time (Fig. 10). MAP 
increased in F-HT from day 2 (145 ± 7 mm Hg) to day 14 (186 ± 7). MAP in M-HT 
increased from day 0 to 6 then declined and stabilized at a lower MAP than day 6. In 
OVX-HT, MAP changed little until day 8 then exhibited minor insignificant variations 
until day 14 (Table 6).  
During the 14 days post-coarctation, no differences in pressure were identified 
between M-HT and OVX-HT rats (P>0.05). There were some striking differences in 
MAP among some of the other groups during the latter part of the two week study 
period. Prior to and including day 6, M-HT exhibited greater arterial pressure compared 
to F-HT, but this did not reach significance (Table 6). By day 8, the MAP reversed and 
F-HT was then higher than M-HT and remained elevated for the remainder of the study. 
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The MAP of F rats was significantly higher than M rats at days 10, 12 and 14 post-aortic 
coarctation (P< 0.05),  (Table 6, Fig. 10). By day 14, the mean MAP in F-HT (186.1 ± 
7.0 mm Hg) was 14% higher compared to M-HT (160 ± 4 mm Hg). The MAP of OVX-
HT was slightly higher than F-HT on day 2; however, MAP's of both groups were 
similar on day 6, and by day 14, the MAP of F-HT was 35 mm Hg higher than that of 
OVX-HT (P=0.02, Fig. 10).  
Estrogen replacement of OVX rats restored MAP in OE-HT (171 ± 3 mm Hg) 
rats (P<0.05) to that of F-HT rats.  OE-HT exhibited a higher MAP than OVX-HT 
(P<0.05) that did not differ from F-HT as shown in Figure 11 (P>0.05).   The striking 
differences in blood pressure on day 14 were not present in heart rate, as all the groups 
had similar heart rates on day 14 post-aortic coarctation or sham surgery.  
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Figure 10. Time course of mean arterial pressure following aortic coarctation. In M (male), F 
(female), OVX (ovariectomized female), and OE (ovariectomized female estrogen –replaced) 
rats. Mean ± SE (n =5-9 animals per group)
  
84
  
17
0
18
6
11
2
11
7
10
7
12
4
15
0
16
0
9011
0
13
0
15
0
17
0
19
0
F 
HT
(n
=8
)
M
 H
T
(n
=9
)
O
VX
 H
T
(n
=5
)
O
E 
HT
(n
=4
)
F 
NT
(n
=5
)
M
 N
T
(n
=5
)
O
V
X 
NT
(n
=5
)
O
E 
NT
(n
=5
)
Mean Arterial Pressure (mm Hg)
Day 14 Post-Aortic Coarctation
A
A,
B
B
C
D
D
D
D
 
  
Fi
gu
re
 1
1.
 M
ea
n 
ar
te
ria
l p
re
ss
ur
e 
at
 d
ay
 1
4 
po
st
-a
or
tic
 c
oa
rc
ta
tio
n.
 B
ar
s r
ep
re
se
nt
 m
ea
ns
 ±
 S
E,
 n
 =
 4
-9
 (n
, n
o.
 o
f a
ni
m
al
s)
.  
A
-D
: M
ea
n 
va
lu
es
 w
ith
ou
t a
 c
om
m
on
 sc
rip
t a
re
 si
gn
ifi
ca
nt
ly
 d
iff
er
en
t, 
P<
0.
05
.  
  
85
T
ab
le
 6
. T
im
e 
co
ur
se
 o
f m
ea
n 
ar
te
ria
l p
re
ss
ur
e 
fo
llo
w
in
g 
ao
rti
c 
co
ar
ct
at
io
n 
of
 M
, F
, O
V
X
 a
nd
 O
E 
co
ar
ct
ed
 (H
T)
 a
nd
 sh
am
 (N
T)
 ra
ts.
  
M
ea
n 
A
rt
er
ia
l P
re
ss
ur
e 
Fo
llo
w
in
g 
A
or
tic
 C
oa
rc
ta
tio
n 
 
Se
x 
Ex
pe
ri
m
en
ta
l 
G
ro
up
 
D
ay
 2
 
D
ay
 4
 
D
ay
 6
 
D
ay
 8
 
D
ay
 1
0 
* 
D
ay
 1
2 
* 
D
ay
 1
4 
* 
F  
H
yp
er
te
ns
iv
e 
   
n 
= 
8 
14
5 
± 
7.
0a
 
14
6 
± 
7.
0 a
 
15
5 
± 
7.
0a
 
17
5 
± 
7.
3a
 
17
0 
± 
3.
5b
 
18
0 
± 
7.
2b
 
18
6 
± 
7.
0b
 
M
 
H
yp
er
te
ns
iv
e 
   
n 
= 
9 
16
2 
± 
4.
6a
 
16
1 
± 
11
.4
a  
18
0 
± 
 6
.4
a  
16
4 
± 
5.
8a
 
15
1 
± 
6.
5a
 
15
4 
± 
3.
3a
 
16
1 
± 
4.
0a
 
O
V
X
 
H
yp
er
te
ns
iv
e 
n 
= 
5 
15
5 
± 
5.
7a
 
15
6 
± 
6.
5a
 
15
8 
 ±
 8
.1
a  
14
6 
± 
3.
7a
 
16
2 
± 
6.
3a
b  
16
1 
± 
4.
3a
b  
15
0 
± 
8.
2a
 
 F  
N
or
m
ot
en
siv
e-
C
on
tr
ol
 n
 =
 5
 
11
8 
± 
 1
.8
c  
12
0 
 ±
 3
.0
c  
11
0 
 ±
 2
.7
c  
10
9 
± 
 3
.8
c  
10
2 
± 
5.
4c
 
11
4 
± 
6.
3c
 
11
2 
± 
6.
4c
 
M
 
N
or
m
ot
en
siv
e-
C
on
tr
ol
 n
 =
 5
 
12
6 
± 
2.
8c
 
12
4 
± 
13
.0
c  
11
4 
± 
8.
8c
 
11
3 
 ±
 5
.8
c  
11
1 
± 
2.
5c
 
10
6 
± 
1.
5c
 
11
8 
± 
1.
5c
 
O
V
X
 
N
or
m
ot
en
siv
e-
C
on
tr
ol
 
n 
= 
5 
11
7±
 3
.5
c  
10
9 
± 
5.
8c
 
11
7c
 
(n
=2
) 
12
0 
 ±
 2
.8
c  
11
0 
 ±
 9
.0
c  
90
c  
(n
=2
) 
10
7±
 2
.8
c  
R
es
ul
ts
 a
re
 e
xp
re
ss
ed
 a
s m
ea
ns
 ±
 S
E,
 n
= 
5-
9 
un
le
ss
 o
th
er
w
is
e 
st
at
ed
 (n
, n
o.
 o
f a
ni
m
al
s)
. A
-C
: W
ith
in
 c
ol
um
ns
 (d
ay
s)
 a
nd
 ro
w
s  
(e
xp
er
im
en
ta
l g
ro
up
s)
 m
ea
n 
va
lu
es
 w
ith
ou
t a
 c
om
m
on
 s
up
er
sc
rip
t a
re
 si
gn
ifi
ca
nt
ly
 d
iff
er
en
t, 
P<
0.
05
.  
 
  
86
 
3.3 Effects of Acute Thromboxane/Endoperoxide Receptor Antagonism with SQ 
29,548 on Aortic Coarctation-Induced Hypertension  
 Heart rates before infusion, after the SQ 29,548 (SQ) bolus and after the hour-
long SQ infusion are summarized in Table 7 and Figure 12. No differences in heart rate 
were observed between HT and NT groups prior to infusion of SQ. However, heart rate 
decreased significantly following infusion (2-way ANOVA, P<0.05) in all groups. All 
NT groups exhibited similar heart rates following SQ infusion, while heart rates of HT 
groups were more variable. Heart rate was significantly reduced in M-HT compared to F-
HT, OVX-HT and OE-HT (P<0.04). Comparisons of heart rate between NT and HT 
groups revealed that HR differed significantly only between OE-HT and OE-NT 
(P<0.01).  
 
  
Heart Rate During SQ 29,548 Infusion
300
350
400
450
500
550
F-HT M-HT OVX-HT OE-HT F-NT M-NT OVX-NT OE-NT
H
ea
rt
 R
at
e 
(b
pm
)
Preinfusion Post-Infusion
A
B
A
C
A
A
A
A
A
A
B,D B B
B
B
C,D
 
Figure 12: Heart rate prior to and after SQ 29,548 infusion. Bars represent means ± SE, n = 5-9 
(n, no. of animals). A-D: Mean values without a common script are significantly different, 
P<0.05. 
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Table 7:  Heart rate prior to, during, and after intravenous infusion of SQ 29,548.  
Heart Rate (beats per minute) During Infusion of SQ 29,548 
Group Pre-Infusion 
Post-bolus SQ 29,548 
(2 mg/kg iv) 
Post-Infusion  
(2 mg/kg/hour iv) 
F-HT 500 ± 24a 493  ± 22a 455  ± 5a 
M-HT 468  ± 23a 420  ± 45a 375  ± 9b 
OVX-
HT 483  ± 12
a 462  ± 17a 439  ± 19a 
OE-HT 504  ± 10a 477  ± 18a 441  ± 4c 
F-NT 489  ± 10a 420  ± 17b 428  ± 19a,d 
M-NT 465  ± 15a,e 510  ± 30a 440  ± 80b,d,e 
OVX-NT 458  ± 38a 461  ± 34a 386  ± 27a,d 
OE-NT 439  ± 33a,f 431  ± 35a,f 378  ± 23d,f 
Results are means ± SE, n = 5-9 (n, no. of animals). A-F: Within columns and rows for each 
group and experimental treatment (pre-infusion, post-bolus, and post-infusion), mean values for 
heart rates without common superscript are significantly different, P<0.05. 
 
 
 
In general, infusion of SQ exerted a significant attenuating effect (P<0.013) on 
MAP of the various groups of rats. Inter-group variation did not have an effect on the 
response of rats to SQ (P=0.54), Table 8. A One-way ANOVA applied to the maximal 
change in MAP with SQ infusion was significant (P<0.007). With respect to NT groups, 
F-NT and OE-NT rats experienced significant decreases in MAP during the infusion of 
SQ (paired one-tailed t test, P<0.05); however, M-NT and OVX-NT did not (P>0.05). M-
NT had a 5.5 ± 3.8 mm Hg decrease in MAP while the other NT groups exhibited at least 
a 3-fold greater decline in pressure compared to pre-infusion MAP’s (Figure 13b).  
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   Table 8: Maximal decrease in mean arterial pressure following SQ 29,548 administration.  
Maximal Change in Mean Arterial Pressure with Intravenous 
Administration of SQ 29,548 
Mean ± SE 
Sex Group Change in Pressure (mm Hg) 
Female Hypertensive  59.0 ±  8.1a 
Male Hypertensive  20.3 ±  8.4b 
OVX Hypertensive  22.0 ±  10.7b,c 
OE Hypertensive  49.8 ±  13.1a,c 
Female Normotensive-Control  18.7 ±  3.6
b,d 
Male Normotensive-Control  5.5 ±  3.8
b 
OVX Normotensive-Control  20.0 ±  4.6
b,d,e 
OE Normotensive-Control  18.0 ±  9.0
a,b,e 
Data are reported as means ± SE, n = 5-9 (n, no. of animals). A-E:  For each treatment group, 
mean values without common superscript are significantly different, P<0.05. 
 
 
All groups of HT rats exhibited a decrease in MAP with infusion of SQ (Figure 
13a). MAP decreased by 50 mm Hg or more in OE-HT and F-HT rats with infusion and 
by 20 to 22 mm Hg in M-HT and OVX-HT rats, respectively (P<0.05).  The responses to 
intravenous SQ infusion were clearly greater in HT groups. Table 8 shows the maximal 
decreases in MAP that occurred for each group following intravenous SQ. F-HT 
displayed a dramatic fall in MAP with intravenous SQ infusion (P<0.005) to 59 ± 8.1 mm 
Hg. OE-HT had a similar significant decrease in MAP (P<0.05), but the decrease was not 
as rapid as with F-HT as shown in Figure 13a. In contrast, MAP of M-HT and OVX-HT 
did not change significantly during the infusion of SQ (P>0.05). The decline in MAP in 
F-HT was greater than in either M-HT or OVX-HT rats (P<0.02, Fig. 14). OE-HT also 
exhibited a significant reduction in MAP compared to M-HT (P<0.05), but not compared 
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to OVX-HT (P=0.08). These data indicate that the cardiovascular responses to SQ are 
affected by sex of the rat as well as by aortic coarctation.  
 
 
 
  
 
MAP  During SQ 29,548 Infusion-Hypertensives
90
110
130
150
170
0 10 20 30 40 50 60
Time (min)
M
ea
n 
A
rt
er
ia
l P
re
ss
ur
e 
(m
m
 H
g)
F-HT M-HT OVX-HT OE-HT
 
    (a) 
 
MAP During SQ 29,548 Infusion-Normotensives
80
100
120
140
0 10 20 30 40 50 60
Time (min)
M
ea
n 
A
rt
er
ia
l P
re
ss
ur
e 
(m
m
 H
g)
F-NT M-NT OVX-NT OE-NT
 
    (b) 
Figure 13: Time course of mean arterial pressure during intravenous infusion of SQ 29,548; at 14 
days a: post-aortic coarctation or b: sham surgery (normotensive control). SQ 29,548 was 
administered as a bolus from 0 to 1 minute at a dose of 2 mg/kg, then given as a constant rate 
infusion from 1 minute to 60 minutes at a rate of 2 mg/kg/hour. Data points represent means ± 
SE, n = 5-9 (n, no. of animals). 
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Figure 14: Maximal decrease in mean arterial pressure (MAP) following intravenous infusion of 
SQ 29,548 fourteen days after aortic coarctation or sham surgery. Bars represent means ± SE, n = 
4-5 (n, no. of animals).  A-E: Mean values without common script are significantly different, 
P<0.05. 
 
 
 
 
3.4 Effects of Combined Thromboxane A2 Synthase Inhibition and 
Thromboxane/Endoperoxide Receptor Antagonism with Ridogrel on Aortic 
Coarctation-Induced Hypertension 
 Heart rate and blood pressure were recorded every other day during the 14 days of 
Ridogrel treatment following aortic coarctation or sham surgery. Table 9 summarizes 
changes in heart rate during the experiment. A two-way ANOVA detected differences in 
heart rate over time and among the experimental groups (P<0.05). Very few differences 
in heart rate occurred over time within each treatment group; however, differences did 
occur within the first 4 days following aortic coarctation. All groups except OVX-NT had 
slower heart rates on day 2 than on later days in the study (P<0.05). F-HT, OVX-HT and 
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OE-HT (but not M-HT) had slower heart rates on day 4 than on later days in the study 
(after day 6). This suggested that M-HT responded less to Ridogrel early after aortic 
coarctation. From day 6 to day 14, heart rates had stabilized in all groups and no further 
significant changes in their heart rates were detected (P>0.05).  Differences in heart rates 
among groups on a given day were significant in all groups except in M-HT and M-NT. 
M-HT and M-NT had similar heart rates to other treatment groups throughout the study 
(P>0.05). In contrast, F-HT had a slower heart rate than any of the NT groups on days 2, 
4, 6, and 12 (P<0.05). OE-HT also had slower heart rates than any of the NT groups on 
days 4 and 6.  
 
 
Table 9: Mean heart rate during Ridogrel treatment.  
Time Course of Heart Rate (mean ± SE beats per minute) During Ridogrel 
Treatment Following Aortic Coarctation (HT) or Sham Surgery (NT) 
Group F-HT M-HT OVX-HT OE-HT F-NT 
OVX-
NT OE-NT 
Day 2 383 ± 28 398 ± 38 401 ± 35 396 ± 31 458 ± 13 465 ± 29 450 ± 14
Day 4 414 ± 24 430 ± 36 370 ± 26 372 ± 22 480 # 465 ± 11 506 ± 20
Day 6 468 ± 7 468 ± 29 480 # 435 ± 29 503 ± 14 476 ± 9 506 ± 9 
Day 8 500 ± 20 505 ± 13 450 ± 40 448 ± 17 480 # 484 ± 22 503 ± 26
Day 10 420 ± 42 460 ± 20 480 # 480 # 470 ± 26 480 ± 1 518 ± 8 
Day 12 450 ± 17 490 ± 10 465 ± 15 476 ± 16 470 ± 26 458 ± 38 514 ± 13
Day 14 473 ± 19 470 ± 10 446 ± 9 462 ± 12 480 # 420 (n=1) 510 ± 30
Heart rate was recorded in beats per minute at same time that MAP was recorded. Data are means 
± SE, n=3-9 (n, no. of animals). # Heart rates for individuals in that group that day were the same. 
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Table 10: Mean arterial pressure following aortic coarctation or sham surgery in rats treated with 
Ridogrel or vehicle-control.  
Mean Arterial Pressure at 14 Days Post-Aortic Coarctation With or 
Without Ridogrel Administration (Mean ± SE) 
 
Mean Arterial Pressure (mm Hg) 
Group 
With Ridogrel Vehicle Treatment 
Female Hypertensive n=4 132 ± 2.8a 193 ± 9.3b 
Male Hypertensive n=4-9 159 ± 8.1c 161 ± 4.0c 
OVX Hypertensive n=4-5 147 ± 6.2cd 150 ± 9.1cd 
OE Hypertensive n=4-5 134 ± 6.0ad 173 ± 8.1b 
Female Normotensive Control 
n=4 124 ± 2.3
e 109 ± 6.7e 
OVX Normotensive Control 
n=4 110 ± 7.4
e 105 ± 3.2e 
OE Normotensive Control 
n=3-4 121 ± 3.3
e 117 ± 5.7e 
Data are reported as means ± SE; n, no. of animals. A-E: Within columns (experimental groups) 
and rows (Ridogrel treatment versus no Ridogrel treatment), mean values without common 
superscript are significantly different, P<0.05. 
 
 
 Table 10 summarizes the mean arterial pressures recorded over14 days 
following aortic coarctation (HT) or sham surgery (NT). There were no significant daily 
variations in MAP among any of the treatment groups with Ridogrel administration (2-
way ANOVA, P>0.05). Comparison of Ridogrel-treated groups to vehicle-treated groups 
revealed that there was a significant difference (one-way ANOVA, P<0.0001). The NT 
groups did not show any changes in MAP due to Ridogrel treatment (P>0.05). Ridogrel 
administration significantly reduced MAP only in HT groups that had estrogen present 
(i.e., F-HT and OE-HT). Ridogrel significantly reduced mean arterial pressure in F-HT 
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(P<0.008) and OE-HT (P<0.01) rats compared F-HT and OE-HT that received only 
vehicle (Table 10). There were no changes in MAP in M-HT or OVX-HT rats (P>0.05) 
with Ridogrel treatment, compared to vehicle treatment (Table 10, Fig.15). In addition, F-
HT rats given Ridogrel exhibited lower MAP than M-HT and OVX-HT groups that also 
received Ridogrel (P<0.05). OE-HT showed lower MAP than M-HT (P<0.02) as well. At 
14 days post-aortic coarctation, MAP in HT rats was similar to that of NT rats only in the 
groups with estrogen (F and OE, P>0.05), indicating that estrogen replacement restored 
OVX responses to Ridogrel.  
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Figure 15: Mean arterial pressure 14 days after aortic coarctation or sham surgery (NT) with (+) 
and without (-) Ridogrel. Bars represent means ± SE, n = 3-9 (n, no. of animals).  A-E: Bars 
without common script are significantly different, P<0.05. 
 
 
When the differences in MAP among rats that received Ridogrel were compared 
to those that received only vehicle at 14 days post-aortic coarctation, only those with 
  
94
estrogen present responded with a decline in MAP (Fig. 16). F-HT MAP declined by an 
average of 61.5 mm Hg (P<0.008) compared to only 1.4 mm Hg in OVX-HT rats 
(P>0.05). Estrogen supplementation of previously ovariectomized rats restored the 
response to Ridogrel, resulting in a 39 mm Hg decline in MAP in the Ridogrel-treated 
OE-HT rats (P<0.01).  
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Figure 16: Difference in mean arterial pressure with Ridogrel administration 14 days after aortic 
coarctation or sham surgery (NT). Bars represent means of average MAP, n = 3-9 (n, no. of 
animals).  A-B: Bars with different script are significantly different (P<0.05).  
 
 
 
3.5 Effects of Aortic Coarctation on Prostanoid Release 
3.5.1 Thromboxane A2 
Basal release of TXB2 (stable metabolite of TXA2) from aortic rings was 
significantly different among the treatment groups (one-way ANOVA, P<0.0001). 
Basal release of TXB2 was similar between M and F only in NT aortae. With aortic 
coarctation, basal production of TXB2 was 2-fold higher in F-HT than in M-HT 
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(P<0.05, Table 11 and Fig. 17). Although TXB2 release increased in both sexes, the 
increase with coarctation was 7-fold in F-HT but only 4-fold in M-HT.  
Stimulation of TXB2 release by ANG II in thoracic aortae was significantly 
different in F versus M (1-way ANOVA, P<0.0001).  In NT aortae, ANG II-stimulated 
production in F-NT was twice that of M-NT (P<0.05). Hypertensive aortae also 
exhibited sexual dimorphism in ANG II-induced TXB2 release; thus, release of TXB2 
was 28% higher in F-HT than in M-HT. These data reveal that during the development 
of hypertension, both basal and ANG II-stimulated TXB2 release were upregulated to a 
much greater extent in F-HT than M-HT.   
 
Table 11: Basal and ANG II-stimulated release of TXB2 from thoracic aortic rings.  
Sex Experimental Groups 
Basal TXB2 
(pg/mg) 
Mean ± 
Standard Error 
ANG II-Stimulated 
TXB2 Release (pg/mg) 
Mean ± Standard 
Error 
M Normotensive-Control 17.9 ± 1.0a 41.2 ± 2.8b 
F Normotensive-Control 16.9 ± 1.0 a 67.8 ± 7.3c 
M Aortic Coarctation-Induced Hypertension 65.2 ± 12.4
c 132.0 ± 25.2d 
F Aortic Coarctation-Induced Hypertension 114.7 ± 14.7
d 182.7 ± 14.5e 
The amount of TXB2 released is pg/mg dry weight of thoracic aorta/45 minutes. Data are reported 
as means ± SE, n = 4-7 (n, no. of animals). A-E: Within columns (basal versus ANG II-
stimulation) and rows (experimental groups), mean values without common superscript are 
significantly different, P<0.05.  
 
 
In the continuous, pulsatile flow-pressurized aorta experiments, TXB2 release was similar 
in all groups of NT rat aortae at both 100 and 150 mm Hg (Table 12). Two-way ANOVA 
at 100 mm Hg indicated that no differences were present in any group or over time 
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(P>0.05); however, at 150 mm Hg significant differences were identified among the 
groups (P<0.009) and over time (P<0.05). 
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Figure 17: Basal and ANG II-stimulated release of thromboxane B2 from aortic rings. Rings were 
incubated in vitro in absence (basal) or presence of 10-6 M ANG II (stimulated). TXB2 release is 
expressed per mg aorta dry weight per 45-minute incubation period. Bars represent means ± SE 
(n, no. of animals). A-E: Bars without common script are significantly different, P<0.05. 
 
 
 
 
 
TXB2 was elevated 4-fold or more in the aortae of F-HT and OE-HT rats, 
compared to their normotensive-control counterparts at either 100 mm Hg or 150 mm Hg 
(Figs. 18 and 19). At normotensive pressure (100 mm Hg), F-HT released significantly 
more TXB2 than OVX-HT at 10 and 30 minutes of perfusion, P<0.01, Table 12 and Fig. 
18. At hypertensive conditions (150 mm Hg mean pressure), F-HT released significantly 
more TXB2 than OVX-HT after 30 minutes of continuous perfusion (P=0.02, Fig. 18).   
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TXB2 Release at 100 mm Hg
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Figure 18: Thromboxane B2 release by isolated, perfused thoracic aortae during constant flow 
and at 100 mm Hg pressure over a 30 minute time period. Data points are means ± SE (pg/mg 
aorta dry weight), n = 4-7 (n, no. of animals).  
 
 
 
 
        
TXB2 Release At 150 mm Hg
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Figure 19: Thromboxane B2 release by isolated, perfused thoracic aortae during constant flow 
and at 150 mm Hg mean pressure over a 30 minute time period. Data points are means ± SE 
(pg/mg aorta dry weight), n = 4-7 (n, no. of animals).  
 
 
Ovariectomy clearly impaired the release of TXB2 by the thoracic aorta in 
hypertension, as OVX-HT released half as much TXB2 as did F-HT at either 100 or 150 
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mm Hg. Estrogen replacement restored the release of TXB2, since aortae from OE-HT 
rats released the same or greater amounts of TXB2 as did F-HT (Table 12).  
The effects of estrogen on ANG II-stimulated TXB2 release during continuous 
perfusion and 150 mm Hg pressure were similar to those observed under basal 
conditions. ANG II-stimulated TXB2 release in NT rats was similar (Table 12, Fig, 20). 
In F-HT and OE-HT aortae, ANG II-stimulated TXB2 production was elevated 3-fold 
over their respective NT counterparts, whereas OVX-HT increased TXB2 production 
only 1.5-fold over OVX-NT, Fig. 20. OVX-HT aortae appeared to release less TXB2 
when stimulated with ANG II, compared to F-HT and OE-HT, although the difference 
was not significant (P=0.08), Table 12 and Fig, 20. The dose of ANG II significantly 
affected TXB2 production (2-way ANOVA, P<0.02).  
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Figure 20: ANG II-stimulated TXB2 release from isolated, perfused thoracic aortae at constant 
flow and a mean pulse pressure of 150 mm Hg. Increasing dosages of ANG II were given every 
15 minutes with production of TXB2 determined 15 minutes after each dose of ANG II. Data 
points are means ± SE (pg/mg aorta dry weight/15 minutes), n = 4-7 (n, no. of animals).  
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3.5.2 Prostacyclin (PGI2) 
Basal release of 6-keto-prostaglandin F1α (stable metabolite of PGI2) from aortic 
rings was similar in NT groups. With aortic coarctation, basal production of 6-keto-
prostaglandin F1α was 1.5-fold higher in F-HT than in M-HT (P<0.05, Table 13 and Fig. 
21).   Basal release by F-HT was elevated 5-fold, while M-HT release was elevated only 
3-fold, compared to their respective NT counterparts.                              
There were no differences seen in F-NT or M-NT release of 6-keto-PGF1α with 
ANG II-stimulation (P>0.05). ANG II-stimulated PGF1α release was significantly higher 
(2-fold) in F-HT than in M-HT (P< 0.05, Fig. 21, Table 13). This is in contrast to TXB2 
release in F-NT and M-NT aortae, where both hypertensive and normotensive-control 
groups responded to ANG II-stimulation with increased TXB2 release (Fig. 17). ANG II 
stimulated TXB2 production but not 6-keto-PGF1α in the rat aorta in normotension.  
 
 
 
Table 13: Basal and ANG II-stimulated release of 6-keto-prostaglandin F1α from aortic rings 
incubated for 45 minutes.  
Sex Experimental Groups  
Basal 6-keto-PGF1α 
(pg/mg) 
Mean ± SE 
ANG II-Stimulated 
6-keto-PGF1α 
Release (pg/mg) 
Mean ± SE 
M Normotensive-Control 1540 ± 148a 1577 ± 340a 
F Normotensive-Control 1462 ± 163a 1470 ± 131a 
M Aortic Coarctation-Induced Hypertension 4809 ±1218
b 4534 ± 607bc 
F Aortic Coarctation-Induced Hypertension 7559 ± 943
be 9089 ± 1043e 
Results are expressed as means ± SE (pg/mg aorta dry weight/45 minutes), n = 4-7 (n, no. of 
animals). A-E: Within columns (basal versus ANG II stimulated) and rows (treatment groups), 
mean values without common superscript are significantly different, P<0.05.  
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Figure 21. Basal and ANG II-stimulated 6-keto-prostaglandin F1α release from aortic rings. Data 
are in pg/mg aorta dry weight/ 45 min incubation period. Bars represent means ± SE (n, no. of 
animals). A-C: Bars without common scripts are significantly different, P<0.05. 
 
 
 
 
In the continuous, pulsatile flow-pressurized aorta experiments, 6-keto-PGF1α 
production was similar among all NT aortae at both 100 and 150 mm Hg (P>0.05). 6-
keto-PGF1α was elevated 3-fold or more in the F-HT and OE-HT aortae compared to 
their normotensive-control counterparts at either 100 mm Hg or 150 mm Hg (Fig. 22). 
Under normotensive pressure (100 mm Hg), F-HT produced significantly more 6-keto-
PGF1α than OVX-HT (P<0.05). Under hypertensive conditions (150 mm Hg mean 
pressure), F-HT produced significantly more 6-keto-PGF1α than OVX-HT after 30 
minutes of continuous perfusion (P<0.05).  Similar to the effects on TXB2, ovariectomy 
clearly impaired the release of 6-keto-PGF1α by the thoracic aorta in hypertension, as 
OVX-HT released less than half the amount of 6-keto-PGF1α released by F-HT at either 
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100 or 150 mm Hg. Estrogen replacement restored thoracic aortic production of 6-keto-
PGF1α, since OE-HT released similar amounts of 6-keto-PGF1α as F-HT (Table 14).  
Treatment group (F-HT, OVX-HT, OE-HT, F-NT, OVX-NT, OE-NT) had a 
significant effect on 6-keto-PGF1α (P<0.0002) whereas dose of ANG II did not (P>0.05, 
2-way ANOVA). At the highest ANG II dose (0.1 nmol), 6-keto-PGF1α release was 
significantly different between the treatment groups via one-way ANOVA (P=0.02), Fig. 
23. F-HT released more 6-keto-PGF1α than did F-NT in response to 0.1 nmol ANG II; 
however, ovariectomy abolished this response. (Table 14). Estrogen again restored the 
increased production of 6-keto-PGF1α  to 0.1 nmol ANG II, with OE-HT producing more 
6-keto-PGF1α  than OE-NT (P<0.05) as shown in Fig. 23.  
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Figure 22: 6-keto-Prostaglandin F1α release during constant flow and pressure (either 100 mm 
Hg or 150 mm Hg) in pg/mg aorta dry weight/30 minutes. Bars represent means ± SE, n = 4-7 (n, 
no. of animals). A-B: Bars without common script are significantly different, P<0.05. 
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Figure 23: 6-keto-prostaglandin F1α release during constant flow and pressure (150 mm Hg) from 
thoracic aortae stimulated with increasing doses of ANG II. Data points are means ± SE (pg/mg 
aorta dry weight/15 minutes) (post-ANG II administration to perfusate), n = 4-7 (n, no. of 
animals).  
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3.6 Effects of Aortic Coarctation on the Pressure-Diameter Relationship of the 
Thoracic Aorta in Response to Angiotensin II 
The aortic diameter was determined off-line from videotapes of the in vitro constant 
pressure/flow experiments with the thoracic aorta. A micrometer was recorded on the 
video at the beginning of each experiment in order to determine diameters accurately. 
Pressures and diameters were compared for each group: F-HT, OVX-HT, OE-HT, F-NT, 
OVX-NT, and OE-NT. Pressurization of the aortae to different degrees of distention 
resulted in increases in the diameters of the vessels. The increases in diameter were 
significantly less in F-HT and OE-HT aortae (P<0.05, Fig. 24).  
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Figure 24: Pressure-diameter relationships of in vitro continuous flow experiments in the 
thoracic aortae of NT and HT rats. Each aorta was pressurized to 150 mm Hg before ANG II 
administration and the diameter recorded (1). ANG II (0.005 nmol) was administered and the 
pressure and diameter recorded using a computer and video camera (2).  
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Aortae from OVX-HT rats had the largest increase in diameter with initial 
pressurization (Fig. 24), with little change occurring with ANG II stimulation. All groups 
exhibited increases in diameter with ANG II stimulation; however, after the data were 
normalized, two-way ANOVA did not detect any significant differences among doses or 
groups (P>0.05, Fig. 25). No differences were identified between any of the groups with 
the 0.005 or 0.02 nmol doses of ANG II (P>0.05). However, at the highest dose of ANG 
II (0.1 nmol), OE-HT and OE-NT aortae had increases in diameter compared to F-HT/ F-
NT and OVX-HT/OVX-NT (P<0.05, Fig 25).   
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Figure 25: Aortic diameter 15 minutes after each dose of ANG II (0.005, 0.02, and 0.1 nmol). 
The data were normalized by subtracting the initial diameter (before each ANG II dose) from the 
end diameter and dividing the result by the initial diameter. A-D: For each experimental 
treatment, mean values without common superscript are significantly different, P<0.05. 
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Peak pressures attained by the aortae at increasing doses of ANG II are shown in 
Fig. 26. ANG II stimulation affected peak pressures attained by the aortae with increasing 
dose (2-way ANOVA, dose x experimental group, P<0.003). OE-HT aortae developed 
the highest peak pressure (191 ± 10), while F-NT developed the lowest (161 ± 7). 
Estrogen replacement restored the responses to ANG II and the pressure of OE-HT was 
elevated compared to F-HT at 0.005 and 0.1 n mol ANG II (P<0.03). 
 
 
Peak Pressure with Angiotensin II
0
50
100
150
200
F-HT OVX-HT OE-HT F-NT OVX-NT OE-NT
m
m
 H
g
0.005 nMol 0.02 nMol 0.1 nMol
A A A AB AB AB
B AB B
AB
AB AB
AB AB AB AB AB AB
 
Figure 26: Dose responses of thoracic aortae under constant flow conditions and challenged with 
increasing doses of ANG II (0.005, 0.02, and 0.1 nmol). Prior to ANG II administration, the 
pressure was set to approximately 150 mm Hg. Bars represent means ± SE, n = 3-7 (n, no. of 
animals). A-B: Bars without common script are significantly different, P<0.05. 
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Figure 27 shows the changes in diameter that occurred when the aortae were 
pressurized to 150 mm Hg (but prior to ANG II stimulation) under constant flow. In 
general, there was a significant change in diameter when the aortae were pressurized 
(one-way ANOVA, P<0.008). NT aortae had similar increases in diameter with 
pressurization to 150 mm Hg; however, OE-NT exhibited smaller changes in diameter 
than did F-NT (P<0.05). In the hypertensive groups, F-HT and OE-HT demonstrated 
significantly smaller increases in diameter with pressurization than their respective NT 
control groups (P<0.02). This is in contrast to OVX-HT, which showed similar increases 
in diameter as OVX-NT. Ovariectomy resulted in a significant increase in diameter with 
pressurization (OVX-HT) compared to F-HT (P<0.04). The effect of OVX was 
eliminated with estrogen replacement (i.e., OE-HT had less of an increase in diameter 
than OVX-HT).  
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Figure 27: Changes in diameter with pressurization to 150 mm Hg. The diameter of the aorta was 
determined before pressurization and during constant flow and pressure (150 mm Hg) and before 
ANG II was administered to determine changes in diameter with loading. The data were 
normalized by subtracting the initial diameter (before pressurization) from the pressurized 
diameter and the result divided by the initial diameter. Bars represent means ± SE, n = 3-7 (n, no. 
of animals). A-C: Bars without common script are significantly different, P<0.05. 
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3.7 Effects of Aortic Coarctation on Expression of Thromboxane Synthase Enzyme  
 
3.7.1 Immunohistochemistry 
The presence of the TXA2 synthase enzyme in situ was investigated using 
immunohistochemistry of thoracic aortic segments (one-way ANOVA, P<0.02). All NT 
groups had similar in-situ staining intensity for thromboxane synthase enzyme (P>0.05), 
Figs. 28 and 29. Induction of hypertension increased staining for the enzyme significantly 
in F-HT and OE-HT (P<0.04), whereas M-HT and OVX-HT did not differ compared to 
their respective NT controls, despite the development of hypertension (P>0.05). 
Ovariectomy not only abolished any response to aortic coarctation, but it also reduced the 
content of the enzyme in OVX-NT aortae as well. Estrogen replacement restored TXA2 
synthase enzyme levels in both OE-HT and OE-NT. 
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Figure 28: Intensity of staining of thoracic aortae for the thromboxane synthase enzyme using 
immunohistochemistry. Staining intensity was scored on a relative scale, from 4 (most intense) to 
0 (least intense). Bars represent means ± SE, n = 4-10 (n, no. of animals). A-E: Bars without 
common script are significantly different, P<0.05. 
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Figure 29: Immunohistochemistry of 4 µm sections of thoracic aortae.
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3.7.2 RT-PCR Results 
The expression of thromboxane synthase enzyme (TXS) RNA was determined by 
RT-PCR of TXS mRNA and expressed relative to the mRNA of the housekeeping gene 
GAPDH as shown in Figure 30. A marked sexual dimorphism was present in the 
expression of TXS mRNA in both NT and HT groups (one-way ANOVA P<0.015). In 
the NT groups, both F-NT and OE-NT exhibited significantly more enzyme mRNA in 
their endothelium than M-NT (P<0.05). In the HT groups, F-HT expressed significantly 
more mRNA than did M-HT (P<0.03, Table 15). Ovariectomy abolished the differences 
in mRNA expression between F-HT and M-HT, as OVX-HT and M-HT were similar 
(P>0.05).  
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Figure 30: RT-PCR of thromboxane synthase enzyme expression in the endothelium of the 
thoracic aortae of HT and NT rats. mRNA is expressed as a ratio with GAPDH mRNA. Bars 
represent means ± SE, n = 4-5 (n, no. of animals). A-G: Bars without common script are 
significantly different, P<0.05. 
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Estrogen replacement restored enzyme mRNA expression, and OE-HT had significantly 
more mRNA than M-HT or OVX-HT (P =0.02). 
 
 
Table 15: Thromboxane synthase mRNA content of aortic endothelium and vascular smooth 
muscle, normalized by expression of mRNA of the housekeeping gene GAPDH, obtained by RT-
PCR.  
Aorta Thromboxane Synthase mRNA via RT-PCR 
Group 
Endothelium % 
Thromboxane 
Synthase/GAPDH 
Smooth Muscle % 
Thromboxane 
Synthase/GAPDH 
Female 
Hypertensive n=4 2.16 ± 0.97
a 2.27 ± 1.34a 
Male Hypertensive 
n=4 0.25 ± 0.14
b 0.38 ± 0.19b 
OVX Hypertensive 
n=4 0.44 ± 0.19
abc 0.88 ± 0.45ac 
OE Hypertensive 
n=5 2.87 ± 1.62
ad 1.55 ± 0.15abd 
Female 
Normotensive 
Control n=5 
0.83 ± 0.20acde 0.60 ± 0.16ace 
Male Normotensive 
Control n=4 0.23 ± 0.17
bcf 0.13 ± 0.05bcf 
OVX Normotensive 
Control n=5 0.33 ± 0.25
bcefg 0.24 ± 0.45bcfg 
OE Normotensive 
Control n=4 0.76 ± 0.20
acdegh 0.52 ± 0.06ceh 
Data are reported as means ± SE; n, no. of animals. A-H: Within rows (treatment groups) and 
columns (endothelium versus smooth muscle), mean values without common superscript are 
significantly different, P<0.05. 
 
 
 
 
 
In vascular smooth muscle, Fig. 31 below, striking sexual dimorphism in 
thromboxane synthase enzyme expression was observed, similar to that found in the 
endothelium (one-way ANOVA, P<0.003). F-NT expressed higher levels of mRNA for 
the thromboxane synthase enzyme than M-NT or OVX-NT aortae (P<0.03). Estrogen 
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supplementation restored the mRNA expression that was lost in OVX-NT aortae (OE-
NT, P<0.05, Table 15). In addition, estrogen supplementation in the OE-HT group 
induced higher levels of mRNA than the OE-NT counterpart (P=0.008).  
As with the endothelium in hypertension, vascular smooth muscle expressed 
significantly more thromboxane synthase mRNA in F-HT than in M-HT (P=0.03) and 
this effect was abolished by ovariectomy (OVX-HT, Table 15 and Fig. 32). OE-HT 
expressed more mRNA than M-HT, providing further evidence that estrogen enhances 
the expression of thromboxane synthase mRNA in females during hypertension.   
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Figure 31: RT-PCR of thromboxane synthase enzyme expression in the vascular smooth muscle 
of the thoracic aortae of hypertensive and normotensive-control rats. Bars represent means ± SE, 
n = 4-5 (n, no. of animals). A-F: Bars without common script are significantly different, P<0.05. 
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Figure 32: Representative example of gel from RT-PCR analysis of TXA2 synthase and GAPDH 
in endothelial and vascular smooth muscle cells. Each lane from left to right is: DNA fragment 
ladder, endothelial GAPDH from OVX-HT, endothelial TXA2 synthase from OVX-HT, vascular 
smooth muscle GAPDH from OVX-HT, vascular smooth muscle TXA2 synthase from OVX-HT, 
endothelial GAPDH from OE-HT, endothelial TXA2 synthase from OE-HT, vascular smooth 
muscle GAPDH from OE-HT, vascular smooth muscle TXA2 synthase from OE-HT.  
 
 
 
3.8 Effects of Aortic Coarctation on Aortic Morphology 
3.8.1 Aortic Wall Thickness, Area, and Wall: Lumen Area Ratio 
 Aortic wall thickness is the cross-sectional wall thickness (mm) and aortic wall 
area is the area of the vessel wall in cross-section (mm2), while aortic wall to lumen ratio 
is the ratio of the areas of the wall and lumen. All values were normalized by body 
weights of the individual rats in grams. See Table 16 for statistical results. 
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Figure 33: Aortic wall cross-sectional thickness in mm x 10-4. Bars represent means ± SE, n = 4-
13 (n, no. of animals). A-G: Bars without common script are significantly different, P<0.05. 
 
 
 
A significant sexual dimorphism was identified in relative aortic wall thickness in 
both NT and HT groups as shown in Fig. 33 (one-way ANOVA, P<0.002). In 
normotension, the aortic wall was thicker in F-NT than in M-NT and this difference was 
abolished by ovariectomy (OVX-NT). Estrogen replacement restored the difference in 
wall thickness in OE-NT aortae (Table 16). Remarkably, M-NT had the thinnest aortic 
wall compared to any of the other NT or HT groups (P<0.05).  
In hypertension, wall thickness of the OVX-HT aortae was less than either F-HT 
or OE-HT (P<0.05). Wall thickness of M-HT and F-HT aortae were significantly greater 
than their respective NT groups (P<0.05). This response to aortic coarctation was 
abolished by ovariectomy (OVX-HT versus OVX-NT, P>0.05). Estrogen replacement in 
OVX rats restored the increase in wall thickness in response to HT in OE-HT aortae (OE-
HT versus OE-NT, P<0.05).  
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Table 16: Aortic morphology of HT and NT rats following aortic coarctation or sham surgery.  
Aortic Wall Thickness, Area, and Ratio of Wall to Luminal Areas 
Group 
Ridogrel 
Administered
?  (+/-) 
Aorta Wall 
Thickness (mm 
x 10-4) 
Aorta Wall Area 
(mm2 x 10-4) 
Wall Area: 
Luminal Area 
(ratio) 
+  6.0 ± 0.3abd 28.9  ± 1.5abcd 0.0019  ± 0.0001adei Female Hypertensive 
n= 13 - 6.1 ± 0.4a 30.8 ± 1.5a 0.0019 ± 0.0002a 
+ 4.6 ± 0.4abce 25.6 ± 2.0abcdij 0.0013 ± 0.0001abceghi Male Hypertensive 
n= 5 - 4.9 ± 0.5ab 26.0 ± 2.8ab 0.0014 ± 0.0002ab
+ 4.6 ± 0.2abceghjk 24.6 ± 0.1abcdijk 0.0014 ± 0.0001abcdeghijk OVX Hypertensive 
n= 6 - 4.2 ± 0.4bc 23.4 ± 3.2bc 0.0012 ± 0.0001bc
+ 5.7 ± 0.2abd 31.4 ± 2.1abcdijk 0.0018 ± 0.0001abdi OE Hypertensive 
n= 5 - 5.7 ± 0.2abd 28.9 ± 1.8abcd 0.0017 ± 0.0001bd
+ 4.0 ± 0.5bceghkl 22.4 ± 1.4bceghijkl 0.0014 ± 0.0001abceghjkl Female Normotensive 
Control n=12 - 4.5 ± 0.3bce 20.8 ± 1.0bce 
0.0013 
±0.0001bcde 
+ N/A N/A N/A Male 
Normotensive 
Control   n= 4 - 2.3 ± 0.2f 14.7 ± 0.9f 0.0007 ± 0.0007f 
+ 3.9 ± 0.3bceghl 19.6 ± 0.6bceghl 0.0011 ± 0.0000bcghj OVX Normotensive 
Control   n= 4 - 3.4 ± 0.4cg 16.6 ± 1.9cfg 0.0011 ± 0.0002bcefg 
+ 4.9 ± 0.4abcdeghijkl 23.5 ± 0.6
bcdeijk 0.0015 ± 0.0001abceghl OE Normotensive 
Control   n= 4 - 4.0 ± 0.2bcegh 19.2 ± 1.2cegh 0.0012 ± 0.0001bcegh 
Values are means ± SE, n, no. of animals. A-L: Within columns for each morphologic parameter, 
mean values of treatment groups without common superscript are significantly different, P<0.05
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A clear sexual dimorphism was identified in both NT and HT groups for relative 
aortic wall area, as shown in Fig. 34 (one-way ANOVA, P<0.0001). In normotension, F-
NT exhibited a larger wall area than M-NT and this difference was abolished by 
ovariectomy (OVX-NT), but restored by estrogen replacement in OE-NT aortae (Table 
16). M-NT and OVX-NT had the smallest aortic wall areas compared to any of the other 
NT or HT groups (P<0.05).  
Aortic wall area increased with hypertension, and both M-HT and F-HT exhibited 
significant increases in aortic wall area (P<0.05) and abolished the M-F difference in 
aortic wall area in HT rat aortae. This response to aortic coarctation was abolished by 
ovariectomy (OVX-HT versus OVX-NT, P>0.05), and estrogen replacement of OVX rats 
restored the increase in wall area in OE-HT rats (P<0.05).  
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Figure 34: Cross-sectional aortic wall area in mm2 x 10-4 per gram body weight. Bars represent 
means ± SE, n = 4-13 (n, no. of animals). A-G: Bars without common script are significantly 
different, P<0.05. 
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Figure 35 shows the wall: luminal area ratios, which also exhibited sexual 
dimorphism (one-way ANOVA, P<0.0001). Among the NT groups, M-NT exhibited the 
smallest wall to luminal ratio (P<0.05, Fig. 35). In the HT groups, OVX-HT had the 
smallest ratio (P<0.05). Wall to luminal area ratios increased significantly in M-HT and 
F-HT compared to their NT counterparts (P<0.02). This effect was abolished in females 
by ovariectomy, as OVX-HT had a similar ratio to OVX-NT (P>0.05). The increase in 
ratio seen in F-HT was restored in OE-HT by estrogen supplementation (P<0.02). F-HT 
and OE-HT ratios were greater than OVX-HT (P<0.05, Fig. 35).   
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Figure 35:  Aortic wall: lumen area ratios. Bars represent means ± SE, n = 4-13 (n, no. of 
animals). A-G: Bars without common script are significantly different, P<0.05. 
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3.8.2 The Effect of Ridogrel on Aortic Wall Thickness, Area, and Wall to Luminal 
Area Ratio 
The contrasting effects of Ridogrel and vehicle-control treatments on aortic 
thickness are shown in Figure 36a. Ridogrel treatment did not abolish the sexual 
dimorphism found in aortic thickness (one-way ANOVA, P<0.001). With the exception 
of OE-NT, aortic thickness of NT groups was not affected by Ridogrel administration 
(P>0.05), Tables 16 and 17 and Fig. 36a. OE-NT exhibited an increase in aorta thickness 
(mm2/gram body weight) with the administration of Ridogrel (P<0.04). Similar to the 
vehicle-control treated groups (see Section3.8.1 above and Fig. 36a), F-HT and OE-HT 
exhibited aortic walls thicker than those of M-HT and OVX-HT rats (P<0.04). F-HT, 
OVX-HT, and OE-HT rats developed increased wall thicknesses with aortic coarctation 
despite Ridogrel administration (P<0.05, Fig. 36a). Estrogen replacement restored the 
sexual dimorphism in aortic wall thickness in OE-HT that was reduced by OVX and was 
not affected by TXB2 receptor and synthase inhibition with Ridogrel. 
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F-HT M-HT OVX-
HT
OE-HT F-NT OVX-
NT
OE-NT
Control
Ridogrel
0.0
2.0
4.0
6.0
8.0
Mean Aortic Wall Thickness (mm x10-4)
Control 6.1 4.9 4.2 5.7 4.5 3.4 4.0
Ridogrel 6.0 4.6 4.6 5.7 4.0 3.9 4.9
F-HT M-HT OVX-HT OE-HT F-NT OVX-NT OE-NT
 
(a) 
F-HT M-HT OVX-
HT
OE-HT F-NT OVX-
NT
OE-NT
Control
Ridogrel
0.0
10.0
20.0
30.0
Mean Aortic Wall Area (mm2 x 10-4)
Control 30.8 26.0 23.4 28.9 20.8 16.6 19.2
Ridogrel 28.9 25.6 24.6 31.4 22.4 19.6 23.5
F-HT M-HT OVX-HT OE-HT F-NT OVX-NT OE-NT
 
(b) 
Figure 36: Aortic morphology with and without Ridogrel (a: wall thickness in cross-section, mm; 
b: wall area in cross-section, mm2, c: wall to luminal ratio). All values were normalized by 
dividing the parameter by the weight of the rat in grams. Bars represent means ± SE, n = 4-13 (n, 
no. of animals).  
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F-HT M-HT OVX-HT OE-HT F-NT OVX-NT OE-NT
Control
Ridogrel
0.0000
0.0004
0.0008
0.0012
0.0016
0.0020
Mean Aortic Wall:Lumen Ratio
Control 0.0019 0.0014 0.0012 0.0017 0.0013 0.0011 0.0012
Ridogrel 0.0019 0.0013 0.0014 0.0018 0.0014 0.0011 0.0015
F-HT M-HT OVX-HT OE-HT F-NT OVX-NT OE-NT
 
(c) 
Figure 36 (continued) 
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Changes in aortic wall area in response to Ridogrel or vehicle-control treatments are 
shown in Fig. 36b and Table 18. The observed sexual dimorphism in wall area with HT 
remained despite Ridogrel treatment (one-way ANOVA, P<0.001). Ridogrel 
administration resulted in larger aortic areas in OE-NT compared to OVX-NT (P<0.002); 
otherwise, there were no significant differences in the NT groups with Ridogrel versus 
vehicle (P>0.05). All HT groups exhibited increases in aortic area compared to their 
respective NT counterparts (P<0.02). Wall area did not differ between F-HT and M-HT 
with Ridogrel, which was similar to F-HT and M-HT groups that received the vehicle-
control (P>0.05). However, OE-HT exhibited a larger wall area than M-HT only when 
Ridogrel was administered (P<0.05). Both Ridogrel and vehicle-treated F-HT and OE-HT 
animals showed increased aortic wall areas compared to OVX-HT (P<0.05) indicating 
estrogen’s effect on aortic wall area in hypertension was not inhibited and may be 
enhanced by TXB2 receptor and synthase inhibition with Ridogrel (Table 18). 
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Aortic wall area: lumen area ratios with Ridogrel and vehicle -control treatments 
are shown in Fig. 36c. The observed sexual dimorphism in aortic wall: lumen area ratio 
remained following aortic coarctation even with Ridogrel administration (one-way 
ANOVA, P<0.001). No significant differences were observed among the wall: lumen 
ratios in any of the treatment groups with administration of Ridogrel (P>0.05, when 
Ridogrel treatment was compared to vehicle-control treatment for each group, Table 19). 
In the Ridogrel and vehicle-control groups, both F-HT and OE-HT exhibited elevated 
ratios compared to M-HT and OVX-HT aortae (P<0.02). No differences were observed in 
ratios of M-HT and OVX-HT aortae (P>0.05). There was a significant difference 
between the ovariectomized groups, however. Without Ridogrel OVX-HT did not differ 
from OVX-NT, but with Ridogrel, the wall: lumen ratio of OVX-HT rats was 
significantly higher than that of OVX-NT rats (P<0.03).  In the absence of ovarian 
steroids (OVX), Ridogrel increased the aortic ratio with the induction of HT; however, 
when estrogen or testosterone was present (F, M and OE), Ridogrel had no effect (Table 
19).
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3.9 Effects of Aortic Coarctation on Aortic Collagen and Elastin  
3.9.1 Collagen and Elastin Density  
Aortic collagen density following aortic coarctation is shown in Figs. 37 and 
38.The effects of Ridogrel on aortic collagen and elastin will be addressed in Section 
3.9.2 below. Significant differences in collagen density of the thoracic aortae were 
observed (one-way ANOVA, P<0.004). If all groups of rats were compared excluding 
male rats, significant differences were still present (one-way ANOVA, P<0.003). Aortic 
collagen density was similar among NT groups of rats. F-HT increased in collagen 
content with aortic coarctation compared to the F-NT control (P<0.016). In females, 
ovariectomy abolished collagen responses to HT, since collagen density in OVX-HT 
remained unchanged after coarctation compared to OVX-NT aortae. Estrogen 
replacement in OE-HT rats restored the response to coarctation lost with OVX, resulting 
in an increase in collagen (P<0.016). Collagen density was significantly higher in F-HT 
than in M-HT or OVX-HT (P<0.04), but F-HT and OE-HT exhibited similar densities 
(P>0.05). See Tables 20 and 21.  
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Figure 37: Collagen density following aortic coarctation-induced hypertension. Normotensive-
control males were not administered Ridogrel. Bars represent means ± SE, n = 4-7 (n, no. of 
animals). A-M: Bars without common script are significantly different, P<0.05. 
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FHT  M-HT  OVX-HT OE-HT 
 
 
 
  F-NT  M-NT  OVX-NT OE-NT 
 
   
  
Ridogrel F-HT     Ridogrel M-H         Ridogrel OVX-HT Ridogrel OE-HT 
 
 
 
Ridogrel F-NT        Ridogrel OVX-NT Ridogrel OE-NT 
        
 
 
Figure 38: Movat’s stain for elastin and collagen density. Elastin stains black to dark purple and 
collagen stains yellow. Note the yellow appearance of F-HT and OE-HT aortae compared to their 
respective controls (F-NT and OE-NT) and the other hypertensive aortae: M-HT and OVX-HT. 
Aortae of Ridogrel-treated F-HT and OE-HT rats exhibited much less collagen staining than F-
HT and OE-HT not treated with Ridogrel.  
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Table 21: Aortic elastin and collagen densities and collagen: elastin ratio of HT and NT aortae. 
Aorta Elastin Density, Collagen Density, and Collagen: Elastin Ratio 
Mean ± SE 
Group Ridogrel ?  (+/-) 
Elastin Density (% 
of Wall) 
Collagen Density 
(% of Wall) 
Collagen: Elastin 
(ratio) 
+ 32.1 ± 3.9a 5.0 ± 0.5a 0.16 ± 0.02a Female Hypertensive 
n=4-7 - 53.3 ± 2.3b 18.7 ± 5.5b 0.35 ± 0.10ab 
+ 33.4 ± 3.9ac 3.5 ± 1.1ac 0.11 ± 0.04ac Male Hypertensive 
n=4-7 
- 37.3 ± 3.5acd 7.8 ± 3.2acd 0.26 ± 0.09abcd 
+ 27.6 ± 2.4ace 2.2 ± 0.2ce 0.08 ± 0.01cdeOVX Hypertensive 
n=4-6 - 46.9 ± 3.7df 2.8 ± 1.5acde 0.06 ± 0.03cef
+ 24.0 ± 2.1aeg 2.3 ± 0.5cdef 0.10 ± 0.03acdefg 
OE 
Hypertensive 
n=5 
- 34.4 ± 3.5cdeh 11.3 ± 1.8bdg 0.36 ± 0.09bdh
+ 32.5 ± 6.3acdeghi 5.4 ± 1.2
acdeh 0.19 ± 0.06abcdeghi 
Female 
Normotensive 
Control n=4-
7 - 39.6 ± 3.7acdehij 4.6 ± 1.3acdefhi 0.11 ± 0.02acdefgij 
+ 34.5 ± 3.5adcehijk 6.1 ± 2.1
abcdeghij 0.17 ± 0.06abcdeghij 
OVX 
Normotensive 
Control n=4 
- 41.9 ± 7.3acdefhijkl 4.5 ± 1.8
acdefhijk 0.12 ± 0.06abcdefgijk 
+ 30.2 ± 2.9acdeghijklm 4.8 ± 1.5
acdefhijkl 0.17 ± 
0.02abcdefghijkl 
OE 
Normotensive 
Control n=4 
- 46.2 ± 9.0abcdfhijklmn 2.2 ± 0.4
cdefijk 0.06 ± 0.02cdefgjklm 
+ N/A N/A N/A Male 
Normotensive 
Control n=4 - 47.2 ± 7.1bcdfhijkln 3.7 ± 0.6
acdefhijkl 0.09 ± 
0.02cdefgijklm 
Data are reported as means ± SE; n, no. of animals. A-N: Within columns only for each 
experimental treatment, mean values without common superscript are significantly different, 
P<0.05. 
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Aortic elastin density following aortic coarctation is shown in Figs. 38 and 39, 
and in Tables 21 and 22. Significant differences in elastin density of the thoracic aortae 
were seen (one-way ANOVA, P<0.05). When all female groups were compared 
(excluding all male rats), significant differences persisted (one-way ANOVA, P<0.04). 
Aortic elastin density was similar among all NT groups of rats. Among the HT groups, F-
HT increased in elastin content with aortic coarctation compared to the F-NT control 
(P<0.05). OVX-HT also increased elastin content compared to OVX-NT (P<0.02). 
Estrogen replacement in OE-HT rats did not increase elastin (P>0.05), indicating elastin 
content is not dependent upon estrogen. M-HT elastin content did not differ from M-NT, 
either. Among the HT groups, F-HT had the highest elastin content (P<0.05).   
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Figure 39: Elastin density following aortic coarctation or sham surgery. Bars represent means ± 
SE, n = 4-7 (n, no. of animals). A-N: Bars without common script are significantly different, 
P<0.05.
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Aortic collagen: elastin density ratios following aortic coarctation .are shown in 
Figs. 38 and 40, and in Tables 21 and 23. Aortic collagen: elastin ratio was significantly 
different among the treatment groups (one-way ANOVA, P<0.015). Significant 
differences were present among the female groups even without the influence of the male 
groups (one-way ANOVA, P<0.006). The ratio was similar among all NT groups of rats 
(P>0.05). In, the HT groups, F-HT increased in collagen: elastin ratio with aortic 
coarctation compared to F-NT (P<0.05). In F, ovariectomy abolished the response to HT 
with respect to collagen: elastin ratio since the ratio in OVX-HT remained unchanged 
after coarctation compared to OVX-NT aortae (P>0.05).  
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Figure 40: Collagen: elastin ratio following aortic coarctation or sham surgery. Bars represent 
means ± SE, n = 4-7 (n, no. of animals). A-N: Bars without common script are significantly 
different, P<0.05. 
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Estrogen replacement in OE-HT rats restored the response to coarctation with an 
increase in collagen: elastin ratio (P<0.05). Collagen: elastin ratio was significantly 
higher in F-HT, M-HT and OE-HT compared to OVX-HT (P<0.01).  
 
 3.9.2 The Effects of Ridogrel on Collagen and Elastin Density in Aortic Coarctation 
See Figs. 37,38, and 39 and Tables 20, 21, 22, and 23 for elastin density, collagen 
density, and collagen: elastin ratio with the administration of Ridogrel, the thromboxane 
synthase inhibitor/thromboxane-endoperoxide receptor antagonist. Ridogrel treatment 
during the 14 days following aortic coarctation had no effect on collagen, elastin or 
collagen: elastin ratios in the NT groups (P>0.05). Ridogrel was not administered to M-
NT rats.  
Ridogrel administration abolished any differences in collagen density (one-way 
ANOVA, P>0.05). Ridogrel significantly reduced collagen density in F-HT aortae 
(P<0.05), so that the density was similar to F-NT (P>0.05). Ridogrel had no effect on 
collagen density in M-HT or OVX-HT when compared to same groups that received only 
vehicle (P>0.05). Estrogen supplementation restored the effects of Ridogrel on collagen 
density in OE-HT in that the collagen density was significantly less than OE-HT 
receiving vehicle (P<0.05), and similar to OE-NT treated with Ridogrel or vehicle 
(P>0.05). Even with the administration of Ridogrel, F-HT still exhibited elevated 
collagen density compared to OVX-HT treated with Ridogrel (P<0.02). Ovariectomy 
effectively abolished any changes in collagen density of the aorta whether or not the rats 
were hypertensive or treated with Ridogrel.  
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Ridogrel administration abolished any differences in elastin density (one-way 
ANOVA, P>0.05) and this effect remained even if all males were excluded from analysis 
(one-way ANOVA, P>0.05). Ridogrel did not affect elastin density in any of the NT 
groups (P>0.05). Elastin content of M-HT aortae was not affected by Ridogrel (P>0.05). 
Ridogrel treatment did prevent hypertension-induced increases in elastin density in F-HT, 
OVX-HT or OE-HT aortae (P<0.02).  
 As with elastin density, Ridogrel administration abolished any differences in 
collagen: elastin ratios (one-way ANOVA, P>0.05) and this effect remained even if only 
the female groups were compared (one-way ANOVA, P>0.05). Ridogrel administration 
did not affect collagen: elastin ratios in any of the NT groups (P>0.05, Fig. 40). F-HT 
exhibited a similar ratio with Ridogrel or vehicle treatment (P>0.05), as did M-HT and 
OVX-HT. Conversely, OE-HT exhibited a much smaller ratio with Ridogrel treatment 
than with vehicle treatment (P<0.004). In the HT groups treated with Ridogrel, F-HT had 
a higher ratio than OVX-HT (P=0.014). Estrogen replacement did not restore the elevated 
ratio in OE-HT Ridogrel-treated rats, indicating again that collagen density is likely 
estrogen- and TXB2-dependent while elastin density may only be TXB2- (but not 
estrogen)-dependent. 
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CHAPTER IV 
 
 
SUMMARY AND DISCUSSION 
 
 
 
 
 This study investigated the effects of estrogen on CP function and the 
development of aortic coarctation-induced hypertension. The central hypothesis tested 
was that ovarian steroid hormones upregulate CP function in the female rat aorta during 
the development of aortic coarctation-induced hypertension, thereby altering the 
functional and structural responses of the aorta to a greater extent in female than in male 
rats. If so, then CP-mediated changes in vascular reactivity, vascular structure, and 
systemic blood pressure during the development of aortic coarctation-induced 
hypertension would play a larger role in female than in male rats. Indeed, significant 
sexual dimorphism in the development of aortic coarctation-induced hypertension was 
identified at 12-14 days following aortic coarctation. There was a significant increase in 
MAP in both male and female rats; however, MAP increased to a much greater extent in 
female than in male rats. Ovariectomy abolished, and estrogen-replacement restored, the 
observed sex differences in MAP.  
Confirming the greater role of CP in females during the development of aortic-
coarctation-induced hypertension, release of the CP TXA2 in vitro was markedly higher 
in F-HT than in M-HT or OVX-HT. In vivo blockade of the thromboxane/endoperoxide 
receptor acutely (with SQ 29,548) or chronically (with Ridogrel which also blocked 
thromboxane synthase) resulted in a significantly lower MAP in F-HT than in M-HT or 
OVX-HT. Physiological estrogen replacement restored CP function and hypertension in 
OE-HT rats to levels indistinguishable from those of F-HT rats. Expression of the 
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enzyme responsible for TXA2 production, thromboxane synthase, was elevated to a much 
greater extent in both endothelial and vascular smooth muscle cells in F-HT than in M-
HT or OVX-HT aortae, explaining, at least in part, the enhanced release of TXA2 and the 
greater response to CP antagonism observed in F-HT and OE-HT.  Upregulation of the 
CP pathway also resulted in morphologic changes in the aortae of F-HT rats; but perhaps 
most strikingly, it also resulted in increased collagen and elastin density with an elevated 
collagen: elastin ratio in the aortic wall. Upregulation of the TXA2 pathway and the 
resultant morphologic changes identified in aortae from F-HT and OE-HT rats are 
consistent with the higher MAP present in these rats compared to either M-HT or OVX-
HT rats.  
 
4.1 Effects of Aortic Coarctation-Induced Hypertension on Mean Arterial Blood 
Pressure 
The present study revealed that MAP was significantly higher in female than in 
male rats 12 to 14 days following aortic coarctation. The elevation in blood pressure in 
female rats was abolished by OVX, but was restored by estrogen replacement, revealing 
that estrogen plays a key role in the development of this form of HT in female rats. 
Similar to the findings in the male rat in the present study, previous investigators 
reported that arterial pressure peaked at 4-6 days post-coarctation and then declined to a 
stable MAP of approximately 160 mm Hg by 14 days (64; 148).  A peak and subsequent 
decline in MAP was not observed in female or OVX rats; instead, a steady increase in 
MAP was measured over the 14 day period. Indeed, female rats exhibited a lower MAP 
during the first week following aortic coarctation compared to males; however, MAP 
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increased dramatically during the second week. In addition to the estrogen-dependent 
contribution of CP to the elevated MAP, female rats may also produce more ANG II due 
to the effects of estrogen on the renin angiotensin system. Hypertensive women receiving 
estrogen replacement therapy develop elevations in plasma renin activity, and in plasma 
ANG I and ANG II levels (258).  At the molecular level, estrogens may stimulate 
angiotensinogen synthesis 2-fold (34; 136) more in females than in males and  estrogen-
responsive elements (DNA sequences that bind the estrogen-estrogen receptor dimer) 
have been identified in the 5’ flanking region of the rat angiotensinogen gene (7). 
Functionally, when estradiol is administered to ovariectomized rats, there is also a 
significant increase in the vasopressor response to angiotensin II (compared to 
ovariectomized controls) (219). 
Previous studies of aortic coarctation-induced hypertension have not examined 
arterial blood pressure in female rats, with the exception of two short-term investigations. 
A single study of the acute effects of estrogen 45 minutes after partial acute aortic 
coarctation revealed that in OVX rats, estrogen increases the sensitivity of the carotid 
arteries to ANG II-induced vasoconstriction (220). This finding is consistent with those 
of the present study that MAP was higher in females than in males, and was reduced by 
OVX but restored by estrogen replacement.  The effects of partial aortic coarctation also 
have been investigated in pregnant and virgin female rats for a duration of 10 to 11 days 
(96). Increases in mean arterial pressure were identified only in pregnant rats. The most 
likely reason for the lack of a significant increase in arterial pressure in virgin female rats 
is that only partial rather than total aortic occlusion was performed, unlike the present 
investigation.  
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Sex differences in CP release and/or action in female versus male rats that are 
ovarian steroid hormone (probably estrogen) dependent, have been identified (10; 11; 68; 
145). Reactivity to the thromboxane/endoperoxide receptor agonist U-46619 is greater in 
female than in male rat aortae and vascular reactivity to vasopressin and phenylephrine 
are enhanced in female aortae due to the greater release of CP in female than in male rats 
(10; 11; 68; 145). In chronically-coarcted male rats (4 weeks after coarctation), a 
persistent enhanced vascular reactivity to CP and a concomitant modulatory effect of 
nitric oxide are present, suggesting that these two mechanisms, working in direct 
opposition, are responsible for the stable elevated MAP observed in male rats in this form 
of hypertension (232). In females, 17β-estradiol induces rapid release of nitric oxide and 
increases nitric oxide synthase expression in endothelial cells (93; 125; 216); therefore, 
nitric oxide release may prevent a more dramatic early rise in blood pressure in female 
rats, unlike male rats, during the first week following aortic coarctation. The later rise in 
MAP in females is likely due to the increased expression of thromboxane synthase, 
resulting in enhanced release of TXA2, as observed in the present study. The elevated 
MAP and resultant damage to the endothelium, may also decrease nitric oxide 
production, exacerbating the hypertensive effects of TXA2. An additional mechanism 
also may operate through the impaired nitric oxide synthesis, and is related to the rise in 
ANG II levels that occurs with aortic coarctation (13; 14; 82; 95). ANG II stimulates the 
formation of reactive oxygen species (79; 206), which in turn inactivate the nitric oxide 
pathway (13; 14; 82). Thus in female rats, the enhanced production of renin and ANG II, 
resulting from the effects of both aortic coarctation and estrogen, may impair the 
production of nitric oxide to such an extent that estrogen-stimulated elevations in CP 
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such as TXA2 likely result in greater increases in systemic blood pressure than occur in 
male rats. In this manner, the equilibrium between nitric oxide, vasodilator prostanoids, 
and vasoconstrictor prostanoids likely present in normotension may have been altered, 
resulting in greater elevations in systemic blood pressure in females than in males. In 
addition, long-term, estrogen-dependent changes in arterial wall composition may also 
contribute to the continued rise in MAP seen 12 to 14 days after aortic coarctation in F-
HT and OE-HT rats, since estrogen treatment increases aortic stiffness in OVX rats 
(252). Similarly, sex differences in heart rate in response to aortic coarctation also were 
present during the first 4 days, but not later, when MAP was significantly different; 
suggesting that a change in baroreceptor set point may have occurred in F-HT and OE-
HT rats, resulting in higher MAP without any changes in heart rate.  
 
4.2 Effects of Constrictor Prostanoid Pathway Inhibitors on Aortic Coarctation-
Induced Hypertension 
  To determine the role that CP play in aortic coarctation-induced HT, the effects of 
acute and chronic inhibition of CP receptor function were investigated. Acute antagonism 
of the TXA2/PGH2 receptor with SQ 29,548 resulted in a substantially greater decrease in 
MAP in F-HT and OE-HT rats than in M-HT, rats 14 days after aortic coarctation. 
TXA2/PGH2 receptor blockade had little or no effect in OVX-HT rats. The decrease in 
MAP seen in M-HT was similar to that in previous reports (149), but much less than 
occurred in F-HT or OE-HT rats. F-HT and OE-HT rats exhibited about a 3-fold greater 
decrease in blood pressure compared to M-HT, confirming the greater role that the CP 
were believed to play in female than in male rats during the development of HT.  
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Chronic inhibition of TXA2 synthase and the TXA2 /PGH2 receptor with Ridogrel 
over the 2-week period following aortic coarctation did not affect MAP in any NT rats, 
nor in M-HT or OVX-HT rats in the present study. This is similar to previous reports that 
MAP of M-HT was unaffected by Ridogrel (52; 201). MAP was significantly reduced in 
F-HT and this effect was abolished by ovariectomy. The hypotensive effect of Ridogrel 
was restored by estrogen replacement in OE-HT rats. These findings support the central 
hypothesis of the present study that the ovarian steroids (likely estrogen) activate the CP 
pathway to induce much larger increases in MAP following aortic coarctation than in rats 
without estrogen (M, OVX). The present findings are also consistent with studies in 
women with pulmonary hypertension and preeclampsia, in which TXA2 production 
appears to be an important mediator of increases in blood pressure (12; 38; 210; 295). 
Estrogen may also have influenced the heart rate (and baroreflex) responses of F-HT and 
OE-HT to Ridogrel, because both F-HT and OE-HT had slower heart rates than any of 
the NT groups on days 4 and 6.   
 
4.3 Effects of Aortic Coarctation-Induced Hypertension and Ovarian Steroid 
Hormones on Aortic Prostanoid Release  
 Striking sex differences in vascular prostanoid release were observed in both NT 
and HT rats in the present study. While basal release of TXB2 in the incubation studies 
was similar in the aortae of F-NT and M-NT rats, basal release increased 4-fold in F-HT 
and but only 2-fold in M-HT, compared to their respective NT controls. Further, ANG II 
stimulated greater release of TXB2 in F than in M, both in normotension and 
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hypertension, suggesting greater CP-potentiated aortic responsiveness to ANG II in the 
presence of ovarian steroid hormones. 
 In the continuous pressure and flow studies, aortae from both OE and F rats 
produced similar amounts of TXB2, which were greater than OVX rat aortae; however, 
the higher TXB2 production achieved statistical significance only in F-HT rats, likely 
due to greater variability in TXB2 production in the OE-HT aortae. Despite the lack of 
overall significance in the OE-HT aortae, most OE-HT aortae produced at least 3-fold 
more TXB2 than OVX-HT at any pressure or ANG II dose, providing compelling 
evidence that estrogen does indeed play a role in the regulation of vascular tone through 
TXB2.  
 Previous studies have identified differences in CP release and/or action that are 
dependent upon ovarian steroid hormones, probably estrogen (68; 145). Vasopressin and 
PE-induced contractions of the rat aorta exhibit sexual dimorphism that is CP 
dependent, at least in part (67; 68; 145; 248). Vascular reactivity to the 
thromboxane/endoperoxide receptor agonist U-46619 is also greater in female than in 
male rat aortae (68; 145). The increased responsiveness to ANG II identified in OVX-
NT rats replaced with 17β estradiol (219) supports the present findings in the ANG II-
dependent aortic coarctation model, where the presence of estrogen increased CP output, 
especially in the presence of ANG II stimulation.  
 Further evidence for the upregulation of CP synthesis in hypertension in the 
female rat has been identified in the present study. Increases in the expression of 
thromboxane synthase in the aortae of F-HT and OE-HT compared to M-HT and OVX-
HT were identified using immunohistochemistry. RT PCR identified dramatic parallel 
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increases in TXS mRNA in the endothelium and moderate but parallel increases in 
vascular smooth muscle. These findings are entirely consistent with the increased 
release of TXB2 measured in isolated aortae and the increased MAP present in vivo in F-
HT and OE-HT rats. Estrogen, then, appears to upregulate CP production and the renin-
angiotensin system, to result in greater MAP in F-HT and OE-HT rats in aortic 
coarctation-induced hypertension. 
 Release of the vasodilator prostanoid prostacyclin (PGI2), was also analyzed in 
the present incubation and pressure/flow studies. Release of PGF1α (stable metabolite of 
PGI2) increased more in F-HT than in M-HT rats following aortic coarctation. In the 
aortic ring incubation experiments, basal PGF1α production increased 5-fold in F-HT 
compared to F-NT, but only 3-fold in M-HT compared to M-NT (P<0.05). In the 
presence of ANG II, F-HT again exhibited a 2-fold greater release of PGF1α than M-HT. 
In the continuous pressure/flow experiments on thoracic aortae, PGF1α release was 
elevated at all pressures (100 and 150 mm Hg) in F-HT compared to F-NT. This response 
to HT was abolished by ovariectomy (OVX-HT production was similar to OVX-NT) and 
restored by estrogen replacement (OE-HT was greater than OE-NT). With ANG II (0.1 
nmol) stimulation, production of PGF1α was at least 2-fold higher in F-HT and OE-HT 
than in OVX-HT. In both F and OE, there was likely an upregulation of the PGI2 pathway 
in parallel with the vasoconstrictor (TXA2/PGH2) pathway. This concurrent upregulation 
of vasodilator as well as vasoconstrictor prostanoids may function to balance vascular 
tone and maintain homeostasis. However, oxygen free radical production (increased by 
ANG II) antagonizes the production of PGI2 (156), which may contribute to the 
pathogenesis of vascular diseases where ANG II is increased (79; 206). Although the 
  
146
relative amounts of PGI2 and TXA2 differ in normotensive states, PGH2 may also 
contribute to the balance between vasoconstriction and vasodilation. The relative 
concentrations and binding affinities of each prostanoid for its receptor was not 
investigated in the present studies, and may also contribute to the balance between 
vasoconstriction and vasodilation in the arterial vasculature. Therefore, in hypertensive 
states in which ANG II is not increased, increased production of both TXA2 and PGI2 in 
the female may result in continued homeostatic balance of platelet aggregation and 
vascular tone, because these two prostanoids exert opposing effects on platelets and 
vascular smooth muscle (156; 173; 183; 224). However, in cases where ANG II 
production is increased, such as in aortic coarctation (a renin-angiotensin dependent form 
of hypertension), the release and/or action of constrictor and dilator prostanoids may be 
imbalanced and thus contribute to increased vascular tone and higher systemic blood 
pressure in female rats.  
Preeclampsia and other placental insufficiency syndromes in humans are 
characterized by an overproduction of TXA2 in the placenta and by a deficit in production 
of PGI2 in the fetoplacental tissue, which may account for the enhanced vasoconstriction 
and platelet hyperactivity seen in hypertensive pregnancies (295). Similarly, in 
pulmonary hypertension and Raynaud’s disease, an imbalance between TXA2 and PGI2 
with the overproduction of TXA2 has been reported (38; 218). Furthermore, inhibitors of 
thromboxane synthase (Dazoxiben, CGS-13080) have been used successfully in the 
treatment of primary pulmonary hypertension and Raynaud’s disease (15; 210). In aortic 
coarctation rats in the present study, MAP did not increase as soon as rapidly in F-HT as 
in M-HT rats. Since ANG II production does not peak until 5 to 9 days after aortic 
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coarctation (64), a marked increase in CP and free radical production and subsequent 
inhibition of vasodilator activity probably does not occur until that time. 
 
4.4 Effects of Aortic Coarctation-Induced Hypertension on the Pressure-Diameter 
Relationship of the Thoracic Aorta in Response to Angiotensin II 
The pressure/diameter responses of NT and HT rat aortae were recorded in vitro 
during constant flow/pressure experiments (150 mm Hg). In these experiments, the aorta 
functioned best as a model for humoral events and the structural remodeling that occurs 
throughout the arterial vascular tree, because its function as a conduit vessel precluded 
functional pressure-diameter changes during testing in vitro. Thus, only minor changes in 
pressure occurred with ANG II administration during continuous flow, and changes in 
compliance were more readily apparent than changes in resistance.  
Initial pressurization of the aorta from 0 to 150 mm Hg resulted in significantly 
smaller increases in diameter in F-HT and OE-HT than in other groups. This likely 
reflects morphologic remodeling that occurs with aortic coarctation-induced hypertension 
in the presence of estrogen in F-HT and OE-HT rats. 
ANG II-stimulation of the aorta in vitro resulted in apparent vasodilation of all 
groups (both HT and NT) at the lowest dose of ANG II (0.005 nmol). At subsequent 
higher doses of ANG II (0.02 and 0.1 nmol), much smaller changes in diameter resulted, 
and none differed significantly among the various experimental groups (one-way 
ANOVA, P>0.05). The vasodilation that occurred in response to ANG II in the HT as 
well as NT aortae was likely the result of several factors. ANG II stimulation in 
conjunction with pressurization to 150 mm Hg and continuous flow may have stimulated 
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not only direct and CP-mediated contraction of the aortic wall, but also the release of 
vasodilators such as nitric oxide and vasodilator prostanoids. The release of vasodilators 
may have resulted in the maintenance of equilibrium of tensile and shear stresses so that 
no significant changes in aortic diameter occurred, even though release of 
vasoconstrictors such as TXB2 occurred. In this regard, greater release of TXB2 and 
PGF1α were measured in the perfusates of F-HT and OE-HT aortae than in OVX-HT 
aortae in response to ANG II (P<0.05). Changes in pressure were not marked and 
changes in diameter in any group were minimal, probably due to the function of the aorta 
as a conduit artery, in which only small changes in diameter occur with humoral 
activation (45). The sensitivity of the rat aorta to vasoconstrictor and vasodilator agonists, 
in vitro, is often lower than that of smaller resistance vessels; however, it is well 
established that the functional properties of the rat aorta are more similar to peripheral 
resistance vessels than those of other large artery models such as the rabbit aorta (78). 
This was reflected in the release of prostanoids during the in vitro pressurization 
experiments. Further investigations with small resistance vessels may be warranted to 
determine active responses in the model of complete aortic coarctation in the F rat.  
 
 
4.5 Effects of Aortic Coarctation-Induced Hypertension on Aortic Morphology and 
Extracellular Matrix 
To determine the roles that hypertension, ovarian steroid hormones, and CP play 
in the regulation of aortic morphology, the effects of aortic coarctation, ovariectomy, and 
estrogen replacement therapy on aortic composition were examined. Prostanoids have 
been identified previously as important regulators of cell proliferation, differentiation and 
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apoptosis (143; 199; 238); therefore, their effects on vascular morphology were 
investigated in the present studies. With the induction of hypertension, wall thickness 
increased in F-HT aortae. Ovariectomy abolished HT-mediated increases in aortic wall 
thickness seen in F-HT, while estrogen-replacement restored hypertension-related 
increases in thickness in the OE-HT aorta. Wall area also increased in the presence of 
ovarian steroid hormones and in response to hypertension. Interestingly, M-HT had 
similar increases in wall thickness, area and wall: luminal ratios as F-HT, indicating a 
possible role for androgens as well as estrogens in the response to aortic coarctation. 
Ridogrel administration did not alter hypertension-mediated changes in aortic 
morphology in the present studies. Wall thickness was not affected by Ridogrel and wall 
area was affected only in OE-NT aortae. Wall: luminal ratio did not change with 
Ridogrel, with the exception of OVX aortae. Aortic wall: luminal ratio of OVX-HT 
aortae was elevated following Ridogrel administration, compared to OVX-NT. These 
findings strongly suggest that the morphologic changes seen in the aorta after coarctation 
and the induction of hypertension are mediated through the sex steroid hormones, likely 
estrogen, and do not involve the CP (TXA2/PGH2).  
In contrast, extracellular production of elastin and collagen were markedly 
affected by CP and ovarian steroid hormones. Collagen density increased markedly in F-
HT aortae compared to F-NT control or M-HT aortae. Ovariectomy abolished HT-
mediated increases in collagen, while estrogen replacement restored increases in collagen 
in OE-HT. Elastin content increased in all HT groups, but the greatest increase was seen 
in F-HT. The collagen: elastin ratio exhibited significant sexual dimorphism. The ratio 
increased with the induction of hypertension in F-HT but not in M-HT, and this effect 
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was abolished by ovariectomy (OVX-HT) and restored by estrogen replacement in OE-
HT.  
Ridogrel administration clearly prevented increases in elastin in F-HT, OVX-HT 
and OE-HT rat aortae. Ridogrel also inhibited hypertension-induced increases in collagen 
production in estrogen-replete rats (female and OE). Collagen production in OVX aortae 
was unaffected by the induction of hypertension or by treatment with Ridogrel. 
Ovariectomy abolished any hypertension-mediated increases in elastin seen with aortic 
coarctation. It is unknown whether the ovarian steroid hormones (estrogen) act directly to 
alter extracellular matrix production or through TXA2; however, it seems likely that 
estrogen acts together with the CP to increase elastin and collagen density in the aorta. 
Aortic elastin and collagen contents in the M were unaffected by hypertension or 
Ridogrel administration. This is similar to previous findings in age-matched M 
spontaneously hypertensive rats and their normotensive Wistar-Kyoto counterparts at 3 to 
6 months of age, in that hypertensive and normotensive aortae had similar elastin and 
collagen densities (260). Similarly, in an additional study, male rats administered ANG II 
for 2 weeks developed a significant increase in media area (as seen in male rats in the 
present study) but no change in elastin or collagen density (25). 
The remodeling that occurs with aortic coarctation-induced hypertension differs 
in the presence of ovarian steroids (specifically estrogen), especially with respect to 
collagen production. Collagen production is upregulated in F-HT and OE –HT, but is 
attenuated by inhibition of the CP pathway. These findings suggest that ovarian steroid 
hormones act to upregulate CP function directly or in concert to alter collagen 
production. TXA2 has been identified as a potent mitogen and mediator of vascular 
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remodeling (156), and increases in collagen mRNA due to TXA2 have been documented 
in male rats (26; 164; 165). If estrogen upregulates CP function in aortic coarctation-
induced hypertension, then an increase in collagen production is reasonable, since TXA2 
stimulates collagen production. Indeed, the increased MAP seen 12 to 14 days after aortic 
coarctation in F-HT and OE-HT rats may be due, at least in part, to increased collagen 
expression in the arterial wall, resulting in increased aortic stiffness. Estrogen treatment is 
known to increase aortic stiffness in OVX rats (252) and this appears to involve increased 
collagen production. Previous investigations of aortic coarctation in female have not 
identified changes in extracellular matrix (96); however, these studies were short-term 
and only involved partial coarctation of the aorta. ANG II is reported to stimulate 
collagen production in arterial walls (121); thus, the resulting ANG II levels in these 
previous studies may not have been sufficient to stimulate collagen production in the 
aortic wall. The rats in the present studies underwent complete ligation of the aorta to 
induce the largest possible activation of the renin-angiotensin system. Complete ligation 
of the aorta resulted in a unique model of hypertension for study in female and OE rats, in 
which maximal ANG II levels likely resulted in pronounced interactions among estrogen, 
ANG II and TXA2.  
 
4.6 Conclusions 
Numerous previous investigations established the concept that vascular TXA2 
production is important in the regulation of vascular tone only in hypertension and in 
males but not in females (33; 49; 96; 169; 175). However, recent findings have 
challenged this dogmatic concept and have established the importance of CP in the 
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regulation of vascular tone in the normal systemic vasculature and in females but not 
males (63; 68; 145). The findings of the present study confirm and extend the importance 
of CP in the regulation of tone in the normal female vasculature and establish the 
importance of endogenous estrogen and CP as mediators of increased vascular tone and 
hypertension in the aortic coarctation model. This model is dependent upon the renin-
angiotensin system and induces hypertension only in the upper body. Other models of 
hypertension, such as the Spontaneously Hypertensive rat, do not involve the induction of 
CP systemically (49), although CP may be involved in the renal vasculature (23). Further, 
regional heterogeneity may exist in the modulatory influence of estrogen on vascular 
function and TXA2 production, such that vascular responses may vary with anatomical 
location in the female rat (252).  
In previous studies, ovariectomy attenuated the contractile responses of the rat 
aorta to vasopressin and PE by 25-30% (68; 145), while treatment of OVX animals with 
estrogen resulted in enhanced contractions to both vasopressin and PE in the rat aorta 
(194) and to arachidonic acid in the rabbit aorta (168) and. Contractile responses of 
female rat aortae to vasopressin and PE were attenuated by indomethacin and SQ 29,548 
(68), indicating that constrictor prostanoids are involved in agonist-induced 
vasoconstriction in the female. Estrogen also enhances vasoconstriction by increasing 
vascular smooth muscle reactivity and binding sites to vasopressin in rat mesenteric 
arteries (243). Further, increased release of CP by the vasculature likely underlies the 
enhanced vascular reactivity to vasopressin seen in the female rat aorta (68; 145). The 
present study demonstrated that estrogen plays an important role in the regulation of 
vascular tone in the female, both in normotension and in aortic coarctation-induced 
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hypertension. Following OVX, expression of TXS enzyme and the release of CP declined 
concurrently in the OVX-HT vasculature, resulting in a smaller increase in MAP 
following aortic coarctation compared to female rats. The present research establishes, 
experimentally, the concept that epidemiologic studies have proposed; namely, that ANG 
II-induced hypertension is exacerbated in the female by estrogen-induced CP production. 
This change in vascular function during development of hypertension is exacerbated by 
the structural effect of estrogen to increase collagen density, reducing arterial compliance 
and further enhancing vascular tone. 
Human hypertension may involve the interaction of estrogen, CP and ANG II, as 
in the aortic coarctation model of hypertension described in the present studies. ANG II 
has been implicated as an important component in essential hypertension in humans (107; 
198; 258). Estradiol levels are higher in men and women with essential hypertension than 
in their normotensive counterparts, and estrogen elevates angiotensinogen gene 
expression and blood levels of ANG II as well as renin activity (92; 214; 258), suggesting 
that estrogen may play an important role in the development of HT. Previous studies of 
aortic coarctation-induced hypertension have identified the important role that CP (TXA2 
and PGH2) play in the rat (20; 31; 55; 130; 148; 148) and essential hypertension in the 
human is characterized not only by elevated ANG II and estradiol, but also by enhanced 
release of local constrictor factors such as CP (186; 230; 262; 263). Taken together, the 
past and present findings suggest that ANG II, estrogen, and CP likely function in concert 
to exacerbate the development of hypertension through simultaneous changes in vascular 
function and structure to a substantially greater extent in the female than in the male 
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vasculature. Further, the findings of the present investigation may be important in the 
development of sex-specific treatment of essential hypertension in humans.    
The present studies identify the functional and structural events that occur during 
the induction of HT in the female rat in a renin angiotensin-dependent model. The 
responses of the female vasculature differ from those of the male at the local humoral 
level, with a markedly greater release of CP. Sex differences in prostanoid release were 
observed both in static and perfused aortae in vitro and were verified at the cellular level 
by increases in TXA2 synthase enzyme content (immunostaining) and at the molecular 
level by increased expression of TXA2 synthase mRNA. This local humoral induction 
appeared to result in the elevation of systemic arterial pressure in vivo, and this effect of 
CP was confirmed by the hypotensive actions of the TXA2/PGH2 receptor antagonist SQ 
29,548. The rise in MAP in female rats was likely the combined result of functional and 
structural events, including increased vascular tone (vasoconstriction), increased 
extracellular vascular matrix (increased collagen), increased vascular wall area, and 
altered baroreceptor set points in the systemic vasculature. F-HT and OE-HT rats 
developed more complications after aortic coarctation, including thromboembolism, 
weight loss, paresis, paralysis, and sudden death (in addition to higher MAP) than M-HT 
rats. These sex differences may reflect the altered balance of local vasoconstrictors to 
vasodilators that likely occurs in this form of HT. The aortic coarctation model differs 
from other models such as the Spontaneously Hypertensive Rat, in that induction of HT 
results from a transient elevation in plasma renin and ANG II levels (64). Hypertension 
persists even though plasma renin and ANG II levels return to baseline-precoarctation 
levels. There are, then, persistent changes in vascular structure and function, and perhaps 
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the baroreceptors, which result in the continued maintenance of HT, and this includes 
vascular wall remodeling as demonstrated by the present studies. In the female, the 
extracellular matrix was altered so that aortic stiffness may have increased (due to 
increased collagen density). Whether the vascular remodeling and alterations in 
baroreceptor set point may be reversed with reversal of HT is unknown. Regardless, the 
findings reported herein, supported by previous epidemiological studies, argue that the 
way in which we study, diagnose and treat hypertension should be approached differently 
in premenopausal women than in men. 
It can be concluded from the present investigation that ANG II, estrogen, and CP 
work in concert to induce hypertension by enhancing vascular tone and to sustain this 
pathophysiological state through structural changes in the vascular wall. One or more 
factors may act as facilitators for the others, or they may act synergistically to induce a 
form of HT that is more malignant in the female than in the male rat. Estrogens have been 
shown to increase circulating angiotensinogen (34; 136) and to increase vasoconstrictor 
responses to ANG II (219). There may also be increased ANG II production, either 
systemically or locally at the endothelium, contributing to increased oxygen free-radical 
induced vasodilator inhibition, as well as increased collagen production, resulting in 
reduced vascular compliance. This proposed interaction of factors is consistent with the 
concurrent increases in MAP and collagen density in F-HT and OE-HT rats in this study; 
however, further experiments are required to fully determine the cellular and molecular 
interactions underlying this form of hypertension.  
 
 
 
  
156
REFERENCES 
 
 1.  Ajayi AAL, Mathur RS and Halushka PV. Testosterone increases human 
platelet thromboxane A2 receptor density and aggregation responses. Circ 91: 
2742-2747, 1995. 
 2.  Akimova EV. Prostacyclin and thromboxane A2 levels in children and 
adolescents with an inherited predisposition to coronary heart disease: a family 
study. Coron Artery Dis 5: 761-765, 1994. 
 3.  Altura BM. Sex and estrogens and responsiveness of terminal arterioles to 
neurohypophyseal hormones and catecholamines. J Pharmacol Exp Ther 193: 
403-412, 1975. 
 4.  Anastos K, Charney P, Charon RA, Cohen E, Jones CY, Marte C, Swiderski 
DM, Wheat ME and Williams S. Hypertension in women: what is really 
known? Ann Inter Med 115: 287-293, 1991. 
 5.  Andersson C, Lydrup ML, Ferno M, Idvall I, Gustafsson J and Nilsson BO. 
Immunocytochemical demonstration of oestrogen receptor beta in blood vessels 
of the female rat. J Endocrinol 169: 241-247, 2001. 
 6.  Antikainen R, Kacolley P and Tuomilehto J. Systolic blood pressure, isolated 
systolic hypertension, and risk of coronary heart disease, strokes, cardiovascular 
  
157
disease, and all-cause mortality in the middle-aged population. J Hypertens 16: 
577-583, 1998. 
 7.  Bachmann J, Feldmer M, Ganten U, Stock G and Ganten D. Sexual 
dimorphism of blood pressure: possible role of the renin- angiotensin system. J 
Steroid Biochem Mol Biol 40: 511-515, 1991. 
 8.  Bailie MD, Donoso VS and Gonzalez NC. Role of the renin-angiotensin system 
in hypertension after coarctation of the aorta. J Lab Clin Med 104: 553-562, 1984. 
 9.  Ballermann BJ, Dardik A, Eng E and Liu A. Shear stress and the endothelium. 
Kidney Int 54: S-100-S-108, 1998. 
 10.  Baltzer WI, Kuo L and Stallone JN. Estrogen enhances constrictor prostanoids 
and blood pressure in aortic coarctation-induced hypertension in female rats. 
FASEB J 17: A1234, 2003. 
 11.  Baltzer WI and Stallone JN. Aortic coarctation-induced hypertension is greater 
in females vs. males and is more constrictor prostanoid dependent. FASEB J 16: 
A81, 2002. 
 12.  Barst RJ and Stalcup SA. Endothelial function in clinical pulmonary 
hypertension. Chest 88: 216S-220S, 1985. 
  
158
 13.  Barton CH, Ni Z and Vaziri ND. Effect of severe aortic banding above the renal 
arteries on nitric oxide synthase isotype expression. Kidney Int 59: 654-661, 2001. 
 14.  Barton CH, Ni Z and Vaziri ND. Enhanced nitric oxide inactivation in aortic 
coarctation-induced hypertension. Kidney Int 60: 1083-1087, 2001. 
 15.  Belch JJF, Shaw B, Sturrock RD, Madhok R and Keiberman P FC. Double 
blind trial of CL 115,347 a transdermally absorbed prostaglandin E2 analogue, in 
treatment of Raynaud's phenomenon. Lancet 1: 1180-1183, 1985. 
 16.  Ben Driss A, Benessiano J, Poitevin P, Levy BI and Michel JB. Arterial 
expansive remodeling induced by high flow rates. Am J Physiol 272: H851-H858, 
1997. 
 17.  Berne RM and Levy MN (eds). Physiology. St. Louis, Mo: Elsevier Science, 
1998. 
 18.  Bhagylakshi A, Berthiaume F, Reich KM and Frnagos JA. Fluid shear stress 
stimulates membrane phospholipid metabolism in cultured human endothelial 
cells. J Vasc Res 29: 443-449, 1992. 
 19.  Botting R and Vane JR. The receipt and dispatch of chemical messengers by 
endothelial cells. Prog Clin Biol Res 301: 1-11, 1989. 
  
159
 20.  Boussairi EH, Sacquet J, Sassard J and Benzoni D. Thromboxane A2-
prostaglandin H2 and renovascular hypertension in rats. Am J Physiol 267: 
R1190-R1197, 1994. 
 21.  Bracamonte MP and Miller VM. Vascular effects of estrogens: arterial 
protection versus venous thrombotic risk. Trends Endocrin Metab 12: 204-209, 
2001. 
 22.  Brand FN, Larson MG, Kannel WB and McGuirk JM. The occurrence of 
Reynaud's phenomenon in a general population: the Framingham study. Vasc Med 
2: 296-301, 1997. 
 23.  Brandstrom K and Arendshorst WJ. Thromboxane A2 contributes to the 
enhanced tubuloglomerular feedback activity in young SHR. Am J Physiol 276: 
F758-F766, 1999. 
 24.  Brotherton AF and Hoak JC. Prostacyclin biosynthesis in cultured vascular 
endothelium is limited by deactivation of cyclooxygenase. J Clin Invest 72: 1255-
1261, 1983. 
 25.  Brouwers-Ceiler DL, Nelissen-Vrancken HJ, Smits JF and De Mey JG. The 
influence of angiotensin II-induced increase in aortic wall mass on compliance in 
rats in vivo. Cardiovasc Res 33: 478-484, 1997. 
  
160
 26.  Bruggeman LA, Horigan EA, Horikoshi S, Ray PE and Klotman PE. 
Thromboxane stimulates synthesis of extracellular matrix proteins in vitro. Am J 
Physiol 261: F488-F494, 1991. 
 27.  Bruggeman LA, Pellicoro JA, Horigan EA and Klotman PE. Thromboxane 
and prostacyclin differentially regulate murine extracellular matrix gene 
expression. Kidney Int 43: 1219-1225, 1993. 
 28.  Brunkwall JS, Stanley JC, Graham LM, Burkel WE and Bergqvist D. 
Comparison of static incubation versus physiologic perfusion techniques for 
quantitation of luminal release of prostacyclin and thromboxane in canine arteries 
and veins. J Surg Res 45: 1-7, 1988. 
 29.  Brunkwall JS, Stanley JC, Kresowik TF, Graham LM, Burkel WE and 
Bergqvist D. Prostanoid release from ex vivo perfused canine arteries and veins: 
effects of prolonged perfusion, intermittent perfusion, as well as exposure to 
exogenous arachidonic acid, thrombin, and bradykinin. Thromb Haemost 62: 
1034-1039, 1989. 
 30.  Buzzard CJ, Pfister SL and Campbell WB. Endothelium-dependent 
contractions in the rabbit pulmonary artery are mediated by thromboxane A2. 
Circ Res 72: 1024-1034, 1993. 
  
161
 31.  Carvalho MH, Fortes ZB, Nigro D, Oliveira MA and Scivoletto R. The role of 
thromboxane A2 in the altered microvascular reactivity in two-kidney, one-clip 
hypertension. Endothelium 5: 167-178, 1997. 
 32.  Cayatte AJ, Du Y, Oliver-Krasinski J, Lavielle G, Verbeuren TJ and Cohen 
RA. The thromboxane receptor antagonist S18886 but not aspirin inhibits 
atherogenesis in apo E-deficient mice: evidence that eicosanoids other than 
thromboxane contribute to atherosclerosis. Arterioscler Thromb Vasc Biol 20: 
1724-1728, 2000. 
 33.  Chan PS and Cervoni P. Prostaglandins, prostacyclin, and thromboxane in 
cardiovascular diseases. Drug Dev Res 7: 341-359, 1986. 
 34.  Chang E and Perlman AJ. Multiple hormones regulate angiotensinogen 
messenger ribonucleic acid levels in a rat hepatoma cell line. Endocrinology 121: 
513-519, 1987. 
 35.  Chen S-J, Li H, Durand J Oparil S and Chen Y-F. Estrogen reduces 
myointimal proliferation after balloon injury of the rat carotid artery. Circ 93: 
577-584, 1996. 
 36.  Chen Z, Yuhanna IS, Gallery EDM, Karas RH, Mendelsohn ME and Shaul 
PW. Estrogen receptor alpha mediates the nongenomic activation of endothelial 
nitric oxide synthase by estrogen. J Clin Invest 103: 401-406, 1999. 
  
162
 37.  Christman B.W. Lipid mediator dysregulation in primary pulmonary 
hypertension. Chest 114: 205S-207S, 1998. 
 38.  Christman B.W., McPherson CD, Newman JH, King GA, Buzzard CJ, 
Groves BM and Marte C. An imbalance between the excretion of thromboxane 
A2 and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 327: 
70-75, 1992. 
 39.  Chun TH, Itoh H, Ogawa U, Tamura N, Takaya K, Igaki T, Yamashita J, 
Doi K, Inoue M, Masatsugu K, Korenga R, Ando J and Nakao K. Shear stress 
augments expression of C-type natriuretic peptide and adrenomedullin. 
Hypertension 29: 1296-1302, 1997. 
 40.  Colburn P and Buonassisi V. Estrogen-binding sites in endothelial cell cultures. 
Science 201: 817-819, 1978. 
 41.  Colucci WS, Gimbrone Jr MA, McLoughlin MK, Halpern W and Alexander 
RW. Increased vascular catecholamine sensitivity and alpha adrenergic receptor 
affinity in female and estrogen-treated male rats. Circ Res 50: 805-811, 1982. 
 42.  Concina P, Sordello S, Barbacanne MA, Elhage R, Pieraggi MT, Fournial G, 
Plouet J, Bayard F and Arnal JF. The mitogenic effect of 17beta-estradiol on in 
vitro endothelial cell proliferation and on in vivo reendothelialization are both 
dependent on vascular endothelial growth factor. J Vasc Res 37: 202-208, 2000. 
  
163
 43.  Cornwell TL, Arnold E, Boerth NJ and Lincoln TM. Inhibition of smooth 
muscle cell growth by nitric oxide and activation of cAMP-dependent protein 
kinase by cGMP. Am J Physiol 267: C1405-C1413, 1994. 
 44.  Cox RH. Three dimentional mechanics of arterial segments in vitro: methods. J 
Appl Physiol 36: 381-384, 1974. 
 45.  Cox RH. Differences in mechanics of arterial smooth muscle from hindlimb 
arteries. Am J Physiol 235: H649-H656, 1978. 
 46.  Cox RH. Comparison of arterial wall mechanics using ring and cylindrical 
segments. Am J Physiol 244: H298-H303, 1983. 
 47.  Cruz BV and Escalante B. Renal vascular interaction of angiotensin II and 
prostaglandins in renovascular hypertension. J Cardiovasc Pharmacol 34: 21-27, 
1999. 
 48.  Cunard CM, Maddox YT and Ramwell PW. Endothelium dependent gender 
differences in the response of the rat pulmonary artery to the thromboxane 
mimetic (U46619). J Pharmacol Exp Ther 237: 82-85, 1986. 
 49.  Dantas APV, Scivoletto R, Fortes XB, Nigro D and Carvalho MHC. Influence 
of female sex hormones on endothelium derived vasoconstrictor prostanoid 
  
164
generation in microvessels of spontaneouly hypertensive rats. Hypertension 34: 
914-919, 1999. 
 50.  Davidge ST and Zhang Y. Estrogen replacement suppresses a prostaglandin H 
synthase-dependent vasoconstrictor in rat mesenteric arteries. Circ Res 83: 388-
395, 1998. 
 51.  Davies PF. Flow-mediated endothelial mechanotransduction. Physiol Rev 75: 
519-560, 1995. 
 52.  De Clerck F, Beetens J, de Chaffoy dC, Freyne E and Janssen PA. R 68 070: 
thromboxane A2 synthetase inhibition and thromboxane A2/prostaglandin 
endoperoxide receptor blockade combined in one molecule--I. Biochemical 
profile in vitro. Thromb Haemost 61: 35-42, 1989. 
 53.  De Clerck F, Beetens J, de Chaffoy dC, Vercammen E, Freyne E and Janssen 
PA. R 68 070: thromboxane A2 synthetase inhibition and thromboxane 
A2/prostaglandin endoperoxide receptor blockade, combined in one molecule. 
Prog Clin Biol Res 301: 567-572, 1989. 
 54.  De Clerck F, Beetens J, Van de WA, Vercammen E and Janssen PA. R 68 
070: thromboxane A2 synthetase inhibition and thromboxane A2/prostaglandin 
endoperoxide receptor blockade combined in one molecule--II. Pharmacological 
effects in vivo and ex vivo. Thromb Haemost 61: 43-49, 1989. 
  
165
 55.  Dellipizzi A. and Nasjletti A. Involvement of nitric oxide and potassium 
channels in the reduction of basal tone produced by blockade of thromboxane 
A2/prostaglandin H2 receptors in aortic rings of hypertensive rats. Clin Exp 
Hypertens 20: 903-916, 1998. 
 56.  Dellipizzi A., Pucci ML, Mosny AY, Deseyn K and Nasjletti A. Contribution of 
constrictor prostanoids to the calcium-dependent basal tone in the aorta from rats 
with aortic coarctation-induced hypertension: relationship to nitric oxide. J 
Pharmacol Exp Ther 283: 75-81, 1997. 
 57.  Disshon KA and Dluzen DE. Estrogen reduces acute striatal dopamine responses 
in vivo to the neurotoxin MPP+ in female, but not male rats. Brain Research 868: 
95-104, 2000. 
 58.  Dluzen DE. Estrogen decreases corpus striatal neurotoxicity in response to 6-
hydroxydopamine. Brain Research 767: 340-344, 1997. 
 59.  Dubey RK, Gillespie DG, Mi Z, Rosselli M, Keller PJ and Jackson EK. 
Estradiol inhibits smooth muscle cell growth in part by activating the cAMP-
adenosine pathway. Hypertension 35: 262-266, 2000. 
 60.  Dubey RK, Jackson EK, Gillespie DG, Zacharia LC, Imthurn B and Keller 
PJ. Clinically used estrogens differentially inhibit human aortic smooth muscle 
  
166
cell growth and mitogen-activated protein kinase activity. Arterioscler Thromb 
Vasc Biol 20: 964-972, 2000. 
 61.  Elam MB, Lipscomb GE, Chesney CM, Terragno DA and Terragno NA. 
Effect of synthetic estrogen on platelet aggregation and vascular release of PGI2-
like material in the rabbit. Prostaglandins 20: 1039-1051, 1980. 
 62.  Ermert L, Ermert M, Duncker HR, Grimminger F and Seeger W. In situ 
localization and regulation of thromboxane A(2) synthase in normal and LPS-
primed lungs. Am J Physiol Lung Cell Mol Physiol 278: L744-L753, 2000. 
 63.  Farhat MY, Lavigne MC and Ramwell PW. The vascular protective effects of 
estrogen. FASEB J 10: 615-624, 1996. 
 64.  Fernandes M, Onesti G, Weder A, Dykyj R, Gould AB, Kim KE and Swartz 
C. Experimental model of severe renal hypertension. J Lab Clin Med 87: 561-
567, 1976. 
 65.  Fischer GM, Bashey RI, Rosenbaum H and Lyttle CR. A possible mechanism 
in arterial wall for mediation of sex difference in atherosclerosis. Exp Mol Pathol 
43: 288-296, 1985. 
 66.  Ford SP and Stice SL. Effects of the ovary and conceptus on uterine blood flow 
in the pig. J Reprod Fertil Suppl 33: 83-90, 1985. 
  
167
 67.  Fulton CT and Stallone JN. Ovariectomy abolishes constrictor prostanoid-
potentiated contractions to vasopressin (VP) in the female rat aorta. FASEB J 13: 
A524, 1999. 
 68.  Fulton CT and Stallone JN. Sexual Dimorphism in prostanoid-potentiated 
vascular constraction: roles of endothelium and ovarian steroids. Am J Physiol 
283: H2062-H2073, 2002. 
 69.  Gabbiani G and Badonnel MC. Contractile apparatus in aortic endothelium of 
hypertensive rat. Recent Adv Stud Cardiac Struct Metab 10: 591-601, 1975. 
 70.  Gabbiani G, Badonnel MC and Rona G. Cytoplasmic contractile apparatus in 
aortic endothelial cells of hypertensive rats. Lab Invest 32: 227-234, 1975. 
 71.  Gan L., Sjogren L.S., Doroudi R. and Jern S. A new computerized 
biomechanical model for ex vivo study of fluid mechanical forces in intact 
conduit vessels. J Vasc Res 36: 68-78, 1999. 
 72.  Gao H, Peng B, Welch WJ and Wilcox CS. Central thromboxane receptors: 
mRNA expression and mediation of pressor responses. Am J Physiol 272: R1493-
R1500, 1997. 
  
168
 73.  Gao H, Welch WJ, DiBona GF and Wilcox CS. Sympathetic nervous system 
and hypertension during prolonged TxA2/PGH2 receptor activation in rats. Am J 
Physiol 273: H734-H739, 1997. 
 74.  Ge T, Hughes H, Junquero DC, Wu KK, Vanhoutte PM and Boulanger CM. 
Endothelium-dependent contractions are associated with both augmented 
expression of prostaglandin H synthase-1 and hypersensitivity to prostaglandin 
H2 in the SHR aorta. Circ Res 76: 1003-1010, 1995. 
 75.  Gerhard-Herman M, Hamburg N and Ganz P. Hormone replacement therapy 
and cardiovascular risk. Curr Cardiol Rep 2: 288-292, 2000. 
 76.  Gilligan DM, Badar DM, Panza JA, Ramwell PW and Cannon RO III. Acute 
vascular effects of estrogen in postmenopausal women. Circ 90: 786-791, 1994. 
 77.  Gimeno MF, Borda ES, Lazzari MA and Gimeno AL. Ovarian hormones 
inhibit the release of prostacyclin-like material from isolated rat uterus. 
Prostaglandins 20: 223-232, 1980. 
 78.  Godfraind T, Miller R and Wibo M. Calcium antagonism and calcium entry 
blockade. Pharmacol Rev 38: 321-416, 1986. 
  
169
 79.  Griendling KK, Minieri CA, Ollerenshaw JD and Alexander RW. 
Angiotensin II stimulates NADH and NADPH oxidase activity in cultured 
vascular smooth muscle cells. Circ Res 74: 1141-1148, 1994. 
 80.  Grose JH, Lebel M and Gbeassor FM. Diminished urinary prostacyclin 
metabolite in essential hypertension. Clin Sci 59: 121s-123s, 1980. 
 81.  Gryglewski RJ, Bunting S, Moncada S, Flower RJ and Vane JR. Arterial 
walls are protected against deposition of platelet thrombi by a substance 
(prostaglandin X) which they make from prostaglandin endoperoxides. 
Prostaglandins 12: 685-713, 1976. 
 82.  Guan H, Cachofeiro V, Pucci ML, Kaminski PM, Wolin MS and Nasjletti A. 
Nitric oxide and the depressor response to angiotensin blockade in hypertension. 
Hypertension 27: 19-24, 1996. 
 83.  Guyton JR, Dao DT, Lindsay KL and Taylor AA. Ultrastructure of 
hypertensive rat aorta. Increased basement membrane- like material. Hypertension 
15: 56-67, 1990. 
 84.  Halushka PV. Pharmacology of thromboxane A2 receptor antagonists. Z Kardiol 
78 Suppl 3: 42-47, 1989. 
  
170
 85.  Halushka PV, Mais DE and Morinelli TA. Thromboxane and prostacyclin 
receptors. Prog Clin Biol Res 301: 21-28, 1989. 
 86.  Hanasaki K and Arita H. Characterization of thromboxane A2/prostaglandin H2 
(TXA2/PGH2) receptors of rat platelets and their interaction with TXA2/PGH2 
receptor antagonists. Biochem Pharmacol 37: 3923-3929, 1988. 
 87.  Hanasaki K, Nakano K, Dasai H and Arita H. Biochemical characterization 
and comparison of rat thromboxane A2/prostaglandin H2 receptors in platelets 
and cultured aortic smooth muscle cells. Biochem Pharm 38: 2967-2976, 1989. 
 88.  Hanasaki K, Nakano K, Kasai H, Arita H, Ohtani K and Doteuchi M. 
Specific receptors for thromboxane A2 in cultured vascular smooth muscle cells 
of rat aorta. Biochem Biophys Res Commun 150: 1170-1175, 1988. 
 89.  Hannaford P. Health consequences of combined oral contraceptives. Br Med 
Bull 56: 749-760, 2000. 
 90.  Harada N, Sasano H, Murakami H, Ohkuma T, Nagura H and Takagi Y. 
Localized expression of aromatase in human vascular tissues. Circ Res 84: 1285-
1291, 1999. 
  
171
 91.  Harvey PJ, Molloy D, Upton J and Wing LM. Dose response effect of 
conjugated equine oestrogen on blood pressure in postmenopausal women with 
hypertension. Blood Press 9: 275-282, 2000. 
 92.  Hassager C. The long-term effect of oral and transdermal estradiol on plasma 
renin substrate and blood pressure. Circ 76: 753-758, 1987. 
 93.  Hayashi T, Yamada K, Esaki T, Kuzuya M, Satake S, Ishikawa T, Hidaka H 
and Iguchi A. Estrogen increases endothelial nitric oxide by a receptor-mediated 
system. Biochem Biophys Res Commun 214: 847-855, 1995. 
 94.  Haynes MP, Sinha D, Russell KS, Collinge M, Fulton D, Morales-Ruiz M, 
Sessa WC and Bender JR. Membrane estrogen receptor engagement activates 
endothelial nitric oxide synthase via the PI3-kinase-Akt pathway in human 
endothelial cells. Circ Res 87: 677-682, 2000. 
 95.  Hegde LG, Shukla R, Srimal RC and Dikshit M. Attenuation in rat brain nitric 
oxide synthase activity in the coarctation model of hypertension. Pharmacol Res 
36: 109-114, 1997. 
 96.  Henzel MK and Alsip NL. Systemic vascular reactivity in an aortic coarctation 
model of preeclampsia in the rat. Pathophysiology 8: 133-140, 2001. 
  
172
 97.  Herrington D.M. and Klein KP. Invited review: pharmacogenetics of estrogen 
replacement therapy. J Appl Physiol 91: 2776-2784, 2001. 
 98.  Herrington D.M., Reboussin DM, Brosnihan KB, Sharp PC, Shumaker SA, 
Snyder TE, Furberg CD, Kowalchuck GJ, Stuckley TD, Rogers WJ, Bivens 
DH and Waters D. Effects of estrogen replacement on the progression of 
coronary-artery atherosclerosis. N Engl J Med 343: 522-529, 2000. 
 99.  Higashuira K, Mather RS and Halushka PV. Gender-related differences in 
androgen regulation of thromboxane A2 receptors in rat aortic smooth-muscle 
cells. J Cardiovasc Pharmacol 29: 311-315, 1997. 
 100.  Hodges YK, Tung L, Yan XD, Graham JD, Horwitz KB and Horwitz LD. 
Estrogen receptors alpha and beta: prevalence of estrogen receptor beta mRNA in 
human vascular smooth muscle and transcriptional effects. Circulation 101: 1792-
1798, 2000. 
 101.  Horowitz KB and Horowitz LD. Canine vascular tissues are targets for 
andorgens, progestins, and glucocorticoids. J Clin Invest 69: 750-758, 1982. 
 102.  Hsia J, Simon JA, Lin F, Applegate WB, Vogt MT, Hunninghake D and Carr 
M. Peripheral arterial disease in randomized trial of estrogen with progestin in 
women with coronary heart disease: the Heart and Estrogen/Progestin 
Replacement Study. Circulation 102: 2228-2232, 2000. 
  
173
 103.  Hsieh HJ, Li NQ and Frangos JA. Pulsatile and steady flow induces C-fos 
expression in human endothelial cells. J Cell Physiol 154: 143-151, 1993. 
 104.  Huang A, Sun D, Kaley G and Koller A. Superoxide released to high intra-
arteriolar pressure reduces nitric oxide-mediated shear stress- and agonist-induced 
dilations. Circ Res 83: 960-965, 1998. 
 105.  Huang A, Sun D and Koller A. Shear stress-induced release of prostaglandin H2 
in arterioles of hypertensive rats. Hypertension 35: 925-930, 2000. 
 106.  Huang A, Wu Y, Sun D, Koller A and Kaley G. Effect of estrogen on flow-
induced dilation in NO deficiency: role of prostaglandins and EDHF. J Appl 
Physiol 91: 2561-2566, 2001. 
 107.  Hughes GS, Mathur RS and Margolius HS. Sex steroid hormones are altered in 
essential hypertension. J Hypertens 7: 181-187, 1989. 
 108.  Hully SB, Grady D, Bush T, Fursberg C, Riggs B and Vittinghoff E. 
Randomized trial of estrogen and progestin for secondary prevention of coronary 
heart disease in postmenopausal women. JAMA 280: 605-613, 1998. 
 109.  Humphrey JD. Arterial wall mechanics: review and directions. Crit Rev Biomed 
Engr 23: 1-162, 1995. 
  
174
 110.  Humphrey JD, Kang T, Sakarda P and Anjanappa M. Computer-aided 
vascular experimentation: a new electromechanical system. Ann Biomed Eng 21: 
33-43, 1993. 
 111.  Hutcheson IR and Griffith TM. Central role of intracellular calcium stores in 
acute flow- and agonist-evoked endothelial nitric oxide release. Br J Pharmacol 
122: 117-125, 1997. 
 112.  Hyman BT, Stoll LL and Spector AA. Prostaglandin production by 3T3-L1 
cells in culture. Biochim Biophys Acta 713: 375-385, 1982. 
 113.  Jackson EK, Oates JA and Branch RA. Indomethacin decreases arterial blood 
pressure and plasma renin activity in rats with aortic ligation. Circ Res 49: 180-
185, 1981. 
 114.  Jones DA and Fitzpatrick FA. Thromboxane A2 synthase. Modification during 
"suicide" inactivation. J Biol Chem 266: 23510-23514, 1991. 
 115.  Joswig M, Hach-Wunderle V, Ziegler R and Nawroth PP. Postmenopausal 
hormone replacement therapy and the vascular wall: mechanisms of 17 beta-
estradiol's effects on vascular biology. Exp Clin Endocrinol Diabetes 107: 477-
487, 1999. 
  
175
 116.  Kahonen M, Tolvanen JP, Sallinen K, Wu X and Porsti I. Influence of gender 
on control of arterial tone in experimental hypertension. Am J Physiol 275: H15-
H22, 1998. 
 117.  Kamiya A and Togawa T. Adaptive regulation of wall shear stress to flow 
change in the canine carotid artery. Am J Physiol 239: H14-H21, 1980. 
 118.  Kang T, Resar J and Humphrey JD. Heat-induced changes in the mechanical 
behavior of passive coronary arteries. J Biomech Eng 117: 86-93, 2001. 
 119.  Karanian JW and Ramwell PW. Effect of gender and sex steroids on the 
contractile response of canine coronary and renal blood vessels. J Cardiovasc 
Pharmacol 27: 312-319, 1996. 
 120.  Karas RH, Patterson BL and Mendelsohn ME. Human vascular smooth 
muscle cells contain functional estrogen receptor. Circulation 89: 1943-1950, 
1994. 
 121.  Kato H, Suzuki H, Tajima S, Ogata Y, Tominaga T, Sato A and Saruta T. 
Angiotensin II stimulates collagen synthesis in cultured vascular smooth muscle 
cells. J Hypertens 9: 17-22, 1991. 
 122.  Katusic ZS and Shepherd JT. Endothelium-derived vasoactive factors: II. 
Endothelium-dependent contraction. Hypertension 18: III86-III92, 1991. 
  
176
 123.  Kauser K and Rubanyi GM. Gender differences in endothelial dysfunction in 
the aorta of spontaneous hypertensive rats. Hypertension 25: 517-523, 1995. 
 124.  Keen HL, Brands MW, Smith MJ, Jr., Shek EW and Hall JE. Thromboxane 
is required for full expression of angiotensin hypertension in rats. Hypertension 
29: 310-314, 1997. 
 125.  Kelly MJ and Levin ER. Rapid actions of plasma membrane estrogen receptors. 
Trends Endocrinol Metab 12: 152-156, 2001. 
 126.  Kent RS, Diedrich SL and Whorton AR. Regulation of vascular prostaglandin 
synthesis by metabolites of arachidonic acid in perfused rabbit aorta. J Clin Invest 
72: 455-465, 1983. 
 127.  Keppel G. Design and Analysis-A Researcher's Handbook. Englewood Cliffs, 
NJ: Prentice-Hall, 1982. 
 128.  Kinsella BT, O'Mahony DJ and Fitzgerald GA. Phosphorylation and regulated 
expression of the human thromboxane A2 receptor. J Biol Chem 269: 29914-
29919, 1994. 
 129.  Kleiger RE, Boxer M, Ingham RE and Harrison DC. Pulmonary hypertension 
in patients using oral contraceptives. Chest 69: 143-147, 1976. 
  
177
 130.  Ko FN. Low-affinity thromboxane receptor mediates proliferation in cultured 
vascular smooth muscle cells of rats. Arterioscler Thromb Vasc Biol 17: 1274-
1282, 1997. 
 131.  Koller A. and Kaley G. Endothelial regulation of wall shear stress and blood 
flow in skeletal muscle microcirculation. Am J Physiol 260: H862-H868, 1991. 
 132.  Koller A. and Sun D. Corelease of nitric oxide and prostaglandins mediates 
flow-dependent dilation of rat gracilis muscle arterioles. Am J Physiol 267: H326-
H332, 1994. 
 133.  Kolodgie FD, Jacob A, Wilson PS, Carlson GC, Farb A, Verma A and 
Virmani R. Estradiol attenuates directed migration of vascular smooth muscle 
cells in vitro. Am J Pathol 148: 969-976, 1996. 
 134.  Krasinski K, Spyridopoulos I, Asahara T, van der Zee R, Isner JM and 
Losodo DW. Estradiol accelerates functional endothelial recovery after arterial 
injury. Circ 95: 1768-1772, 1997. 
 135.  Ku EC, McPherson SE, Signor C, Chertock H and Cash WD. 
Characterization of imidazo[1,5-a]pyridine-5-hexanoic acid (CGS13080) as a 
selective thromboxane synthetase inhibitor using in vitro and in vivo biochemical 
models. Biochem Biophys Res Commun 112: 899-906, 1983. 
  
178
 136.  Kunapuli SP, Benedict CR and Kumar A. Tissue specific hormonal regulation 
of the rat angiotensinogen gene expression. Arch Biochem Biophys 254: 642-646, 
1987. 
 137.  Kwon YM, Shinozuka K, Kagota S, Yamaguchi Y, Nakamura K and 
Kunitomo M. Both extracellular ATP and shear stress regulate the release of 
nitric oxide in rat caudal artery. Clin Exp Pharmacol Physiol 26: 465-469, 1999. 
 138.  Lagarde M. Control of arachidonic acid release in platelets and endothelial cells. 
Prog Clin Biol Res 301: 13-20, 1989. 
 139.  Langille BL, Bendeck MP and Keeley FW. Adaptations of carotid arteries of 
young and mature rabbits to reduced carotid blood flow. Am J Physiol 256: H931-
H939, 1989. 
 140.  Langille BL and O'Donnell F. Reductions in arterial diameter produced by 
chronic decreases in blood flow are endothelium-dependent. Science 231: 405-
407, 1986. 
 141.  Lappe RW and Brody MJ. Hemodynamic, neural, and humoral mechanisms of 
aortic coarctation hypertension in the rat. J Cardiovasc Pharmacol 8: 656-662, 
1986. 
  
179
 142.  Leffler CW and Busija DW. Prostanoids in cortical and subarachnoid cerebral 
spinal fluid and pial arterial diameter in newborn pigs. Circ Res 57: 689-694, 
1985. 
 143.  Levy GN. Prostaglandin H Synthases, nonsteroidal antiinflammatory drugs, and 
colon cancer. FASEB J 11: 234-247, 1997. 
 144.  Levy BI, Michel JB, Salzmann JL, Azizi M, Poitevin P, Safar M and 
Camilleri JP. Effects of chronic inhibition of converting enzyme on mechanical 
and structural properties of arteries in rat renovascular hypertension. Circ Res 63: 
227-239, 1988. 
 145.  Li M and Stallone JN. Sex dimorphism in constrictor prostanoid-potentiated 
contraction involves greater release of and reactivity to thromboxane in female 
than male rat aorta. FASEB J 15: A1127, 2001. 
 146.  Lin L., Balazy M, Pagano PJ and Nasjletti A. Expression of prostaglandin H2-
mediated mechanism of vascular contraction in hypertensive rats. Relation to 
lipoxygenase and prostacyclin synthase activities. Circ Res 74: 197-205, 1994. 
 147.  Lin L., Mistry M, Stier Jr CT and Nasjletti A. Role of prostanoids in renin-
dependent and renin-independent hypertension. Hypertension 17: 517-525, 1991. 
  
180
 148.  Lin L. and Nasjletti A. Role of endothelium derived prostanoid in angiotensin-
induced vasoconstriction. Hypertension 18: 158-164, 1991. 
 149.  Lin L. and Nasjletti A. Prostanoid-mediated vascular contraction in 
normotensive and hypertensive rats. Eur J Pharmacol 220: 49-53, 1992. 
 150.  Lin M.C., Almusiacobs F, Chen HH, Parry GCN, Mackman J and Shyy JYJ. 
Atherosclerosis, thrombosis, gene expression, hemodynamics, signal transduction: 
shear stress induction of the tissue factor gene. J Clin Invest 99: 737-744, 1997. 
 151.  Ling S, Deng G, Ives HE, Chatterjee K, Rubanyi GM, Komesaroff PA and 
Sudhir K. Estrogen inhibits mechanical strain-induced mitogenesis in human 
vascular smooth muscle cells via down-regulation of Sp-1. Cardiovasc Res 50: 
108-114, 2001. 
 152.  Lipke DW, McCarthy KJ, Elton TS, Arcot SS, Oparil S and Couchman JR. 
Coarctation induces alterations in basement membranes in the cardiovascular 
system. Hypertension 22: 743-753, 1993. 
 153.  Luft FC, Wilcox CS, Unger T, Kuhn R, Demmert G, Rohmeiss P, Ganten D 
and Sterzel RB. Angiotensin-induced hypertension in the rat. Sympathetic nerve 
activity and prostaglandins. Hypertension 14: 396-403, 1989. 
  
181
 154.  Luscher TF, Lie JT and Stanson AW. Arterial fibromuscular dysplasia. Mayo 
Clin Proc 62: 931-952, 1987. 
 155.  Malek AM, Gibbons GH, Dzau VJ and Izumo S. Fluid shear stress 
differentially modulates expression of genes incoding basic fibroblast growth 
factor and platelet-derived growth factor B chain in vascular endothelium. J Clin 
Invest 92: 2013-2021, 1993. 
 156.  Marks F and Ferstenberger G (eds). Prostaglandins, Leukotrienes and Other 
Eicosanoids: From Biogenesis to Clinical Application. Weinheim, Germany: 
Wiley-VCH, 1999. 
 157.  Marttunen MB, Pyrhonen S, Tiitinen AE, Viinikka LU and Ylikorkala O. 
Effect of antiestrogen regimen on prostacyclin and thromboxane A2 in 
postmenopausal patients with breast cancer: evidence of significance of 
hypertension, smoking or previous use of estrogen therapy. Prostaglandins 52: 
317-326, 1996. 
 158.  Masuda A, Mather R and Halushka PV. Testosterone increases thromboxane 
A2 receptors in cultured rat aortic smooth muscle cells. Circ Res 69: 638-643, 
1991. 
 159.  Matsumura Y, Hashimoto N, Taira S, Kuro T, Kitano R, Ohkita M, 
Opgenorth TJ and Takaoka M. Different contributions of endothelin-A and 
  
182
endothelin-B receptors in the pathogenesis of deoxycorticosterone acetate-salt-
induced hypertension in rats. Hypertension 33: 759-765, 1999. 
 160.  McDonald CC, Alexander FE, Whyte BW, Forrest AP and Stewart HJ. 
Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast 
cancer in a randomised trial. The Scottish Cancer Trials Breast Group. BMJ 311: 
977-980, 1995. 
 161.  Meheta P, Meheta J, Crews F, Roy L, Ostrowski N and Noralek C. 
Comparison of umbilical vein models for measurement of relative prostacyclin 
and thromboxane production. Prostaglandins 24: 743-749, 1982. 
 162.  Mendelsohn ME. Mechanisms of estrogen action in the cardiovascular system. J 
Steroid Biochem Mol Biol 74: 337-343, 2000. 
 163.  Mendelsohn ME and Karas RH. The protective effects of estrogen on the 
cardiovascular system. N Engl J Med 340: 1801-1811, 1999. 
 164.  Mene P, Pugliese F, D'Agostino A and Cinotti GA. Thromboxane A2, 
prostaglandins, and mesangial cell proliferation. Kidney Int 41: 554-556, 1992. 
 165.  Mene P, Taranta A, Pugliese F, Cinotti GA and D'Agostino A. Thromboxane 
A2 regulates protein synthesis of cultured human mesangial cells. J Lab Clin Med 
120: 48-56, 1992. 
  
183
 166.  Miller VM. Gender and vascular reactivity. Lupus 8: 409-415, 1999. 
 167.  Miller VM, Lewis DA and Barber DA. Gender differences and endothelium- 
and platelet-derived factors in the coronary circulation. Clin Exp Pharmacol 
Physiol 26: 132-136, 1999. 
 168.  Miller VM and Vanhoute PM. 17Beta-estradiol augments endothelium-
dependent contractions to arachidonic acid in the rabbit aorta. Am J Physiol 258 
(Regulatory Integrative Comp Physiol 27): R1502-R1507, 1990. 
 169.  Mistry M and Nasjletti A. Prostanoids as mediators of prohypertensive and 
antihypertensive mechanisms. Am J Med Sci 295: 263-267, 1988. 
 170.  Mohan D and Melvin JW. Failure properties of passive human aortic tissue. I--
uniaxial tension tests. J Biomech 15: 887-902, 1982. 
 171.  Mohan D and Melvin JW. Failure properties of passive human aortic tissue. II--
Biaxial tension tests. J Biomech 16: 31-44, 1983. 
 172.  Mohan S, Mohan N and Sprague EA. Differential activation of NF-kappa B in 
human aortic endothelial cells conditioned to specific flow environments. Am J 
Physiol 273: C572-C578, 1997. 
  
184
 173.  Moncada S, Gryglewski RJ, Bunting S and Vane JR. A lipid peroxide inhibits 
the enzyme in blood vessel microsomes that generates from prostaglandin 
endoperoxides the substance (prostaglandin X) which prevents platelet 
aggregation. Prostaglandins 12: 715-737, 1976. 
 174.  Moncada S, Herman A, Higgs E and Vane J. Differential formation of 
prostacyclin (PGX or PGI2) by layers of the arterial wall. An explanation for the 
antithrombotic properties of vascular endothelium. Thromb Res 11: 323-344, 
1977. 
 175.  Moncada S and Higgs E. Arachidonate metabolism in blood cells and the vessel 
wall. Clinics in Haematology 15: 273-287, 1986. 
 176.  Mosca L, Collins P, Herrington DM, Mendelsohn ME, Pasternak RC, 
Robertson RM, Schenck-Gustafsson K, Smith SC, Taubert KA and Wenger 
NK. Hormone replacement therapy and cardiovascular disease: a statement for 
healthcare professionals from the American Heart Association. Circ 104: 499-
503, 2001. 
 177.  Nabulsi AA, Folsom AR and White A. Association of hormone replacement 
therapy with various cardiovascular risk foactors in postmenopausal women. N 
Engl J Med 328: 1069-1075, 1993. 
  
185
 178.  Nadal A, Diaz M and Valverde MA. The estrogen trinity: membrane, cytosolic, 
and nuclear effects. News Physiol Sci 16: 251-255, 2001. 
 179.  Nadal A, Ropero AB, Laribi O, Maillet M, Fuentes E and Soria B. 
Nongenomic actions of estrogens and xenoestrogens by binding at a plasma 
membrane receptor unrelated to estrogen receptor alpha and estrogen receptor 
beta. Proc Natl Acad Sci USA 97: 11603-11608, 2000. 
 180.  Nagel T, Resnick N, Atkinson WJ, Dewey CF Jr and Gimbrone MA Jr. Shear 
stress selectively upregulates intercellular adhesion molecule-1 expression in 
cultured human vascular endothelial cells. J Clin Invest 94: 885-891, 1994. 
 181.  Narumiya S, Sugimoto Y and Ushikubi F. Prostanoid receptors: structures, 
properties, and functions. Physiol Rev 79: 1193-1226, 1999. 
 182.  Nasr A and Breckwoldt M. Estrogen replacement therapy and cardiovascular 
protection: lipid mechanisms are the tip of an iceburg. Gynecol Endocrinol 12: 
43-59, 1998. 
 183.  Needleman P, Turk J, Jakschik BA, Morrison AR and Lefkowith JB. 
Arachidonic acid metabolism. Annu Rev Biochem 55: 69-102, 1986. 
 184.  Nerem RM. Shear force and its effect on cell structure and function. ASGSB Bull 
4: 87-94, 1991. 
  
186
 185.  Nie D, Lamberti M, Zacharek A, Li L, Szekeres K, Tang K, Chen Y and 
Honn KV. Thromboxane A2 regulation of endothelial cell migration 
angiogenesis and tumor metastasis. Biochem Biophys Res Commun 267: 245-251, 
2000. 
 186.  Noll G, Tschudi M, Nava E and Luscher TF. Endothelium and high blood 
pressure. Int J Microcirc Clin Exp 17: 273-279, 1997. 
 187.  Nordoy A, Svensson B, Haycraft D, Hoak JC and Wiebe D. The influence of 
age, sex, and the use of oral contraceptives on the inhibitory effects of endothelial 
cells and PGI2 (prostacyclin) on platelet function. Scand J Haematol 21: 177-187, 
1978. 
 188.  Obayashi M, Yano M, Kohono M, Kobayashi S, Yamamoto T, Ohkusa M 
and Matsuzaki M. Effect of angiotensin II receptor antagonism on vascular 
hypertrophy and aortic impedance in abdominal aortic-banded rat. Am J 
Hypertens 12: 381-387, 1999. 
 189.  Ohno M, Cooke JP, Dzau VJ and Gibbons GH. Fluid shear stress induces 
endothelial transforming growthfactor beta-1 transcription and production: 
modulation by potassium channel blockers. J Clin Invest 95: 1363-1369, 1995. 
  
187
 190.  Oparil S, Levine RL, Chen S-J, Durand J and Chen Y-F. Sexually dimorphic 
response of the balloon-injured rat carotid artery to hormone treatment. Circ 95: 
1301-1307, 1997. 
 191.  Owens GK and Reidy MA. Hyperplastic growth response of vascular smooth 
muscle cells following induction of acute hypertension in rats by aortic 
coarctation. Circ Res 57: 695-705, 1985. 
 192.  Pakala R and Benedict CR. Thromboxane A2 fails to induce proliferation of 
smooth muscle cells enriched with eicosapentaenoic acid and docosahexanenoic 
acid. Prostaglandins Leukotrienes & Essential Fatty Acids 60: 275-281, 1999. 
 193.  Palmer KT, Griffin MJ, Syddall H, Pannett B, Cooper C and Coggon D. 
Prevalence of Raynaud's phenomenon in Great Britain and its relation to hand 
transmitted vibration: a national postal survey. Occup Environ Med 57: 448-452, 
2000. 
 194.  Paredes-Carbajal MC, Juarez-Oropeza MA, Ortiz-Mendoza CM and 
Mascher D. Effects of acute and chronic estrogenic treatment on vasomotor 
responses of aortic rings from ovariectomized rats. Life Sci 57: 473-486, 1995. 
 195.  Patrono C, Davi G and Ciabattoni G. Thromboxane biosynthesis and 
metabolism in relation to cardiovascular risk factors. Agents Actions Suppl 37: 10-
17, 1992. 
  
188
 196.  Petitti DB. Hormone replacement therapy and heart disease prevention. JAMA 
280: 650-652, 1998. 
 197.  Pfister SL and Campbell WB. Role of endothelium-derived metabolites of 
arachadonic acid in enhanced pulmonary artery contractions in female rabbits. 
Hypertension 27: 43-48, 1996. 
 198.  Phillips GB, Jing TY, Laragh JH and Sealey JE. Serum sex hormone levels 
and renin-sodium profile in men with hypertension. Am J Hypertens 8: 626-629, 
1995. 
 199.  Prescot SM and White RL. Self Promotion? Intimate connections between APC 
and prostaglandin H synthase 2. Cell 87: 183-186, 1996. 
 200.  Pucci ML, Miller KB, Dick LB, Guan H, Lin L and Nasjletti A. Vascular 
responsiveness to nitric oxide synthesis inhibition in hypertensive rats. 
Hypertension 23: 744-751, 1994. 
 201.  Quest DW and Wilson TW. Effects of ridogrel, a thromboxane synthase 
ingibitor and receptor antagonist, on blood pressure in the spontaneously 
hypertensive rat. Jpm J Pharmacol 78: 479-486, 1998. 
  
189
 202.  Raddino R, Pela G, Uberti D, Portera C, Ferrari R, Scarabelli TM, Cooper 
TJ and Manca C. Estrogen derivative relaxes rabbit aorta via the endothelial 
receptor system. Ital Heart J 2: 49-54, 2001. 
 203.  Radomski MW, Palmer RM and Moncada S. Endogenous nitric oxide inhibits 
human platelet adhesion to vascular endothelium. Lancet 2: 1057-1058, 1987. 
 204.  Radomski MW, Palmer RM and Moncada S. The anti-aggregating properties 
of vascular endothelium: interactions between prostacyclin and nitric oxide. Br J 
Pharmacol 92: 639-646, 1987. 
 205.  Radomski MW, Palmer RM and Moncada S. The role of nitric oxide and 
cGMP in platelet adhesion to vascular endothelium. Biochem Biophys Res 
Commun 148: 1482-1489, 1987. 
 206.  Rajagopalan S, Griendling KK and Harrison DG. Angiotensin II increases 
vascular superoxide production in vivo. FASEB J 9: A315, 1995. 
 207.  Rangarajan U and Kochar MS. Hypertension in women. WMJ 99: 65-70, 2000. 
 208.  Ranjan V, Xiao Z and Diamond SL. Constitutive NOS expression in cultured 
endothelial cells is elevated by fluid shear stress. Am J Physiol 269: H550-H555, 
1995. 
  
190
 209.  Resnick N, Collins T, Atkinson W, Bonthron DT, Dewey CF Jr and 
Gimbrone MA Jr. Platelet derived growth factor B chain promoter contains a 
cis-acting fluid shear stress-responsive element. Proc Natl Acad Sci USA 90: 
4591-4595, 1993. 
 210.  Rich S, Hart K, Kieras K and Brundage BH. Thromboxane synthase inhibition 
in primary pulmonary hypertension. Chest 91: 356-360, 1987. 
 211.  Rojo-Ortega JM and Genest J. A method for production of experimental 
hypertension in rats. J Physiol Pharmacol 46: 883-885, 1968. 
 212.  Romero J.C. and Reckellhoff J.F. Role of angiotensin and oxidative stress in 
essential hypertension. Hypertension 34: 943-949, 1999. 
 213.  Rosenfeld L, Grover GJ and Stier CT, Jr. Ifetroban sodium: an effective 
TxA2/PGH2 receptor antagonist. Cardiovasc Drug Rev 19: 97-115, 2001. 
 214.  Rosenthal T and Oparil S. Hypertension in women. J Human Hypertens 14: 
691-704, 2000. 
 215.  Ruehlmann DO and Mann GE. Actions of oestrogen on vascular endothelial 
and smooth-muscle cells. Biochem Soc Trans 25: 40-45, 1997. 
  
191
 216.  Russell KS, Haynes MP, Sinha D, Clerisme E and Bender JR. Human vascular 
endothelial cells contain membrane binding sites for estradiol which mediate 
rapid intracellular signaling. Proc Natl Acad Sci USA 97: 5930-5935, 2000. 
 217.  Saito S, Aras RS, Lou H, Ramwell PW and Foegh ML. Effects of estrogen on 
nitric oxide synthase expression in rat aorta allograft and smooth muscle cells. J 
Heart Lung Transplant 18: 937-945, 1999. 
 218.  Sakamoto K, Houya I, Inoue K, Tanaka M, Suzuki T, Sakamoto Y and 
Matsuo H. An imbalance in plasma prostanoids in patients with Raynaud's 
phenomenon and pulmonary vasospasm. Eur Respir J 13: 137-144, 1999. 
 219.  Salgado MC, Castania JA, Ballejo G and Salgado HC. Effect of chronic 
estradiol administration on the acute pressor response to aortic coarctation in 
conscious rats. Braz J Med Biol Res 28: 881-888, 1995. 
 220.  Salgado HC and Salgado MC. Acute aortic coarctation hypertension: role of 
vasopressin and angiotensin II. Am J Physiol 257: H1480-H1484, 1989. 
 221.  Schirner M and Taube C. U 46619 induces different blood pressure effects in 
male and female spontaneously hypertensive rats (SHR). Prostaglandins 
Leukotrienes & Essential Fatty Acids 48: 469-473, 1993. 
  
192
 222.  Schmitz PG, Zhang K and Dalal R. Eicosapentaenoic acid supresses PDGF-
induced DNA synthesis in rat mesangial cells: involvement of thromboxane A2. 
Kidney Int 57: 1041-1051, 2000. 
 223.  Schrapner HW, Albuquerque MLC, Runyan C, Hubchak SC, McGuirre J 
and Kim-Schulze S. Modulation of endothelial cell function by estrogen. In: 
Angiogenesis in Health and Disease, edited by Rubani GM.  New York: Marcel 
Dekker Inc, 2000, p. 175-190. 
 224.  Schror K (ed.). Prostaglandins and Other Eicosanoids in the Cardiovascular 
System: Experimental Data-Clinical Experience. New York: Karger, 1985. 
 225.  Schutze N, Vollmer G, Tiemann I, Geiger M and Knuppen R. 
Catacholestrogens are MCF-7 cell estrogen receptor agonists. J Steroid Biochem 
Mol Biol 46: 781-789, 1993. 
 226.  Schwarzacher SP, Lim TT, Wang B, Kernoff RS, Niebauer J, Cooke JP and 
Yeung AC. Local intramural delivery of L-arginine ehances nitric oxide 
generation and inhibits lesion formation after balloon angioplasty. Circ 95: 1863-
1869, 1997. 
 227.  Shan J, Resnick LM, Liu QY, Qu XC, Barbagallo M and Pang PKT. 
Vascular effects of 17Beta-estradiol in male Sprague Dawley rats. Am J Physiol 
266: H967-H973, 1994. 
  
193
 228.  Shaul PW. Novel role of estrogen receptors in vascular endothelium. Semin 
Perinatol 24: 70-74, 2000. 
 229.  Shepherd JT and Katusic ZS. Endothelium-derived vasoactive factors: I. 
Endothelium-dependent relaxation. Hypertension 18: III76-III85, 1991. 
 230.  Shimokawa H. Endothelial dysfunction in hypertension. J Atheroscler Thromb 4: 
118-127, 1998. 
 231.  Shyy JYJ, Li YS, Lin MC, Chen W, Yuan SL, Usami S and Chen S. Multiple 
cis elements mediate shear stress-induced gene expression. J Biomech 28: 1451-
1457, 1995. 
 232.  Sigmon DH and Beierwaltes WH. Endothelium-derived constricting factor in 
renovascular hypertension. Hypertension 25: 803-808, 1995. 
 233.  Simon JA, Hsia J, Cauley JA, Richards C, Harris F, Fong J, Barrett-Connor 
E and Hylley SB. Postmenopausal hormone therapy and risk of stroke: the heart 
and estrogen-progestin replacement study (HERS). Circ 103: 638-642, 2001. 
 234.  Simpson ER, Clyne C, Rubin G, Boon WC, Robertson K, Britt K, Speed C 
and Jones M. Aromatase- A brief overview. Annu Rev Physio 64: 93-127, 2002. 
  
194
 235.  Smith EF III. Role of thromboxane receptor antagonists in cardiovascular 
disease. Prog Clin Biol Res 301: 29-38, 1989. 
 236.  Smith EF III. Thromboxane A2 in cardiovascular and renal disorders: is there a 
defined role for thromboxane receptor antagonists or thromboxane synthase 
inhibitors? Eicosanoids 2: 199-212, 1989. 
 237.  Smith EF III., Griswold DE, Egan JW, Hillegass LM and DiMartino MJ. 
Reduction of myocardial damage and polymorphonuclear leukocyte accumulation 
following coronary artery occlusion and reperfusion by the thromboxane receptor 
antagonist BM 13.505. J Cardiovasc Pharmacol 13: 715-722, 1989. 
 238.  Smith W.L. and DeWitt DL. Prostaglandin endoperoxide H synthases 1 and 2. 
Adv Immunol 62: 167-215, 1996. 
 239.  Soltis EE. Alterations in vascular structure and function after short-term losartan 
treatment in spontaneously hypertensive rats. J Pharmacol Exp Ther 266: 642-
646, 1993. 
 240.  Sonesson B, Lanne T, Vernersson E and Hansen F. Sex difference in the 
mechanical properties of the abdominal aorta in human beings. J Vasc Surg 20: 
959-969, 1994. 
  
195
 241.  Spyridopoulos I, Brogi E, Kearney M, Sullivan AB, Cetrulo C, Isner JM and 
Losordo DW. Vascular endothelial growth factor inhibits endothelial cell 
apoptosis induced by tumor necrosis factor-alpha: balance between growth and 
death signals. J Mol Cell Cardiol 29: 1321-1330, 1997. 
 242.  Spyridopoulos I, Sullivan AB, Kearney M, Isner JM and Losordo DW. 
Estrogen-receptor-mediated inhibition of human endothelial cell apoptosis. 
Estradiol as a survival factor. Circulation 95: 1505-1514, 1997. 
 243.  St-Louis J, Parent A, Larivierre R and Schiffrin EL. Vasopressin responses 
and receptors in the mesenteric casculature of estrogen-treated rats. Am J Physiol 
251: H885-H889, 1986. 
 244.  Stallone JN. Role of endothelium in sexual dimorphism in vasopressin-induced 
contraction of rat aorta. Am J Physiol 265: H2073-H2080, 1993. 
 245.  Stallone JN. Sex differences in nitric oxide-mediated attenuation of vascular 
reactivity to vasopressin are abolished by gonadectomy. Eur J Pharmacol 259: 
273-283, 1994. 
 246.  Stallone JN. Mesenteric vascular responses to vasopressin during development of 
DOCA-salt hypertension in male and female rats. Am J Physiol 268: R40-R49, 
1995. 
  
196
 247.  Stallone JN, Crofton JT and Share L. Sexual dimorphism in vasopressin-
induced contraction of the rat aorta. Am J Physiol 260: H453-H458, 1991. 
 248.  Stallone JN and Li M. Constrictor prostanoid potentiated constraction of female 
rat aorta involves estrogen-dependent upregulation of cyclooxygenase 2 function. 
FASEB J 15: LB-16, 2001. 
 249.  Stampfer MJ, Colditz GA and Willett WC. Menopause and heart disease: a 
review. Biochem Mo Biol 61: 281-286, 1997. 
 250.  Stewart KG, Zhang Y and Davidge ST. Estrogen decreases prostaglandin H 
synthase products from endothelial cells. J Soc Gynecol Investig 6: 322-327, 
1999. 
 251.  Tamaya T, Misao M, Makagawa M, Itoh T, Wda K, Fugimoto J and Imai A. 
Estrogen and androgen receptors in the aorta of the rabbit and regulation by 
estrogen and androgen. Res Comm Chem Pathol Pharmacol 82: 3-11, 1993. 
 252.  Tatchum-Talom R, Martel C and Marette A. Influence of estrogen on aortic 
stiffness and endothelial function in female rats. Am J Physiol 282: H491-H498, 
2002. 
  
197
 253.  Taube C and Schirner M. Sexual dimorphism in blood pressure response to 
thromboxane agonist U 46619 and to endothelin. Agents Actions Suppl 37: 369-
375, 1992. 
 254.  Timaran CH, Stevens SL, Grandas OH, Piercy KT, Freeman MB and 
Goldman MH. Influence of hormone replacement therapy on graft patency after 
femoropopliteal bypass grafting. J Vasc Surg 32: 506-516, 2000. 
 255.  Topper JN, Cai J, Falb D and Gimbrone MA Jr. Identification of vascular 
endothelial growth genes differentially responsive to fluid mechanical stimuli: 
cyclooxygenase 2, manganese superoxide dismutase, and endothelial cell nitric 
oxide synthase are selectively upregulated by steady laminar shear stress. Proc 
Natl Acad Sci USA 93: 10417-10422, 1996. 
 256.  Ueno H, Kanellakis P, Agrotis A and Bobik A. Blood flow regulates the 
development of vascular hypertrophy, smooth muscle cell proliferation, and 
endothelial cell nitric oxide synthase in hypertension. Hypertension 36: 89-98, 
2000. 
 257.  Ullrich V and Haurand M. Thromboxane synthase as a cytochrome P450 
enzyme. Adv Prostaglandin Thromboxane Leukot Res 11: 105-110, 1983. 
  
198
 258.  Umeda M, Ichikawa S, Kanda T, Sumino H and Kobayashi S. Hormone 
replacement therapy increases plasmal level of angiotensin II in postmenopausal 
hypertensive women. Am J Hypertens 14: 206-211, 2001. 
 259.  Urade Y and Hayaishi O. Prostaglandin D synthase: structure and function. 
Vitam Horm 58: 89-120, 2000. 
 260.  van Gorp AW, Schenau DS, Hoeks AP, Boudier HA, De Mey JG and 
Reneman RS. In spontaneously hypertensive rats alterations in aortic wall 
properties precede development of hypertension. Am J Physiol 278: H1241-
H1247, 2000. 
 261.  van Loon P. Length-force and volume-pressure relationships of arteries. 
Biorheology 14: 181-201, 1977. 
 262.  Vanhoutte PM. Endothelial dysfunction in hypertension. J Hypertens 14: S83-
S93, 1996. 
 263.  Vanhoutte PM and Boulanger CM. Endothelium-dependent responses in 
hypertension. Hypertens Res 18: 87-98, 1995. 
 264.  Verdecchia P, Porcellati C, Schillaci G, Borgioni C, Ciucci A, Battistelli M, 
Guerrieri M, Gatteschi C, Zampi I and Santucci A. Ambulatory blood 
  
199
pressure. An independent predictor of prognosis in essential hypertension. 
Hypertension 24: 793-801, 1994. 
 265.  Verdecchia P, Schillaci G, Boldrini F, Guerrieri M and Porcellati C. Sex, 
cardiac hypertrophy and diurnal blood pressure variations in essential 
hypertension. J Hypertens 10: 683-692, 1992. 
 266.  Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Sacchi N, Battistelli M, 
Guerrieri M, Comparato E and Porcellati C. Gender, day-night blood pressure 
changes, and left ventricular mass in essential hypertension. Dippers and peakers. 
Am J Hypertens 8: 193-196, 1995. 
 267.  Verdecchia P, Schillaci G, Gatteschi C, Zampi I, Battistelli M, Bartoccini C 
and Porcellati C. Blunted nocturnal fall in blood pressure in hypertensive women 
with future cardiovascular morbid events. Circulation 88: 986-992, 1993. 
 268.  Verdecchia P, Schillaci G and Porcellati C. Dippers versus non-dippers. J 
Hypertens Suppl 9: S42-S44, 1991. 
 269.  Vinall PE and Simeone FA. Whole mounted pressurized in vitro model for the 
study of cerebral arterial mechanics. Blood Vessels 24: 51-62, 1987. 
 270.  Virdis A, Ghiadoni L, Pinto S, Lombardo M, Petraglia F, Gennazzani A, 
Buralli S, Taddei S and Salvetti A. Mechanisms responsible for endothelial 
  
200
dysfunction associated with acute estrogen deprivation in normotensive women. 
Circulation 101: 2258-2263, 2000. 
 271.  Voulgari PV, Alamanos Y, Papazisi D, Christou K and Papanikolaou C. 
Prevalence of Raynaud's phenomenom in a healthy Greek population. Ann Rheum 
Dis 59: 206-210, 2000. 
 272.  Wagonvoort CA and Wagonvoort N. Primary pulmonary hypertension. A 
pathologic study of the lung vessels in 156 clinically diagnosed cases. Circ 62: 
1163-1184, 1970. 
 273.  Wang JL, Cheng HF and Harris RC. Cyclooxygenase-2 inhibition decreases 
renin content and lowers blood pressure in a model of renovascular hypertension. 
Hypertension 34: 96-101, 1999. 
 274.  Wang LH, Tazawa R, Lang AQ and Wu KK. Alternate splicing of human 
thromboxane synthase mRNA. Arch Biochem Biophys 315: 273-278, 1994. 
 275.  Weiner CP, Lizasoain I, Baylis SA, Knowles RG, Charles IG and Moncada S. 
Induction of calcium-dependent nitric oxide synthases by sex hormones. Proc 
Natl Acad Sci USA 91: 5212-5216, 1994. 
 276.  Weis MT and Malik KU. Regulation by calcium of arachadonic acid metabolism 
in the isolated prefused rabbit heart. Circ Res 59: 694-703, 1986. 
  
201
 277.  Welch WJ. The pathophysiology of renin release in renovascular hypertension. 
Semin Nephrol 20: 394-401, 2000. 
 278.  Welch WJ, Peng B, Takeuchi K, Abe K and Wilcox CS. Salt loading enhances 
rat renal TxA2/PGH2 receptor expression and TGF response to U-46,619. Am J 
Physiol 273: F976-F983, 1997. 
 279.  Welch WJ, Wilcox CS and Dunbar KR. Modulation of renin by thromboxane: 
studies with thromboxane synthase inhibitor, receptor antagonists, and mimetic. 
Am J Physiol 257: F554-F560, 1989. 
 280.  Wellman GC, Bojnev AD, Nelson MT and Brayden JE. Gender differences in 
coronary artery diameter involve estrogen, nitric oxide, and Ca 2+ dependent K+ 
channels. Circ Res 79: 1024-1030, 1996. 
 281.  Westheim A, Klemetsrud T, Tretli S, Stokke HP and Olsen H. Blood pressure 
levels in treated hypertensive patients in general practice in Norway. Blood Press 
10: 37-42, 2001. 
 282.  Wetzka B, Charnock-Jones DS, Viville B, Cooper JC, Nusing R, Zahradnik 
HP and Smith SK. Expression of prostacyclin and thromboxane synthases in 
placental and placental bed after pre-eclamptic pregnancies. Placenta 17: 573-
581, 1996. 
  
202
 283.  White RE, Darkow DJ and Lang JKF. Estrogen relaxes coronary arteries by 
opening BKCa channels through a cGMP-dependent mechanism. Circ Res 77: 
936-942, 1995. 
 284.  White CR, Shelton J, Chen SJ, Darley-Usmar V, Allen L, Nabors C, Sanders 
PW, Chen YF and Oparil S. Estrogen restores endothelial cell function in an 
experimental model of vascular injury. Circulation 96: 1624-1630, 1997. 
 285.  White MM, Zamudio S, Stevens T, Tyler R, Lindenfeld J, Leslie K and 
Moore LG. Estrogen, progesterone, and vascular reactivity: potential cellular 
mechanisms. Endocr Rev 16: 739-751, 1995. 
 286.  Wilcox C.S., Cardozo J and Welch WJ. AT1 and TxA2/PGH2 receptors 
maintain hypertension throughout 2K,1C Goldblatt hypertension in the rat. Am J 
Physiol 271: R891-R896, 1996. 
 287.  Wilcox C.S. and Welch WJ. Thromboxane mediation of the pressor response to 
infused angiotensin II. Am J Hypertens 3: 242-249, 1990. 
 288.  Wild RA and Reis SE. Estrogens, progestins, selective estrogen receptor 
modulators, and the arterial tree. Am J Obstet Gynecol 184: 1031-1039, 2001. 
 289.  Williams JK, Adams MR and Klopfenstein HS. Estrogen modulates responses 
of atherosclerotic coronary arteries. Circulation 81: 1680-1687, 1990. 
  
203
 290.  Winn R, Harlan J and Hidebrant J. Thromboxane A2 mediates lung 
vasoconstriction but not permeability after endotoxin. J Clin Invest 72: 911-918, 
1983. 
 291.  Writing Group for the Estradiol Clotting Factors Study. Effects of hemostasis 
of hormone replacement therapy with transdermal estradiol and oral sequential 
medroxyprogesterone acetate: a one-year, double blind, placebo-controled study. 
Thromb Haemost 75: 476-480, 1996. 
 292.  Xiao ZS, Zhang ZH and Diamond SL. Shear stress induction of the endothelial 
nitric oxide synthase gene is calcium dependent but not calcium activated. J Cell 
Physiol 171: 205-211, 1997. 
 293.  Yasujima M, Abe K, Tanno M, Kohzuki M, Sato M, Omata K, Takeuchi K, 
Hagino T and Yoshinaga K. Role of the prostaglandin-thromboxane system in 
the development and maintenance of spontaneous hypertension in the rat. Agents 
Actions Suppl 22: 133-138, 1987. 
 294.  Yin FC, Spurgeon F.C. and Kallman CH. Age-associated alterations in 
viscoelastic properties of canine aortic strips. Circ Res 53: 464-472, 1983. 
 295.  Ylikorkala O and Makila UM. Prostacyclin and thromboxane in gynecology 
and obstetrics. Am J Obstet Gynecol 152: 318-329, 1985. 
  
204
 296.  Yu H, Rakugi H, Higaki J, Morishita R, Mikami H and Ogihara T. The role 
of activated vascular angiotensin II generation in vascular hypertrophy in one-
kidney, one clip hypertensive rats. J Hypertens 11: 1347-1355, 1993. 
 297.  Yue TL, Vickery-Clark L, Louden CS, Gu JL, Ma XL, Narayanan PK, Li X, 
Chen J, Storer B, Willette R, Gossett KA and Ohlstein EH. Selective estrogen 
receptor modulator idoxifene inhibits smooth muscle cell proliferation, enhances 
reendothelialization, and inhibits neointimal formation in vivo after vascular 
injury. Circulation 102: III281-III288, 2000. 
 298.  Zancan V, Santagati S, Bolego C, Vegeto E, Maggi A and Puglisi L. 17Beta-
estradiol decreases nitric oxide synthase II synthesis in vascular smooth muscle 
cells. Endocrinology 140: 2004-2009, 1999. 
 299.  Zhang Y and Davidge ST. Effect of estrogen replacement on vasoconstrictor 
responses in rat mesenteric arteries. Hypertension 34: 1117-1122, 1999. 
 300.  Zoorob RJ, Arif AM and Morelli V. Hypertension. Prim Care 27: 589-614, 
2000. 
 
  
205
VITA 
 
Wendy Irene Baltzer 
College of Veterinary Medicine, Mail Stop 4474 
College Station, TX 77843-4474 
 
EDUCATION: 
 
2003 Doctor of Philosophy Cardiovascular Physiology Texas A&M University, 
College of Veterinary Medicine, College Station, TX. 
 
1994 Doctor of Veterinary Medicine University of California, School of 
Veterinary Medicine, Davis, CA. 
 
1992 Bachelor of Science, Veterinary Science 
  University of California, Davis, CA. 
 
AWARDS: 
 
2002 Texas A&M Veterinary Faculty Auxiliary Graduate Award 
2002 Caroline tum Suden/Frances A Hellebrandt Professional Opportunity 
Award for Meritorious Research 
2001  Women’s Faculty Network Texas A&M University Graduate Scholarship 
2000 Graduate Student Research Week Scholarship, Texas A&M University 
1994 ACVS Senior Student Award for Excellence: Small Animal Surgery 
1992-1994 Phi Sigma Alpha Honor Society- Veterinary Medicine 
1994 SCAVMA/ Hills Scholarship 
1992 Dr. and Mrs. Miller Companion Animal Scholarship 
 
SELECTED PUBLICATIONS: 
 
Baltzer, WI, Kuo L, Stallone JN. Estrogen enhances constrictor prostanoids and 
blood pressure in aortic coarctation-induced hypertension in female rats. FASEB J 
2003, 17(5), A1234. 
 
Baltzer W, Stallone JN. Aortic coarctation-induced hypertension is greater in 
females vs. males and is more constrictor prostanoid dependent (Abstract) FASEB 
J 2002, 16: A81. 
 
Baltzer, WI, Schulz, KS, Stover, SM, Taylor, KT, Vasseur, PB: Biomechanical 
Analysis of Suture Anchors and Suture Materials for Toggle Pin Stabilization of 
Hip Joint Luxation in Dogs. Am J Vet Res. 2001; 62: 721-728. 
 
